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Abstract 
 
The Effect of Substrate Stiffness on Endothelial Cell Stiffness and Monolayer 
Permeability in Response to Inflammation 
Rebecca Lownes Urbano 
Alisa Morss Clyne, PhD 
 
Cardiovascular diseases represent a major risk to global health, contributing to 
approximately one-third of all deaths worldwide. Inflammation and arterial stiffening are 
key in the pathogenesis of many cardiovascular diseases, including hypertension and 
atherosclerosis.  However, little is known about their combined impact on vascular 
endothelial dysfunction.  The central objective of this thesis is to investigate the 
contribution of arterial stiffness to endothelial cell stiffening and barrier loss in response 
to inflammation through actinomyosin contractility and reactive oxygen species.  
A novel dielectrophoretic (DEP) device for assessing deformability of 
micropatterned single attached cells was simulated, fabricated, and tested.  The device 
was validated by showing that endothelial cells with cytoskeletal disruption and epithelial 
cells with induced tumorigenicity were softer by atomic force microscopy (AFM) and 
more deformable in response to directed DEP pushing force.  Next, the effect of sub-
endothelial stiffness on endothelial monolayer permeability in response to inflammation 
was explored ex vivo and in vitro.  Elastin haploinsufficient (ELN+/-) mice exhibited 
stiffer sub-endothelium by AFM and increased vinculin at aortic endothelial cell-cell 
junctions.  In vitro, porcine aortic endothelial cells (PAEC) on collagen-coated 
polyacrylamide gels of varying stiffness (6-50 kPa) showed increased vinculin 
localization to cell-cell junctions and junction loss in response to tumor necrosis factor 
alpha (TNF-α) and thrombin.  These effects were abolished when cell contraction was 
inhibited.  Substrate stiffness also enhanced functional barrier loss in response to 
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thrombin, but not TNF-α; however, cells exhibited substrate-dependent stiffening 
following TNF-α exposure.  Lastly, substrate stiffness enhanced endothelial reactive 
oxygen species (ROS) production in response to phorbol 12-myristate 13-acetate (PMA).  
On stiff substrates PMA-induced ROS elicited greater actin fiber formation and cell-cell 
junction loss, which was independent of cell contractility but prevented by ROS 
scavenging.  Ex vivo, peripheral actin fiber formation was greater in the ELN+/- mouse 
abdominal aorta following exposure to PMA. 
These results demonstrate that sub-endothelial stiffness affects endothelial cell 
contractile and non-contractile (ROS-mediated) mechanisms of endothelial barrier 
dysfunction.  This research supports studying the integrated effects of arterials stiffness 
and inflammation to develop new therapies to prevent endothelial dysfunction.
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1.  Background 
 
1.1. Clinical motivation  
 
1.1.1. Hypertension 
Approximately 37% of American adults suffer from hypertension, according to 
the Centers for Disease Control and Prevention (CDC, 2011).  Recent studies indicate 
that out of the approximately 76 million hypertensive Americans, 39 million are 
undiagnosed, untreated or suffer from uncontrolled high blood pressure [1].  Overall, the 
prevalence of hypertension is approximately equal in men and women.   Prevalence 
steadily increases with age, from about 10% of individuals age 20-34 to about 70% of 
individuals over the age of 75.  Hypertension was a primary or contributing factor in 
348,000 deaths in 2009 and costs approximately $47.5 billion annually to treat (CDC).  
By 2025, the number of individual with hypertension is projected to reach 1.56 billion 
[2].  Clearly, hypertension is a widespread and costly affliction, and the number of 
hypertensive individuals will continue to rise as the American population ages. 
Hypertension is defined as chronic elevated blood pressure, resulting in cardiac, 
vascular, renal and/or retinal damage.  There are two main classifications of 
hypertension:  primary/essential and secondary.  Primary hypertension, which accounts 
for more than 90% of cases, is not attributable to another pathological condition and can 
be associated with a myriad of factors.  Some of these factors include inappropriate 
dietary consumption (inadequate calcium/potassium or excessive long-term sodium 
intake), increased activation of the renin-angiotensin-aldosterone system, increased 
sympathetic nervous system (SNS) stimulation, and decreased availability of 
vasodilators.  Increased blood pressure as a consequence of other pathologies, including 
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renovascular disease and sleep apnea, is classified as secondary hypertension.  The 
disease progression is characterized into three stages.  In the least severe stage, Stage 1, 
resting blood pressure is >115/75 mm Hg.  Individuals in Stage 1 begin to show early 
signs of hypertensive effects (e.g., increased central arterial or small artery stiffness, 
increased atrial filling pressure), but do not yet display signs of target organ damage (e.g., 
mild or severe left ventricular hypertrophy, peripheral or carotid arterial disease).  In 
Stage 2, resting blood pressure is >140/90 mm Hg.  Individuals begin to display multiple 
hypertensive effects and may show signs of early target organ damage.  In Stage 3, both 
resting blood pressure is regularly >140/90 mm Hg or higher and target organ damage 
has occurred [3]. 
Hypertension is associated with increased arterial stiffness. Pulse wave velocity 
(PWV), a direct indicator of arterial stiffness, was 8.6 ± 1.5 m/s in normotensive 
individuals [4].  In individuals with increased blood pressure, PWV significantly 
increased to 10 ± 2.5 m/s [5]. In 2001, a large clinical study of 1980 patients showed that 
increased PWV was significantly associated with cardiovascular mortality in 
hypertensive individuals [6].  In a larger and more recent clinical study, increased PWV 
was found to be a predictor of cardiovascular events, even after adjusting for age, sex, 
systolic blood pressure and cholesterol, among other factors [7].  Interestingly, elevated 
aortic stiffness was significantly associated with future development of hypertension, 
suggesting that stiffness changes may precede blood pressure changes [8].  PWV is also 
correlated with higher cardiovascular mortality, coronary heart disease, and stroke in 
outwardly healthy older adults [9], and fatal stroke in individuals with hypertension [10].   
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Several animal models of hypertension exist:  diet-induced hypertensive rats and 
mice (obesity and high salt intake), L-NAME infused rats, Dahl salt-sensitive rats, 
spontaneously hypertensive rats (SHR), DOCA-salt rats, and elastin haploinsufficient 
(ELN+/-) mice) [11-13], which can also be used to study the effects of arterial stiffness.  
Mice fed a high-fat/high-sucrose diet (HFHS) developed stiffened arteries by PWV at 1 
month and showed increased systolic blood pressure at 6 months [11]. PWV was 
approximately 1.4-fold higher in SHR compared to normotensive Wistar-Kyoto (WKY) 
rats [14].  Thus, arterial stiffening has been shown to precede hypertension in both 
humans and animal models.   
Inflammation plays a role in hypertension, although the exact nature of this role 
remains to be elucidated. While many inflammatory cytokines exist, this work focuses on 
the effects of tumor necrosis factor alpha (TNF-α).  TNF-α is expressed by several cell 
types, including macrophages, fibroblasts, neuronal cells, and endothelial cells [15]. 
Blood levels of TNF-α were elevated in individuals with both hypertension and pre-
hypertension, suggesting a role in the progression of the disease [16].  Specifically, TNF-
α production by T-cells has been implicated in the hypertension progression [17]. 
In general, people with hypertension have elevated levels of the inflammatory 
molecules C-reactive protein, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and 
adhesion molecules such as P-selectin and sICAM-1 [18]. TNF-α and IL-6 are also 
elevated in women with preeclampsia [19]. RAG-1-/- mice, which lack both T cells and 
B cells immune cells, show less hypertension from chronic angiotensin II infusion. 
Adoptive T cell transfer restored angiotension II-induced hypertension in these mice [20]. 
These studies further showed that chronic angiotensin II infusion increases activated 
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effector T cells in the circulation and perivascular fat. Thus hypertensive stimuli may lead 
to activated T cell perivascular accumulation and the local release of cytokines such as 
TNF-α. In this work, the TNF-α antagonist etanercept reduced hypertension caused by 
angiotensin II.  In a mouse model of hypertension induced through high fructose diet, 
chronic treatment with etanercept prevented an increase in blood pressure and rescued 
acetylcholine-stimulated vasodilation and eNOS expression, but did not affect levels of 
angiotensin II [21].  Inflammation can also increase arterial stiffness through ECM 
changes [22].  In patients with hypertension, arterial stiffness (measured by pulse wave 
velocity) was increased in patients with elevated TNF-α levels in the blood, among other 
inflammatory markers [23].  
 
1.1.2. Atherosclerosis 
Atherosclerosis is an inflammatory disease characterized by hardening of the 
arteries and the formation of sub-endothelial plaques [24, 25].  In early stages of the 
disease, “fatty streaks” form under the endothelial layer that contain lipids, macrophage 
foam cells, and T-cells.  Low-density lipoprotein (LDL) binding to proteoglycans in the 
extracellular matrix (ECM) leads to sub-endothelial accumulation, a development which 
is considered one of the earliest steps in atherosclerotic pathogenesis [26].  Accumulated 
LDL can be modified through oxidation or enzymatic degradation.  This modified LDL 
stimulates an immune response from surrounding endothelial cells, resulting in up-
regulated expression of cell-surface receptors such as vascular-cell adhesion molecule-1 
(VCAM-1) that recruit circulating monocytes to the plaque [27].  The plaque continues to 
grow with increased migration of immune cells into the region and develops a fibrous 
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cap.  Eventual plaque rupture leads to clot formation (thrombosis), which can result in the 
restriction of blood flow to the immediate area or other tissues should the clot become 
dislodged [24].  In fact, large atherosclerotic plaques (>4mm thick) were associated with 
brain infarction in individuals older than 60 years of age [28].  While the roles of 
inflammation and endothelial barrier dysfunction in atherogenesis are well-established, 
the early triggers are less well understood.    
 
1.1.3. Motivation summary 
Hypertension is a major risk factor for atherosclerosis and exacerbates 
atherogenesis [29, 30].  In addition, recent studies suggest arterial stiffening both 
precedes and follows increased blood pressure in hypertension [7].  We hypothesize that 
early reversible increases in arterial stiffness in conjunction with inflammation worsens 
endothelial barrier loss.  This work investigates the mechanisms involved in the 
substrate-dependent aggravation of endothelial dysfunction (specifically endothelial 
monolayer permeability) in response to inflammation, as a way to better understand the 
role of arterial stiffening in the progression of hypertension and atherosclerosis.            
 
1.2. Aorta Structure and Vascular Stiffness 
1.2.1. Aortic wall structure 
 
The aortic wall is constructed of three domains moving out radially from the 
vessel lumen – the tunica intima, the tunica media, and the tunica adventitia [31].  The 
tunica intima consists of the endothelium, which lines the lumen in a single cell layer and 
acts as a barrier between the blood and the vessel wall.  Beneath the endothelium is a 
basement membrane consisting of collagen type IV, laminin, and perlecan among other 
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components [32].  The internal elastic lamina (IEL) separates the tunica intima from the 
tunica media.  The tunica media is constructed of alternating layers of vascular smooth 
muscle cells (VSMC) and elastin lamina, and its outer border is marked by the external 
elastic lamina.  Collagen types I, III, and V are found near the elastin lamina [33].  
Collagen type I and III are localized to the tunica media, but absent from the tunica 
lamina [34]; these two types of collagen make up approximately 90% of the aorta’s 
collagen content [32].  Collagen type IV is found to a lesser extent in the tunica media, 
although it is distinctly present in the basement membrane of the tunica intima [34].  The 
outermost layer of the aorta is the tunica adventitia, which contains collagen fibers along 
with fibroblast and nerve cells.  The vasa vasorum is a network of smaller vessels that 
innervates the tunica adventitia and the outer layers of the tunica media to supply the 
thickest, most proximal part of the aorta with nutrients [31].   
 
1.2.2. Passive and active control of aortic stiffness 
 
The extracellular matrix (ECM), a protein mesh that mechanically and 
biochemically supports cells, affects arterial stiffness following changes in the balance of 
collagen and elastin.  Collagen and elastin play complimentary roles in the mechanical 
behavior of the aorta; elastin confers the vessel its compliance and collagen provides 
vascular strength [35].  In the arteries of healthy individuals, the vessel ECM is 
constructed of fenestrated elastin sheets interwoven with collagen fibers (type I and III).  
The elastin, which is highly distensible, gives the blood vessel its elasticity.  Collagen 
distributed through the elastin meshwork and in the tunica adventitia provides structural 
support and strengthens the vessel wall, particularly at high strains [35]. At low pressures, 
when circumferential stretch is low, highly distensible elastin fibers in the aortic wall 
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bear the load while less than 10% of collagen fibers straighten [36].  At higher pressures, 
when circumferential stretch is high, collagen fibers are engaged and circumferential 
stress increases with stretch at a faster rate [37].  The importance of elastin in vascular 
mechanics can be seen in the effects elastin-related diseases and aging.      
Arterial stiffening can occur due to changes in extracellular matrix composition or 
more active processes, such as endothelial cell nitric oxide release and VSMC 
hypertrophy. Increases in “passive” arterial stiffness can be due to several factors, 
including decreased elastin content due to degradation by matrix metalloproteases 
(MMPs) and increased collagen cross-linking by advanced glycation end products 
(AGEs) [38, 39].  Elastin degradation is also responsible for increased arterial stiffness 
that occurs with aging [40].  In addition to elastin degradation or cross-linking, genetic 
deletion results in increased arterial stiffness. In humans, elastin gene (ELN) mutations 
and ELN allele deletion (Williams-Beuron syndrome) are both associated with 
hypertension [41-43].  In genetically modified elastin haploinsufficient (ELN+/-) mice, 
the elastin layer beneath the endothelial cell layer is severely diminished, and sub-
endothelial cell ECM deposition is increased [44].  In one study, arterial compliance was 
decreased in ELN+/- mice by postnatal day 7; by postnatal day 14, systolic blood 
pressure in ELN+/- was significantly higher than the wild type [45].  These findings 
demonstrate that increased blood pressure followed arterial stiffening, suggesting that the 
increase in pressure was not solely due to decreased elastin content. 
Endothelial cells, which line all blood contacting surfaces in the body, control 
“active” arterial stiffness through production and release of the vasodilator nitric oxide 
(NO) and the vasoconstrictor endothelin-1.  NO is produced by endothelial cells in 
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response to a variety of biochemical and biophysical stimuli, including vascular 
endothelial growth factor (VEGF), acetylcholine, and shear stress.  Upon stimulation, the 
enzyme endothelial nitric oxide synthase (eNOS) converts oxygen and L-arginine to 
nitric oxide, producing citrulline as a by-product.  NO readily diffuses to the intima 
media, where it causes VSMC relaxation and an effective decrease in vascular stiffness 
[46].  Production of NO by eNOS is crucial to blood pressure regulation, as mice lacking 
eNOS due to genetic mutations (eNOS -/-) display a 15% increase in blood pressure over 
eNOS +/+ mice [47].  Endothelial cells also produce the peptide endothelin-1 (ET-1), 
which can cause contraction of VMSC [48].  ET-1 stimulates contraction through 
increasing intracellular calcium in VSMC; it is also capable of stimulating cell growth 
and mitogenesis [49].  NO and ET-1 represent two major endothelium-produced effectors 
of VSMC in the regulation of vascular tone.   
Smooth muscle cells, which form the vascular media surrounding the endothelial 
cells, determine vascular tone through their contractility.  VSMC contractility is 
controlled in part by endothelial cell paracrine signaling through NO and endothelin-1, as 
previously mentioned.  VSMC contraction is also determined by the renin-angiotensin-
aldosterone system (RAAS).  Angiotensin II, one peptide in this system, acutely 
stimulates VMSC contraction.  Prolonged angiotensin II stimulation results in increased 
VSMC proliferation (hyperplasia) and increased sized (hypertrophy) in the intima media 
[50].  Both VSMC hyperplasia and hypertrophy occurs in animal models of hypertension 
(SHR) [51] and hypertensive humans [52].   
The endothelium must react to changes in the complex environment of the aortic 
wall to maintain vascular homeostasis.  Vascular stiffness, controlled actively and 
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passively as described above, is one of the many stimuli experienced by the endothelium.  
A summary of the literature relevant to endothelial cell response to substrate/tissue 
stiffness is provided below. 
 
1.3. Cell-matrix attachment 
 
1.3.1. Substrate stiffness introduction 
 Adherent cell types require a surface on which to attach for proper cell function.  
In vivo, this surface is the tissue in which the particular cell type resides.  In vitro, plastic 
tissue culture dishes have historically been used to grow adherent cell types.  The term 
“substrate stiffness” refers to the elastic modulus of the material on which a cell is 
attached.  Most cells in vivo attach to soft tissues.  The elastic moduli for brain, muscle 
and bone are approximately 1, 10, and 100 kPa, respectively [53], whereas normal 
substrates for in vitro studies (glass or plastic) are orders of magnitude stiffer.  While 
early studies used thin sheets of silicon rubber, one way of controlling the stiffness of cell 
culture substrates is the use of polyacrylamide (PA) gels [54, 55].  PA gels are hydrogels 
formed through the cross-linking of acrylamide and bis-acrylamide monomers.   The 
stiffness of the gel is controlled though the relative amount of acrylamide and bis-
acrylamide.  Since polyacrylamide is non-adhesive for cells, an ECM protein is 
covalently linked to the gel surface [56].  One limitation to the use of PA gels for the 
study of cell-substrate mechanics is their behavior as an elastic material, as opposed to 
the viscoelastic behavior of most biological tissues [55, 57].  Although protein-
conjugated PA gels are far less complex than actual tissue, they provide a means to study 
the effects of tissue stiffness in vitro and have been used extensively is substrate stiffness 
studies [58].   
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1.3.2. Endothelial cell response to substrate stiffness 
Substrate stiffness affects a wide variety of cell types, including endothelial cells, 
fibroblasts, breast cancer cells, and stem cells [58, 59].  In vivo, tumors are stiffer than 
their surrounding environment.  Specifically, in the MMTV-Neu rat model of breast 
cancer, mammary gland stiffness increased during the transition from normal to 
cancerous tissue due to increased ECM collagen cross-linking [60].  In humans, 
elastography, which uses tissue stiffness measurements to detect disease, is used to 
diagnose liver fibrosis and breast cancer [61, 62].  In healthy individuals and those with 
either risk factors for or established coronary artery disease, flow-mediated dilation 
increased with increasing aortic compliance, indicating an effect of vascular stiffness on 
endothelial cell function [63]. 
In vitro studies of cell response to substrate stiffness began when Pelham and 
Wang first used protein-coated polyacrylamide gels to show that both rat kidney 
epithelial and 3T3 fibroblast spread to a greater extent on stiff substrates (~0.73 N/m) 
than soft (~0.046 N/m) substrates [55].  Since that seminal paper, many cells types were 
shown to change their morphology [64-67], motility [68, 69], differentiation [53, 70] and 
proliferation [71, 72] in response to substrate stiffness. For endothelial cells specifically, 
single cell spread area increases with substrate stiffness [73].  When single bovine aortic 
endothelial cells (BAECs) were grown on polyacrylamide gels of increasing stiffness 
(180, 2900, or 28600 Pa), cell area increased.  However, as cells proliferated and reached 
confluency, substrate-dependent differences in cell area were no longer observed [74].  
BAECs have also been used on type I collagen-coated polyacrylamide gels to 
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demonstrate that both substrate stiffness and ligand density affect endothelial cell 
network assembly, with enhanced network formation on soft substrates (200 kPa) 
compared to stiffer substrates (>1000 kPa) [64].  Endothelial cell motility is directed 
toward areas of higher substrate stiffness, a phenomenon called durotaxis observed in 
many cell types, as demonstrated by bovine pulmonary arterial endothelial cell movement 
away from soft PDMS areas (12 kPa) to micropatterned stiff PDMS areas (2.5 MPa) after 
24-48 hours [75].  Durotaxis occurs due to several factors, including the force generated 
by the cell on its substrate, which is referred to as traction force.  When single BAECs 
were seeded on collagen-coated polyacrylmade gels ranging from 1-10 kPa, both cell 
area and traction stress increased with substrate stiffness [76].  Substrate stiffness can 
also affect endothelial cell proliferation; the percent of proliferative HUVECs (as 
measured by BrdU) decreased with decreasing stiffness over a range of 1.72 to 21.5 kPa 
on fibronectin-coated polyacrylamide gels [77].   
Substrate stiffness can modulate cell mechanics. Endothelial cell stiffness 
(measured by atomic force microscopy), and cell-matrix and cell-cell forces (measured 
by traction force microscopy) all increased with substrate stiffness [78]. Single 
endothelial cells show similar stiffening in response to stiffer substrates; individual 
BAECs on 9 kPa fibronectin-coated polyacrylamide gels were more stiff than cells on 1.7 
kPa gels as measured by microaspiration [79].  When in a confluent monolayer, there was 
a significant increase in HUVEC stiffness on 0.87 kPa versus 280 kPa gels coated with 
fibronectin; however, no significant difference in cell stiffness was observed between 
cells on 0.87 or 5 kPa gels [80].  To provide better insight into how endothelials sense 
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and respond to substrate stiffness, cellular structures involved in this process are 
reviewed in the following sections.   
 
1.3.3. Focal adhesion structure 
 
Focal adhesions 
 
 Cellular response to substrate stiffnesss begins at specialized structures called 
focal adhesions.  Focal adhesions are punctate structures at the basolateral cell surface at 
which specialized proteins that bind the ECM aggregate [81].  Focal adhesions act as 
conduits of information between the cell’s substrate and the inside of the cell.  Integrins, 
discussed in detail below, are a main feature as they span the outer cell membrane and are 
composed of extracellular ECM-binding domains and intracellular cytoskeletal-linking 
domains.  On the intracellular side of the focal adhesion, integrins bind many proteins 
that provide structural support, such as the ability to bind the actin cytoskeleton.  In fact, 
more than 50 intracellular proteins have been localized to focal adhesions [82].  Some of 
these intracellular focal adhesion proteins can also serve as signaling molecules, 
interacting with other proteins to trigger signaling cascades.  Key focal adhesions 
proteins are detailed below.  
 
Integrins 
 
 Integrins are heterodimers of transmembrane proteins largely responsible for the 
interaction between adherent cells and the ECM, although some non-integrin adhesion 
receptors exist [83].  All integrins are composed of two sub-units, termed the α and β sub-
units.  There are 18 α and 8 β sub-units, and these components form 24 known 
combinations [84].  The particular combination of individual sub-units determines the 
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specificity of the integrin-ECM interaction; for example, α2β1 binds collagen while αvβ3 
binds multiple proteins including fibronectin and vitronectin [85].  Integrin binding of 
ECM proteins allows cells to contract and pull against the resistance provided by their 
environment.  This cell-generated force is called a “traction force” [54, 86].  
Interestingly, the force that a cell exerts on ECM proteins through integrin interactions 
can cause the uncoiling of some ECM proteins, such as fibronectin [87].  This applied 
force reveals previously unavailable cryptic binding sites and allows for increased 
integrin-ECM interaction.  
Integrin binding induces cytoskeletal changes and activates intracellular signaling 
pathways through the vast number of focal adhesion-associated proteins.  Integrins are 
unable to interact with the actin cytoskeleton directly; actin-binding proteins such as 
talin, vinculin, filamin, and tensin act as linkers between integrins and the cytoskeleton 
[88].  Scaffolding proteins, such as paxillin, contain binding sites for multiple proteins 
and thus contribute to the construction of focal adhesions.  Paxillin can bind the signaling 
proteins focal adhesion kinase (FAK) and Src, both of which are tyrosine kinases and 
play an important role in integrin-mediated signal transduction pathways [89-91].  
Integrins play a role in the RhoA/ROCK signaling pathway, which is key to cell 
contractility and will be discussed in more detail.  For example, applying tension to 
integrins results in the activation of the RhoA signaling pathway through the guanine 
nucleotide exchange factors (GEFs) LARG and GEF-H1 [92].   
Just as environmental cues are transmitted into the cell through focal adhesions, 
“inside-out” activation of integrins is also possible, meaning cells can activate integrins 
prior to extracellular integrin-ECM interaction [93].  For example, talin interaction with 
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the β sub-unit is sufficient for integrin activation without external interactions with ECM 
proteins [94, 95].  Talin binding to the β3 sub-unit disrupts an inhibitory interaction 
between the tails of α and β sub-units [96].  In addition, the intracellular protein migfilin 
also activates β sub-units by displacing filamin from integrins [97].  Filamin also acts as 
an actin-crosslinking protein; inhibiting “inside-out” integrin activation is not its sole 
function [98].  Thus, both integrins and the intracellular proteins they interact with are 
key to focal adhesion structure and function.      
 
Vinculin 
 
Vinculin, a highly conserved 117 kDa intercellular protein, was first described in 
the literature by Geiger et al. in 1980 and shown to locate to cell-matrix and cell-cell 
adhesions [99-101].  Study of vinculin’s structure by electron microscopy revealed an N-
terminal head, a flexible neck, and a C-terminal tail region [102, 103].  Intramolecular 
interaction between the head and tail regions results in self-inactivation, masking binding 
sites for multiple binding partners including talin, actin, α-actinin, and vasodilator-
stimulated phosphoprotein (VASP) [104-107].  This self-inactivation can be disrupted by 
binding of phosphatidylinositol-4,5-bisphosphate (PIP2) to vinculin’s tail region [108].  
Other vinculin binding partners include paxillin, ponsin and vinexin [109-111].  As 
discussed in the following section, vinculin also binds the cell-cell junction protein alpha-
catenin.  Due to its ability to bind several cytoskeletal proteins, vinculin plays a key role 
in regulating a cell’s attachment to its substrate and neighboring cells. 
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Focal adhesions and mechano-sensing 
 
Focal adhesions are integral to cellular mechano-sensing capability, specifically 
the ability to differentially respond to substrates of different stiffness [112, 113].  One 
way that focal adhesions enable mechano-sensing is through cytoplasmic mechano-
sensitive proteins at the intracellular side of integrins.  For example, talin is unfolded by 
the application of force, and this unfolding results in the unveiling of a vinculin binding 
site [114].  Vinculin binding following force application stabilizes the focal adhesion 
structure [115].  Focal adhesion kinase (FAK) is another intracellular focal adhesion 
protein involved in mechanosensitive signal transduction.  In vitro cyclic stretch induces 
phosphorylation of FAK in multiple endothelial sub-types, including bovine aortic 
endothelial cells and human lung endothelial cells [116, 117].  In epithelial cells, FAK 
phosphorylation at Y397 was significantly lower on soft substrates (< 2 kPa) compared to 
stiff substrates (24 kPa), and FAK activation was linked to Rac-dependent differences in 
cell cycle progression on substrates of varying compliance [118].   Downstream of FAK, 
force-activated stretching is also thought to play a role in increased activation of 
p130Cas, a signaling molecule phosphorylated by Src upstream of Rap-1 [119].  Force-
induced unwinding of filamin A, which causes dissociation of the Rac-inactivator 
FilGAP and unveils cryptic binding cites for the β7 integrin sub-unit, may also play a role 
in increased cell contraction on stiffer substrates [120, 121].  Thus, while focal adhesions 
are key to cell-substrate mechano-sensing, the exact mechanisms involved are still an 
area of intensive study.     
 
 
16 
 
 
1.3.4. Cell contractility signaling and substrate stiffness 
Substrate stiffness determines the level of resistance a cell experiences when it 
contracts and pulls against the surface to which it is attached.   Thus, the study of cell 
contractility mechanisms is key to better understanding how tissue stiffness, specifically 
blood vessel wall compliance, modulates cell function.  The Rho family of GTPases 
contains over 20 different proteins; the most widely studied of these are RhoA (Ras 
homolog gene family, member A), Rac1 (Ras-related C3 botulinum toxin substrate 1), 
and Cdc42 (Cell division control protein 42 homolog).  Rho GTPases are bound by GTP 
in their activated state or GDP in their inactive state [122].  Guanine nucleotide exchange 
factors (GEFs), GTPase activating factors (GAPs), and guanine dissociation inhibitors 
(GDIs) control the activation state of these proteins. GEFs, such as p115RhoGEF, LARG, 
and GEF-H1, activate Rho GTPases.  Interestingly, some GEFs interact with the outer 
cell membrane and thereby control the localization of Rho activation.  GAPs, such as 
p190RhoGAP and p73RhoGAP, inactivate Rho.  GDIs down-regulate Rho activity by 
blocking Rho GTP activation [123].  Several sub-types of Rho GAPs and GEFs are 
expressed in endothelial cells in vitro and in vivo, and play key roles in endothelium 
barrier function [124, 125]. 
  Although other members of the Rho GTP family also influence actin 
reorganization, RhoA is particularly important in cell contractility signaling due to its 
effects on the serine/threonine kinase Rho-associated protein kinase (ROCK).  ROCK 
contains an auto-inhibitory region that is deactivated through interaction with active Rho-
GTP.  Downstream of RhoA, ROCK increases the pool of active phosphorylated myosin 
light chain (MLC) through inhibition of MLC phosphatase, which de-phosphorylates 
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MLC [126].  Active myosin then interacts with the actin cytoskeleton to produce 
intracellular contractile forces [127].    
Myosin light chain kinase (MLCK) also plays a role in modulating cell 
contractility, controlled through direct interaction with the Ca2+/calmodulin complex.  
Binding of Ca2+ to calmodulin induces a conformational change necessary for MLCK 
activation [128].  Interaction with Ca2+/calmodulin releases an auto-inhibitory domain in 
MLCK and triggers direct phosphorylation of MLC [129].  MLCK can also be activated 
by other kinases, such as protein kinase A [130].  Activation of MLC induces myosin 
filament formation along actin fibers [131].  Early studies on myosin phosphorylation, 
actin fiber formation and endothelium monolayer contractility were conducted using a 
custom isometric tension monitoring apparatus capable of detecting contractility of 
endothelial layers in culture.  Thrombin-induced contraction of a HUVEC monolayer 
preceded actin stress fiber formation [132].  In a follow-up study, treatment of HUVECs 
with thrombin was found to increase phosphorylated myosin at serine-19/threonine-18 
and induce co-localization of myosin II with actin fibers, in addition to spurring 
measurable cell contraction [133].  Traction force microscopy, which measures 
deformation of a pliable substrate due to cellular forces, is also used to study the state of 
cell contraction; traction forces of single endothelial cells were diminished following the 
inhibition of ROCK, indicating decreased cell contractility [86, 134].   
Chemical inhibitors of signaling molecules in the contractility pathway are widely 
available.  ROCK can be inhibited by the small molecule Y-27632 [(+)-(R)-trans-4-(1-
aminoethyl)-N-(4-pyridyl)cyclohex- anecarboxamide dihydrochloride], which binds to its 
catalytic site [135, 136].  Multiple inhibitors exist for MLCK, including ML-7 (1-(5-
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Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride) and ML-9 (1-
(5-Chloronaphthalenesulfonyl)homopiperazine hydrochloride), which work by binding 
MLCK near its ATP-binding site [137].  In addition, the small molecule blebbistatin 
affects myosin directly by preventing its association with actin [138].  While both MLCK 
and ROCK are instrumental in determining the level of activated myosin, studies suggest 
their control of actin fiber formation may be specific to different intracellular locations. 
Interestingly, inhibition of ROCK decreases longitudinal stress fibers while inhibition of 
MLCK decreases peripheral actin bundles in single fibroblasts [139].  Similar results 
have been observed in sub-confluent fibroblasts [140]. 
Rho/ROCK signaling is activated in response to thrombin in vitro and ex vivo, and 
thrombin-induced Rho/ROCK signaling is amplified on stiff substrates in vitro.  
Thrombin is a protease in the cascade responsible for blood clot formation [141]. It is 
known to induce endothelial contraction though the activation of both MLCK and the 
Rho/ROCK pathways [142].  In vitro, treatment with thrombin results in increased levels 
of phosphorylated MLC in several endothelial cell types [143, 144].  In the endothelium 
of intact rat renal arteries, pre-treatment with Y-27632 attenuated actin fiber formation 
and MLC phosphorylation in response to thrombin [145].  Thrombin-stimulated RhoA 
signaling was increased to a greater extent in cells on 90 kPa polyacrylamide gel versus 
1.2 kPa gel [146]. In sub-confluent monolayers of human lung microvascular endothelial 
cells, MLC phosphorylation magnitude and duration in response to thrombin treatment 
increased with increasing substrate stiffness (from 0.55 to 42 kPa) [147].  
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 As this dissertation aims to investigate how substrate stiffness affects cell-cell 
junctions, key intercellular junction components are described below followed by a 
background on the mechanisms involved in endothelial monolayer permeability. 
 
 
1.4. Cell-cell attachment 
 
1.4.1.   Cell-cell attachment structure 
 
Inter-cellular attachment is crucial to endothelial barrier function.  Specialized 
structures form endothelial cell-cell junctions:  tight junctions and adherens junctions.   
Tight junctions and adherens junctions differ in their components, particularly the 
transmembrane adhesion proteins that form homophilic linkages between adjacent cells.  
Claudins, occludin, junctional adhesion molecules (JAMs), and nectin compose tight 
junctions while cadherins (particularly VE-cadherin in the endothelium) compose 
adherens junctions [148].  VE-cadherin is supported by several intracellular proteins that 
link VE-cadherin to the actin cytoskeleton.  Discussed in more detail below, α-catenin 
and β-catenin co-localize at the membrane in adherens junctions.  Plakoglobin (γ-catenin) 
also localizes to adherens junctions, but only in stably confluent monolayers [149].  
While endothelial cells expressing truncated VE-cadherin (unable to form the cadherin-
catenin complex) formed cell-cell contacts, these cells could not establish an effective 
barrier to high molecular weight molecules [150]. Thus, the cadherin-catenin complex is 
necessary for proper endothelial barrier function.  In addition to linking VE-cadherin to 
the cytoskeleton, intracellular adherens junction proteins also play a role in signal 
transduction pathways.  For example, p120-catenin binds VE-cadherin but none of the 
adherens junction actin-binding proteins; p120-catenin acts as a substrate for the 
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signaling molecule Src [151].  Similar to focal adhesions, adherens junctions represent an 
area in the cell where structural and signaling components spatially coincide. 
 
VE-cadherin/Cadherin-5 
 
Vascular endothelial cadherin (VE-cadherin) was first identified in 1992 and is an 
endothelial-specific protein at cell-cell junctions both in vivo and in vitro [152].  VE-
cadherin belongs to the cadherin superfamily of glycoproteins [153, 154].  The 
superfamily includes several subfamilies:  the “classical” cadherins (including E-, N-, P- 
and VE-cadherin), desmosomal cadherins, proto-cadherins, 7TM-cadherin, T-cadherin, 
and FAT-family cadherin.  Along with VE-cadherin, endothelial cells also express N-
cadherin [155]. Most cadherins, excluding T-cadherin, span the cell membrane with both 
extracellular and intracellular regions.  The extracellular region is comprised of multiple 
cadherin repeats and allows for calcium-dependent homophilic binding of cadherin 
molecules between adjacent cells [156, 157].  The intracellular tail of VE-cadherin 
contains several binding sites for other intracellular proteins at cell-cell junctions which 
link cell-cell junctions to both the actin cytoskeleton and intermediate filaments [158].  
Two proteins instrumental in the linkage between VE-cadherin and the actin 
cytoskeleton—alpha- and beta-catenin—are detailed below.     
 
Alpha-catenin 
 
The role of alpha-catenin (α-catenin) at adherens junctions is still debated and an 
area of ongoing research [159].  β-catenin binds the intracellular tail of VE-cadherin, and 
α-catenin binds β-catenin forming the cadherin-catenin complex [160, 161].  Alpha-
catenin is capable of binding actin directly [162]; however, the ability of α-catenin to 
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simultaneously bind VE-cadherin/β-catenin and actin was called into question [163, 164].  
Recently, an in vitro optical trap-based assay using purified VE-cadherin, β-catenin, α-
catenin and F-actin demonstrated that tension strengthens the interaction between the 
cadherin-catenin complex and F-actin up until approximately 10 pN of applied force, 
after which the duration of the bond decreases [165].  In addition to its direct interaction 
with actin, α-catenin also binds several other actin-binding adherens junction proteins 
including vinculin and α-actinin, an intracellular adherens junction protein very similar 
sequence to vinculin [166]. 
 
Beta-catenin 
 
Beta-catenin (β-catenin) was first identified as a 92 kDa cadherin-associating 
protein in epithelial cells in 1991 [167].  β-catenin is highly conserved and structurally 
similar to γ-catenin, another intracellular cell-cell junction protein [168].  Conditional 
deletion of β-catenin in mice resulted in pericardial swelling and other vascular 
abnormalities; in vitro endothelial cells lacking β-catenin exhibited low levels of α-
catenin at cell-cell junctions and lack of barrier function [169].  Aside from its role in 
stabilizing adherens junctions, β-catenin functions as a nuclear co-transcription factor in 
T-cell factor/leukocyte enhancing factor (TCF/LEF) inducible gene transcription [170].  
The behavior of β-catenin as a co-transcription factor has been well-studied as part of the 
Wnt signaling pathway in non-vascular cells; however, recent evidence suggests possible 
cross-talk between the Wnt pathway and cell-cell junction signaling through β-catenin in 
vascular development and disease [171].  For example, in thrombin-treated HUVECs 
cell-cell junction disruption increased nuclear p120-catenin and β-catenin, where it 
induced target gene expression [172].  In addition, increased TCF/β-catenin transcription 
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was observed in both sub-confluent and VE-cadherin-null cells [173].  Thus, there exists 
some interaction between β-catenin’s roles as an adherens junction protein and co-
transcription factor.  This work, however, will focus only on β-catenin at cell-cell 
junctions.    
 
1.4.2.   Effect of force on adherens junctions 
 
Forces at adherens junctions increase as cells contract.  Similar to the force-
responsive elements of focal adhesions, certain proteins localized to adherens junctions 
are sensitive to changes in intracellular tension.  For example, the three dimensional 
structure of α-catenin endows this protein with mechano-sensitive properties.  
Specifically, the application of tension (~5 pN) to α-catenin using magnetic tweezers 
causes it to unfold and unveil a binding site for vinculin; vinculin binding then prevents 
α-catenin refolding [174].  Local creation of tension by magnetic twisting cytometry with 
E-cadherin coated beads in MDCK epithelial cells resulted in vinculin recruitment that 
required α-catenin [175].  In multiple studies, treatment of several epithelial cell types 
with blebbistatin abolished vinculin from apical cell-cell junctions [176, 177].  In 
HUVECs vinculin was recruited to adherens junctions following VEGF, TNF-α, and 
thrombin treatment; vinculin localization to junctions was abolished by the Rho inhibitor 
C3 transferase, Y-27632, blebbistatin, and a VE-cadherin blocking antibody (to disrupt 
VE-cadherin homophilic intercellular binding).  Interestingly, the cell-cell junctions of 
HUVECs expressing an α-catenin variant without the vinculin binding site were disrupted 
more severely and took more time to reform following thrombin treatment, compared to 
the control.  This study suggested that vinculin recruitment to adherens junctions 
functions to reinforce cell-cell contacts in response to tension [178].      
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While increased tension at cell-cell junctions is often associated with junction 
loss, some basal level of force is needed for proper maintenance of junctions.  Using a 
non-endothelial cell type (C2 mouse myogenic cells), it was shown that single cells 
spread to a greater extent on stiffer cadherin-coated polyacrylamide gel surfaces, and that 
blebbistatin treatment to inhibit cell contractility abolished cadherin adhesions [179].  
Cellular traction forces can be measured using arrays of polydimethylsiloxane (PDMS) 
microneedles, and these substrates have also been used to better understand the 
relationship between cell-matrix forces and cell-cell junctions.  Human pulmonary artery 
endothelial cells (HPAECs) were seeded on micropatterned microneedle arrays to form 
interacting cell pairs of controlled size and shape, and the size of the junctional area 
between the cell pair was determined using β-catenin labeling.  Treatment of cells with 
blebbistatin and Y-27632 decreased both the force at the junction (calculated using the 
traction force) and the junction size.  However, treatment with thrombin also decreased 
junction size [180].  These and similar studies have indicated that the state of endothelial 
adherens junctions is force-sensitive.  
 
1.4.3.   Mechanisms of adherens junction disruption 
 
The disruption of adherens junctions can occur due to several mechanisms.  Two 
types of mechanisms key to this work are discussed below—barrier disruption due to 
cellular contractility and the production of reactive oxygen species. 
 
Contractility dependent adherens junction disruption:  Rho/ROCK-mediated permeability  
 The role of Rho signaling in endothelial monolayer permeability is well-
established and plays a role in barrier disruption due to several agents, such as thrombin, 
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lipopolysaccharide (LPS), TNF-α, and VEGF [181].  In vitro, the ROCK inhibitor Y-
27632 prevented thrombin-induced adherens junction disruption and decreased the 
diffusion of fluorescent molecules through bovine pulmonary arterial endothelial cell 
monolayers [182].  In addition, Y-27632 has been shown to attenuate barrier loss in 
bovine pulmonary artery endothelial monolayers following thrombin treatment using 
transendothelial resistance (TER, also known as transendothelial electrical resistance or 
TEER) [143].  While TNF-α activation of the Rho family of proteins is well-established, 
the role of cell contraction in TNF-α-induced endothelial permeability is more 
controversial [183, 184].  In HUVECs, phospho-MLC was increased after 30 minutes of 
TNF-α treatment, but inhibition by Y-27632 or ML-7 was reported to not prevent TNF-α-
stimulated endothelial permeability; however, these inhibitors were only added to the 
culture for the last hour of a 24-hour TNF-α treatment [185].  Y-27632 did not attenuate 
HUVEC endothelial permeability measured by TER following TNF-α; in this study Y-
27632 was added 30 minutes after treatment with TNF-α [186].  Yet, in another work, Y-
27632 did prevent adherens junction disruption due to TNF-α [187].  In other studies 
using human lung microvascular endothelial cells, Y-27632 did prevent TNF-α-induced 
permeability by TER [188].  The role of contractility in endothelial permeability 
following exposure to TNF-α may depend on endothelial sub-type (i.e. macrovascular or 
microvascular) and represents an area of active research. 
 
Contractility independent adherens junction disruption:  Reactive oxygen species 
Endothelial cells produce reactive oxygen species (ROS), which are highly 
reactive oxygen-containing molecules including superoxide (O2-), hydrogen peroxide 
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(H2O2), hydroxyl radical (˙OH), and peroxynitrite (ONOO-).  In the endothelium, ROS 
can play both physiological and pathological roles and have been implicated in both 
hypertension and atherosclerosis [189].  ROS are formed in response to a variety of 
stimuli, including peptides (angiotensin II, endothelin-1), growth factors (VEGF), 
cytokines (TNF-α), and shear stress.  Both NADPH oxidase and xanthine oxidase 
produce superoxide; superoxide dismutase converts superoxide to hydrogen peroxide 
[190].  Specifically, NADPH oxidase was shown to produce the majority of superoxide in 
cultured bovine coronary artery endothelial cells [191].  NADPH oxidase function 
requires the translocation of multiple sub-units, including Rac, p40phox, p47phox, 
p67phox, and NOX (NOX-1, 2, 3, 4, or 5) [192].  The NOX-2 homolog (also known as 
gp91phox) has been implicated in endothelial-dependent aortic relaxation; the aortae of 
NOX-2 knock-out mice (gp91phox-/-) displayed greater acetylcholine-induced relaxation 
compared to aortae from the wild-type mice, and this difference was abolished by 
treatment with the superoxide scavenger tiron [193].  Both p47phox and Rac play key 
roles in the control of NADPH oxidase assembly and activation [194, 195].  Interestingly, 
Rac activation affects both actin redistribution and superoxide production, and the 
balance between these dual responsibilities may be determined by the specific Rac GEF 
involved [183, 196, 197].  
 ROS production is known to induce actin fiber formation and disrupt endothelial 
cell-cell junctions.  The interaction between ROS and actin can be both direct and 
indirect, through physical modification of actin and stimulation of intracellular signaling 
pathways, respectively. [198].  Effects of superoxide and its byproduct hydrogen 
peroxide on actin fibers have been demonstrated in many studies, although the observed 
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changes in actin structure may be dependent on endothelial cell sub-type and oxidant 
source [199].  Actin stress fibers formed in sub-confluent re-oxygenated hypoxic cultured 
aortic endothelial cells.  In this study actin fiber formation was inhibited by 
overexpression of superoxide dismutase, suggesting a key role for the sustained presence 
of superoxide [200].  In migrating mouse aortic endothelial cells, incorporation of actin 
monomers into actin fibers was diminished following treatment with the NADPH oxidase 
inhibitor diphenylene iodonium (DPI) and a superoxide dismutase mimetic [201].  In the 
protrusions of epithelial cells, treatment of cells with H2O2 resulted in increased actin 
polymerization, increased cofilin activity, and increased barbed ends; interestingly, 
myosin IIA did not co-localize with actin fibers in protrusions of H2O2-treated cells 
[202].  In addition to its role in actin remodeling, ROS may increase endothelial 
permeability through mediating the phosphorylation of adherens junctions proteins.  
Phosphorylation of adherens junction proteins is associated with junction disruption; 
treatment of cultured endothelial cells with permeability agonists, such as VEGF and 
histamine, results in tyrosine phosphorylation of VE-cadherin [203, 204].  In HUVECs, 
treatment with the ROS scavenger N-acetyl-L-cysteine (NAC), prevented the 
phosphorylation of VE-cadherin following TNF-α [205].  In HUVECs, transduction with 
a constitutively active form of Rac (Tat-RacV12) resulted in actin fiber formation, 
increased ROS production, increase monolayer permeability and phosphorylation of α-
catenin but not VE-cadherin; α-catenin phosphorylation was diminished through ROS 
scavenging by NAC [206].   
One well-characterized inducer of ROS in endothelial cells is phorbol 12-
myristate 13-acetate (PMA, also known as 12-O-tetradecanoylphorbol-13-acetate or 
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TPA).  PMA is known to increase ROS production in endothelial cells; 1 μM of PMA 
resulted in near-immediate increased detection of ROS in HUVECs [193].  Bovine 
pulmonary artery endothelial (BPAEC) monolayer integrity, as measured by TER, was 
maximally disrupted by 100 nM PMA after ~90 mins of treatment [207].  Junction loss 
has been observed at even earlier timepoints (30 min) in other endothelial cell types 
[208].  In BPAEC, actin fibers formed within 5 minutes of treatment and eventually 
formed a grid-like pattern; only stress fibers formed in human pulmonary endothelial 
cells (HPAEC) without formation of the actin grid.  Both mono-phosphorylated (Ser19 p-
MLC) and di-phosphorylated (Ser19/Thr18 pp-MLC) MLC co-localized with actin fibers.  
However, in this study PMA did not increase overall phosphorylated MLC by Western 
blot or MLCK activity, and did not induce wrinkling of the silicon membrane to which 
the cells were attached (indicating lack of contractility) [207].  In a separate study using 
BPAEC, PMA did not induce MLC phosphorylation but did increase monolayer 
permeability [144].  Actin fiber redistribution aside from contractility may be key in 
PMA-induced endothelial permeability, as stabilizing actin fibers with phalloidin 
prevented PMA-induced monolayer disruption by TER [209].  PMA initiates intracellular 
signaling through interaction with protein kinase C (PKC) [210].  Activation of PKC 
occurs rapidly; after 5 minutes of treatment with 100 nM PMA, 95% of total PKC was 
found in the membrane fraction of confluent BPAECs, indicating activation [211].  
Blocking PKC using calphostin C prevented monolayer disruption produced by PMA 
[212].  These studies suggest PMA-induced ROS production causes endothelial junction 
disruption due mainly to actin redistribution instead of increased contractility.   
 
28 
 
 
1.4.4. Evidence for substrate-dependent adherens junction disruption and ROS 
production 
While stiffer substrates have been shown to decrease endothelial barrier function 
in vitro, few studies have investigated the role of substrate stiffness on cytokine-induced 
endothelial permeability.  Increasing substrate stiffness from 2.5 to 10 kPa increased the 
permeability of an unstimulated bovine aortic endothelial cell (BAEC) monolayer 
through a ROCK-dependent mechanism.  In vivo, aged mice (20-25 months) showed 
increased subendothelial stiffness by atomic force microscopy (AFM) and greater 
permeability to Evan’s blue dye compared to young mice (9 weeks) [134].  In groups of 
confluent HUVECs, thrombin produced greater traction forces and cells experienced 
greater separation on 11 and 90 kPa PA gels compared to 1.2 kPa gels [213].  One in vivo 
study tested the hypothesis that lung stiffening due to lysyl oxidase ECM cross-linking 
worsened permeability in response to LPS.  Mice treated with the irreversible LOX 
inhibitor β-aminopropyl nitrile (BAPN) showed decreased LPS-induced pulmonary 
uptake of injected Evan’s blue dye.  Interestingly, BAPN treatment also lessened the 
expression of the RhoGEF GEF-H1 following LPS administration [214].   
There is also support in the literature for the hypothesis that substrate stiffness 
will increase agonist-stimulated ROS production.  In sub-confluent epithelial cells, 
treatment with matrix metalloproteinase 3 (MMP3) induced more ROS with increasing 
substrate stiffness between 130 and 4020 Pa through a Rac1b-dependent mechanism.  
Specifically, Rac1b (a highly active variant of Rac1) translated to the membrane on stiff 
substrates but not soft substrates.  In addition, MMP3-induced ROS production was 
eliminated by knock-down of the β1 integrin sub-unit [215].  This suggests a link between 
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substrate stiffness, integrin activation, and ROS production.  It is known that integrin 
activation affects Rac localization to the membrane.  Rac1 was localized to the membrane 
in attached fibroblasts but not fibroblasts in suspension.  In addition, the activity of the 
Rac1 effector PAK was increased following serum stimulation of attached but not 
suspended fibroblasts [216].  Later studies indicated that integrin activation may mediate 
Rac1 localization through control of lipid rafts [217].  Treatment of bovine coronary 
arterial endothelial cells with Fas ligand (FasL) induced the clustering of lipid rafts co-
localized with gp91phox.  Additionally, in bovine small intramural coronary arteries, the 
prevention of bradykinin-induced vasorelaxation by FasL was attenuated by pre-
incubation with apocynin (NADPH oxidase inhibitor) or nystatin (lipid raft disruptor) 
[218].  In fact, NADPH oxidase may localize to caveolae, a subset of lipid rafts.  
Constituents of NADPH oxidase (gp91phox, p47phox, and p22phox) were found in 
caveolae of cultured bovine aortic endothelial cells, and cholesterol depletion inhibited 
production of superoxide following treatment with either TNF-α or angiotensin II [219].  
These studies suggest an integrin-mediated component to NAPDH oxidase control, 
possibly through lipid rafts; yet, the connection between substrate stiffness and ROS 
production in confluent endothelial monolayers has not been well-studied.            
While these studies support a possible role for substrate stiffness in modulating 
endothelial barrier loss in response to permeability agonists through contractile and non-
contractile (ROS-mediated) pathways, additional study is needed to better understand the 
interplay between biomechanical and biochemical stimuli in the inflamed endothelium. 
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1.5.  Endothelial cell stiffness 
1.5.1. Relation to endothelial cell function 
Endothelial cells, in addition to acting as a barrier between the blood and the 
vessel wall, actively control arterial stiffness through production and release of 
vasodilators; as previously mentioned, one key vasodilator is nitric oxide (NO).  While 
changes in the actin fiber structure have been implicated in increased endothelial 
permeability, the actin cytoskeleton is almost a major determinant of endothelial cell 
stiffness.  Endothelial cell stiffness has been linked to the ability to produce NO.  
Stiffness of both human dermal microvascular endothelial cells (HMEC) and an 
immortalized HUVEC cell line (EA.hy926) within confluent monolayers anti-correlated 
with NO concentration over a TNF-α timecourse, as determined by atomic force 
microscopy and the Griess assay, respectively [220].  One proposed reason for this 
observation was disruption of the interaction between eNOS and G-actin, which is known 
to enhance eNOS activity, as G-actin is integrated into actin fibers [221].  Similarly, actin 
fiber disruption by cytochalasin D (thus increasing the available pool of G-actin) 
increased NO production in BAECs within a confluent monolayer [222].  The 
relationship between endothelial stiffening and increased blood pressure due to 
insufficient NO production has recently been termed “stiff endothelial cell syndrome” 
[223].  Thus, improved tools for studying endothelial cell stiffness will enhance the study 
into the mechanisms behind the development of hypertension. 
 
1.5.2. Current analytical techniques 
A wide variety of methods exist to test cell mechanical properties. Through 
techniques such as micropipette aspiration [224, 225], optical tweezers [226, 227], and 
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the optical stretcher [228, 229], forces can be applied across the entire cell to enable 
measurement of whole cell stiffness.  Alternatively, magnetic bead microrheometry 
[230], magnetic twisting cytometry [113, 231], and atomic force microscopy (AFM) 
[232, 233]  apply forces to specific cell locations to measure the stiffness of specific 
cellular regions.  AFM is widely used to measure cell stiffness and is described in detail 
below.  
The atomic force microscope is a multi-functional instrument consisting of a 
cantilever used to apply force to a sample and a laser-based detection system to measure 
the resulting cantilever deflection [232].  It was originally developed in 1986 as a 
modification to the scanning tunneling microscope (STM), which can only examine 
conductive samples.  The AFM enables researchers to study a vast range of materials 
under a variety of conditions in both air and liquid [234].  Briefly, at the end of the 
cantilever is a small tip, usually pyramidal or spherical in geometry.  The instrument 
controls the movement of the cantilever and brings the tip into contact with the sample 
surface.  The control of cantilever movement in the z-direction is generally accomplished 
using two modes:  contact and tapping mode.  In contact mode the tip remains in contact 
with the surface, scanning over areas of the substrate and constructing a topograph.  In 
tapping mode the tip is oscillated over the surface at a user-defined frequency.  AFM is 
often used for studying material mechanical properties (reviewed in [235, 236]).  
Cantilever deflection is detected using a laser beam, which reflects off the cantilever and 
hits a photodiode.  The deflection can be transformed into force using Hooke’s law based 
on the stiffness coefficient of the cantilever.   
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Researchers have adapted the AFM to serve many purposes due to its elegant 
design and ability for high resolution.  Its development and application to numerous areas 
of research have been well reviewed [234, 237].  In addition to the determination of cell 
stiffness [238, 239], other uses include measurement of the elastic modulus for soft and 
stiff materials [240], single molecule recognition and interaction [241, 242], imaging of 
crystals [243], and patterning of molecules with nanoscale resolution [244], among 
several others.  In this work, AFM is used for the measurement of cell, substrate, and sub-
endothelial stiffness.   
 
1.5.3. Dielectrophoresis 
Dielectrophoresis (DEP) is the force induced on a polarizable particle in a 
spatially non-uniform electric field.  When a polarizable object is placed in an electric 
field, charges distribute unevenly across the body to create a dipole. In a uniform electric 
field, this dipole experiences no net force. However, in a non-uniform electric field, the 
forces exerted on each dipole end are unequal, leading to a net force on the dipole. The 
force direction is determined by competition between the induced polarization in the cell 
and the medium. If the cell is less polarizable than the medium, the overall effective 
dipole draws the particle towards the field minimum (negative DEP) [245, 246]. 
Dielectrophoresis (DEP) has been effectively used for many biological 
applications involving bioparticle manipulation. DEP traps immobilized micron sized 
particles, beads and cells, as well as submicron sized viruses into large arrays using both 
positive and negative DEP [245, 247-250].  DEP can separate different cell populations 
based on their dielectric properties. Breast cancer cells have been detected in blood [251], 
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and CD34+ stem cells were enriched from a larger stem cell pool [252]. Additionally, 
DEP has been used to pattern cells on uncoated substrates [253], on microprinted 
adhesive regions [254], or within a three-dimensional hydrogel [255].  DEP has also been 
used to study the morphology and mechanics of floating, unattached cells. Changes in T 
cell membrane architecture, either during stimulation or apoptosis, were measured by 
DEP [256, 257].  High DEP forces stretched cell membranes to the point of failure, 
leading to either cell fission in sea urchin eggs [258] or plasma membrane leakage in 
erythrocytes [259].  Recently, the mechanical properties of a wide variety of suspended 
cell types, including Chinese hamster ovarian cells, U937 human promonocytes [260], 
cancerous (MCF-7) and noncancerous (MCF-10A) breast epithelial cells [261], and 
cervical cancer cells (SiHa and ME180)[262] were measured using DEP devices. Despite 
great interest in biological applications for DEP, dielectrophoretic forces have not been 
used to study global mechanical properties of attached cells.  
 
1.6. Objectives and hypothesis 
Arterial stiffness, as measured by pulse wave velocity in vivo, is an independent 
predictor of future cardiovascular events including the development of hypertension and 
cardiovascular mortality.  In addition, hypertension is a major risk factor for 
atherosclerosis, which develops in part to a loss of endothelial barrier function.   In this 
thesis, arterial stiffness in simulated in vitro using polyacrylamide gel substrates of 
varying stiffness and investigated ex vivo using an elastin haploinsufficient mouse model 
of hypertension.   The central objective of this thesis is to investigate the contribution 
of arterial stiffness to endothelial cell stiffness and barrier loss through increased 
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endothelial cell actinomyosin contractility and reactive oxygen species production.  
The underlying hypothesis are: 
 Dielectrophoresis can be used for measuring changes in single attached cell 
stiffness following actin cytoskeleton disruption 
 Substrate stiffness exacerbates TNF-α-induced disruption of adherens junctions in 
endothelial cell monolayers through increased cell contractility 
 Endothelial cell production of reactive oxygen species is greater on stiff substrates 
than soft substrates 
 
1.7. Thesis organization 
This thesis is composed of five chapters. 
Chapter 1 includes the clinical motivation for this work and a summary of relevant 
background information from the literature, including macroscale aortic structure, cell-
matrix attachment, cell-cell attachment, and endothelial cell stiffness.  The background is 
followed by the aims and organization of this thesis. 
Chapter 2 presents the development of a dielectrophoretic device used to measure 
relative changes in single attached cell deformability, including device simulation and 
microfabrication.  Device operation was validated with atomic force microscopy 
elasticity measurements of single micropatterned cells. 
Chapter 3 presents the effect of increasing substrate stiffness (simulating increasing 
aortic stiffness) on endothelial cell-cell junction loss following treatment with the 
inflammatory molecules tumor necrosis factor alpha and thrombin.  This chapter includes 
the atomic force microscopy characterization of sub-endothelial stiffness of aortae from 
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genetically modified elastin haploinsufficient mice (ELN+/-, a mouse model of 
hypertension), in addition to immunofluorescent microscopy labeling of the mouse aortic 
endothelium. 
Chapter 4 presents the effect of increasing substrate stiffness on endothelial 
production of reactive oxygen species (ROS) and cell-cell junction loss following 
treatment with the protein kinase C (PKC) agonist phorbol 12-myristate 13-acetate 
(PMA).  This chapter also compares PMA-induced actin redistribution in the aortic 
endothelium of wild type and ELN+/- mouse vessels.   
Chapter 5 concludes the thesis with a discussion of contributions to the field and 
future work.   
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2. Microfabrication and validation of a dielectrophoretic device for 
measurement of attached single cell stiffness 
 
2.1. Introduction 
 
Recently, microfabricated lab-on-a-chip devices for the analysis of single cells 
have gained popularity [263].  Many miniaturized devices used to study single cells 
employ microfluidics for high through-put analysis of cell suspensions [264].  However, 
the use of cells in suspension prevents the study of the effects of cell attachment to a 
substrate, as most cell types are attached to the surrounding tissue in the body.  While 
endothelial cells exist in a monolayer in vivo, the study of single attached cells provides a 
simplified system that can be used to separate out the relative contributions of cell-matrix 
and cell-cell interactions.  In addition, the study of multiple single cells provides 
information on the variability among individual cells within a population, as opposed to 
other methods that pool millions of cells and provide aggregate values.  The objective of 
the device presented in this chapter is to measure the stiffness of single attached cells.     
Cell stiffness is mainly determined by the actin cytoskeleton, which has both 
structural and functional roles within the cell.  Along with other cytoskeletal elements, 
such as microtubules and intermediate filaments, actin fibers provide internal structural 
support; actin fibers are under tension while microtubules are thought to bear 
compressive loads [265].  In endothelial cells monomeric actin interacts with the nitric 
oxide (NO) producing enzyme eNOS to enhance NO production [221].  Thus, the 
depletion of monomeric actin through actin polymerization into filaments increases cell 
stiffness while decreasing NO production [222].  Improved analytical tools for measuring 
cell stiffness will improve our understanding of the link between cell stiffness and 
endothelial function. 
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In this chapter, I present the simulation, microfabrication, and testing of an 
inverted quadrupole dielectrophoretic device.  The inverted design of this device is novel 
and grants several advantages to the study of single attached cell stiffness.  Device 
operation was demonstrated in two scenarios:  (1) the comparison of endothelial cells 
with and without actin cytoskeleton disruption and (2) the comparison of tumorigenic 
(MCF-10A NeuT) and non-tumorigenic (MCF-10A) mammary epithelial cells.  Both 
these conditions (actin disruption and induced tumorigenicity in MCF-10A cells) have 
previously been shown to affect cell stiffness [266, 267].  Device validation was 
demonstrated through comparison with the gold standard for attached cell stiffness, 
atomic force microscopy.    
   
2.2. Methods 
 
2.2.1. Electric and force field modeling 
 
A quadrupole electrode configuration was simulated using the three-
dimensional AC/DC module of COMSOL Multiphysics software (version 4.3a). The 
quadrupole electrode device was designed as four opposing electrodes (40 µm 
diameter) with a central space (60 µm diameter) large enough to enable the electrodes 
to be lowered over a single attached cell. Since the device is symmetrical, half of the 
device was modeled in COMSOL.  Voltages and ground were set as shown in Figure 
2.1a.  A range of voltages was simulated using the root mean square voltage 
corresponding to each peak-to-peak voltage (Vpp) in Table 2.1 [268].  Frequency was 
set to 1 MHz.  Distributed impedance boundary conditions were set along the sides 
and top of the modeled electrode, and the bottom surface was set as an electrically 
insulating boundary. The DEP force was defined as [269]: 
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where εm, r, ω, and E are relative medium permittivity, cell radius, angular frequency, 
and electric field strength, respectively.  For a spherical particle, the Clausius-Mossotti 
factor (CM) was defined as:  
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where εp* and εm* are the complex permittivities of the particle and the medium, 
respectively.  The complex permittivity of the medium was calculated as:   
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where is σm the conductivity of the medium [253].  The complex permittivity of the cell 
was determined using the spherical shell model: 
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where εs* and εint* are the complex permittivities of the cell shell (membrane) and cell 
interior, respectively, and d is the width of the cell membrane.  As derived in [270], 
this equation simplifies to: 
 
ߝ௣∗ ൌ ݎ ൤ܥ௦௣௘௖ െ	݆ܩ௦௣௘௖߱ ൨ 
 
where Cspec and Gspec indicate the specific membrane capacitance and the specific 
membrane conductance, respectively.  The dielectric properties of mammalian cells, 
specifically HL-60 cells, have been published in the literature [262, 271].  In our 
model, specific membrane capacitance and specific membrane conductance were set 
to 0.016 F/m2 and 2200 S/m2, respectively [272]. Cell culture medium conductivity 
(σm) and permittivity (εm) were defined as 1.5 S/m and 80, respectively, based on our 
measurements and the literature [273]. The cell conductivity and permittivity were 
defined as 0.75 S/m and 75 [274].  Cell radius was set as 10 μm.  
 
2.2.2. Device design and fabrication 
The quadrupole DEP device was manufactured using standard microfabrication 
techniques. Square glass substrates (2” x 2”) were selected for the device base to allow 
for cell observation using an inverted microscope. The device photomask was designed in 
AutoCAD and printed at high resolution onto a transparent film (JD Photo-Tools). A 4” x 
4” chrome plate pre-coated with negative SU-8 photo resist (Telic) was exposed to 
ultraviolet light through the transparency mask, baked, and developed to produce the 
patterned chrome mask. The chrome mask was then used to create the electrodes by 
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sequential deposition of titanium and gold, where titanium was used to enhance gold 
adhesion to glass [253, 274]. Futurrex NR9-1000PY (Futurrex) was chosen as the 
photoresist since it can withstand the high temperatures required for metal deposition. 
Titanium and gold were then sequentially deposited by physical vapor deposition in a 
thermal evaporator (Thermionics VE 90) at 20 nm and 200 nm thickness, respectively.  
Photoresist and excess metal were removed using RDG developer. 
Electrical leads were created by soldering copper wire strands onto electrode 
connector pads. The soldered pads were strengthened and sealed from the cell medium by 
curing a thin layer of polydimethlysiloxane (PDMS, Sylgard, Dow Corning) over the 
connector pads.  Electrode thickness was then increased by gold electroplating.  The 
device was submerged in non-cyanide gold electroplating solution (Technigold 25E 
RTU, Technic) maintained between 60-70°C with constant stirring.  Gold was deposited 
by pulse plating (500 mVpp) with a 10% duty cycle using a function generator (BK 
Precision 4010) at a deposition rate of approximately 0.013 μm/minute.  Final electrode 
thickness following electroplating was confirmed by optical profilometry (Zygo 
NewView 6000).         
 
2.2.3. Polyacrylamide gel micropatterning 
PDMS stamps for microcontact printing were fabricated using standard soft 
photolithography methods.  Transparency film photomasks with a 25 µm diameter circle 
array were printed (JD Photo-Tools).  SU-8 2025 (Microchem) was spin-coated on a 
glass substrate, soft baked, exposed for 3 minutes using a UV lamp (NuArc 26-1K 
Mercury Exposure System), post-exposure baked, developed in SU-8 developer and then 
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hard baked.  To ease PDMS release, the SU-8 mold was coated with (tridecafluoro-
1,1,2,2-tetrahydro octyl)-1-trichlorosilane (UCT) by vapor deposition.  PDMS was mixed 
using a 10:1 ratio of base to curing agent, degassed, poured onto the mold and cured at 
70°C for at least three hours. 
Micropatterned polyacrylamide (PA) gels were made by indirect microcontact 
printing [275].  A top coverslip was patterned with fibronectin using a PDMS stamp.  
Stamps were incubated with a mixture of biotinylated tetramethylrhodamine-BSA (5 
µg/mL, Invitrogen) for pattern visualization and biotinylated human plasma fibronectin 
(50 µg/mL, Gibco) for 40 minutes.  The protein solution was then removed from the 
stamps, which were dried and immediately placed onto plasma-cleaned glass coverslips 
(5 mm for DEP device samples or 12 mm for AFM samples) for 5 minutes.  A 
streptavidin polyacrylamide (PA) gel solution was created by adding 0.1 mg/mL 
streptavidin-acrylamide (Invitrogen) to a PA solution of 10% acrylamide (BioRad), 0.3% 
bis-acrylamide (BioRad), 1% ammonium persulfate (BioRad), and 0.3% TEMED 
(BioRad).  A bottom coverslip was activated by sequential incubation in 0.1 M NaOH 
(Sigma Aldrich), (3-aminopropyl)trimethoxysilane (Sigma Aldrich), and  0.5% 
glutaradehyde (Polysciences) for 30 minutes.  The streptavidin-PA solution was added to 
the bottom coverslip, after which the micropatterned top coverslip was quickly inverted 
over the polymerizing gel.  Polymerization was completed in a 37°C, 5% CO2 incubator 
for 15 minutes, after which the top coverslip was removed.  The micropatterned PA gel 
was then rinsed thoroughly and stored in PBS at 4°C for a maximum of 2 days prior to 
use.   
 
42 
 
 
 
2.2.4. Cell culture 
Primary porcine aortic endothelial cells (PAEC) were isolated by the collagenase 
dispersion method and cultured in low glucose Dulbecco’s Modified Eagle’s medium 
(DMEM, Corning) supplemented with 5% fetal bovine serum (Hyclone), 1% glutamine, 
and 1% penicillin-streptomycin (Invitrogen). Cells were used up to passage 8.  Mammary 
epithelial cells (MCF-10A) and transformed mammary epithelial cells (MCF-10A NeuT) 
were a gift from Dr. Adrian Shieh.  Cells were maintained in DMEM/F12 (Corning) 
supplemented with 5% horse serum (Atlanta Biologicals), 20 ng/mL epidermal growth 
factor (Peprotech), 500 ng/mL hydrocortisone (Sigma), 10 ng/mL cholera toxin (Enzo 
Lifesciences), 10 μg/mL insulin (Sigma), and 1% penicillin-streptomycin (Invitrogen).  
Cells were released from tissue culture dishes with trypsin, seeded onto micropatterned 
PA gels, and allowed to attach for 30 minutes. Unattached cells were then removed by 
replacing the medium.  Cells were then incubated on the micropatterned PA gels for 16-
24 hours prior to mechanics testing.  For both AFM and DEP device testing, cells were 
transferred into serum-free CO2-independent medium (Invitrogen).  In some samples, the 
actin cytoskeleton was disrupted with 200 nM cytochalasin D (Sigma Aldrich) for 15 
minutes at room temperature in serum-free CO2-independent medium. 
 
2.2.5. Immunofluorescence 
Endothelial cells attached to a micropatterned PA gel were fixed using 4% 
paraformaldehyde (Sigma Aldrich), permeabilized using 0.1% TritonX-100 (EMD 
Millipore) and rinsed using PBS.  To prevent non-specific binding, samples were blocked 
with 1% BSA in PBS.  Cells were labeled for vinculin using a primary mouse anti-
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vinculin antibody (1:100, Sigma), followed by an AlexaFluor 488 anti-mouse secondary 
antibody (1:100, Invitrogen).  Actin and nuclei were labeled using rhodamine phalloidin 
(16.5 nM, Invitrogen) and bisbenzimide (0.2 μg/mL, Invitrogen), respectively.  Images 
were taken using an Olympus Fluoview 1000 confocal microscope.  
 
2.2.6. Atomic force microscopy 
Atomic force microscopy (AFM, Veeco Bioscope) was used to validate DEP 
device cell stiffness measurements (elastic modulus). A silicon nitride cantilever with 1 
µm spherical tip (196 µm long, 23 µm wide, 600 nm thick, spring constant 0.06 N/m, 
Novascan) was used to indent each measured cell at three distinct locations. Relative 
stiffness was estimated by fitting the first 200 nm of the indentation curves to the Hertz 
model as previously described [276]. Three measurements per cell were averaged and 
defined as the cell stiffness. 
 
2.2.7. Sequential application of DEP “pushing” and “centering” forces 
First, a micropatterned single cell array on a PA gel was mounted on an inverted 
Olympus IX81 fluorescent microscope. The extruded quadrupole DEP device was 
attached to a micromanipulator (Eppendorf), and the electrodes were lowered over a 
single cell. The cell was positioned in the device center with the electrodes approximately 
10 µm above the cell.  
      A directed DEP “pushing” force, created by applying unequal voltages to two 
opposing electrodes, was used to deform the cell in a specified direction.  Electrical 
potential was applied using a function generator (BK Precision 3011B) set to 21 Vpp, 1 
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MHz; the other two electrodes were grounded.  The function generator positive lead was 
diverted into two separate lines, each going to a resistance decade box before connecting 
to diagonally opposing device electrodes.  With no extra resistance applied, opposing 
electrodes received the same voltage.  As resistance between the function generator and 
one of the electrodes was increased using the resistance decade box, unequal volt ages 
were applied to opposing electrodes which created the directed DEP pushing force. Thus, 
increasing resistance to one electrode controlled pushing force magnitude and direction. 
A DEP “centering” force, created by applying equal voltage to two opposing electrodes, 
was used to return the cell to its original position in the device center.  
     The directed DEP pushing force was applied to a cell for 15 seconds. The decade box 
resistance was then returned to zero for the next 15 seconds to apply the DEP centering 
force. For each test sequence, 15 seconds of directed pushing force was followed by 15 
seconds of centering force. 
 
2.2.8. Image processing 
 
During pushing sequences, brightfield images were taken every 0.5 seconds.  
Image processing was completed using Matlab’s Image Processing Toolbox 
(Mathworks).  Image sequences were cropped to include the area immediately 
surrounding the cell.  Each cropped frame in the image sequence was then binarized to 
isolate the cell body as a single connected component.  The threshold for binarization was 
determined by Otsu’s method using the “greythresh” function [277].  If needed, a 
multiplier was used to adjust the threshold for a sequence to prevent any debris in the 
vicinity from being counted as part of the cell.  The two-dimensional cell centroid was 
determined for each frame using Matlab’s “regionprops” function. Cell centroid 
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displacement was quantified by measuring the distance between the cell centroid and the 
lower left corner of the cropped image.  The lower left corner of the cropped image was 
chosen because directed DEP pushing force was consistently applied towards the upper 
right corner of the image; thus, when the cell deformed, the distance between the cell 
centroid and the lower left corner of the image increased.  All measurements were then 
normalized relative to the initial cell position at the beginning of the pushing sequence. 
 
2.2.9. Statistical Analysis 
 
Statistical analyses were conducted using Matlab’s statistics toolbox.  Data are 
shown as mean ± standard deviation.  Experiments were performed in duplicate, and the 
number of cells per experiment is indicated in the figure caption.  For data shown in 
Figure 5c and 6c, Student’s t-test was used to compare two groups.  Comparison of 
multiple groups in Figures 5b and 6b was completed using two-way ANOVA with a 
Tukey-Kramer post-test.  Statistical significance is indicated by #p<0.05, *p<0.01, or 
**p<0.001.           
 
 
2.3. Results 
2.3.1. DEP device modeling 
The extruded quadrupole DEP device was modelled in three dimensions in 
COMSOL to simulate DEP forces (Figure 2.1a).  The set of voltages given in Table 2.1 
was evaluated, corresponding to the increasing resistance applied between the power 
source and Electrode 2.  The simulation predicted that a cell in the device center would 
experience negative DEP, toward the lower voltage Electrode 2, as is expected for cells in 
highly conductive media [278]. As an example, the simulation results for 2000 Ω are 
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given in Figure 2.1.  The electric field strength was highest near the higher voltage 
Electrode 1 (Figure 2.1b).  Figure 2.1c indicates the predicted DEP force in the x-
direction that would be experienced by a cell centered at each location within the device.  
DEP force in the x-direction is toward the right near Electrode 1 and toward the left near 
Electrode 2 (Figure 2.1c).  For a cell positioned in the device center (indicated by the 
asterisk), DEP force is directed toward Electrode 2 because the higher voltage at 
Electrode 1 moves the location of zero force towards Electrode 2.We refer to this force at 
the device center with unequal applied voltages as the directed DEP “pushing” force. 
 
 
Figure 2.1.  COMSOL simulation results predicted negative DEP pushing force in the center of 
an inverted quadrupole device (a) Half of an inverted quadrupole DEP device was modelled, 
taking advantage of the device symmetry.  Voltage at Electrode 1 was held constant while voltage 
at Electrode 2 was varied.  The asterisk (*) indicates the approximate cell position in relation to 
the electrodes, 10 μm beneath the inverted device. (b) Predicted electric field strength. Arrows 
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indicate the relative magnitude and direction of the electric field in the center xz-plane between 
Electrodes 1 and 2.    (c) Predicted DEP force. The DEP force magnitude in the x-direction 
predicted for a cell centered at each location in the device in the xz-plane at the device center.  
Positive values indicate net force toward the right, while negative values indicate net force toward 
the left at each location.  Cell radius was 10 μm. (d) DEP force in the x-direction at the device 
center in the xz-plane was evaluated at increasing intervals below the device.  DEP force was 
consistent at x=0 at distances between 2 and 10 μm away from the device. 
 
Directed DEP pushing force was plotted as a function of position along the x axis 
connecting Electrodes 1 and 2 at increasing distances from the device surface.  Figure 
2.1d shows the predicted DEP forces for 2000 Ω, when 21 Vpp (7.42 Vrms) was applied 
to Electrode 1 and 13.6 Vpp (4.81 Vrms) was applied to Electrode 2.  As expected, the 
directed DEP pushing force magnitude was greatest near the high voltage Electrode 1 and 
closest to the device surface (2 μm).  However at the device center where the cell is 
positioned (x=0), directed DEP pushing force remained approximately 0.35 nN in the x-
direction from 2-10 μm below the device surface, at this applied voltage. The model 
therefore predicts that small deviations in the electrode z position would have little effect 
on the DEP force experienced by the cell.  
Table 2.1. Applied DEP force for varied voltages across opposing electrodes. The voltage at 
Electrode 2 was lowered by applying increasing levels of resistance (shown in the first column) 
between the power source and the electrode.   
Resistance (Ω) 
Voltage at Electrode 1 
(Vpp) 
Voltage at Electrode 2 
(Vpp) 
Predicted DEP force 
(nN) 
100 21 20.7 0.02 
200 21 20.5 0.03 
300 21 20.3 0.04 
400 21 19.8 0.07 
1000 21 17.8 0.17 
2000 21 13.6 0.35 
3000 21 10.7 0.44 
4000 21 8.3 0.51 
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     Table 2.1 summarizes the predicted DEP pushing forces experienced by the cell in the 
device center, 10 μm below the device surface.  Predicted directed DEP pushing forces 
ranged from 0.02 to 0.51 nN.  These forces are similar to those generated in other single 
cell mechanics devices.  For example, single suspended fibroblast deformation was 
achieved using approximately 0.2 to 0.5 nN in an optical stretching device [279].  Red 
blood cells were stretched with optical tweezers by applying forces of up to 0.056 nN to 
opposite sides of each cell [226].  Micropipette aspiration applies between 10 pN and 1 
nN depending on the cell type [280]. Magnetic tweezers can also apply forces within the 
same range, from 10 pN to more than 1 nN [281].  Atomic force microscopy using large 
25 μm spherical tips has also been used to evaluate whole cell stiffness by applying nN-
magnitude forces [282]. 
 
2.3.2. DEP device microfabrication and experimental set-up 
The fabricated DEP device consisted of a quadrupole electrode configuration on a 
single glass microscope slide (Figure 2.2a). The electrodes increased in width as they 
extended outward from the quadrupole at a 45° angle, finally attaching to a 2 mm square 
electrode pad for connecting wires to function generators. Magnified images of a single 
quadrupole electrode show well-defined rounded electrode tips (Figure 2.2b, c).  The 
final electroplated device thickness was 1.1 µm, as measured by optical prolifometry 
(Figure 2.2d).  The DEP device was connected to a function generator using 2 resistance 
decade boxes so that voltage could be modulated across opposing electrodes while 
maintaining the electrodes in phase (Figure 2.2e). The device was then attached to a 
micromanipulator arm, which was assembled on a microscope stage. The 
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micromanipulator was used to center and lower the DEP device over a polystyrene bead 
or single micropatterned cell, using the microscope for manual optical guidance (Figure 
2.2f). 
 
Figure 2.2.  Microfabricated DEP device and experimental set-up. (a) Microfabricated DEP 
device showing one set of quadrupole electrodes with wire connection pads, (b) and (c) magnified 
images of a quadrupole device showing four electrodes and center space, and (d) optical 
profilometer image of the ~1.1 μm extruded gold electrodes. (e) Electrical connections diagram. 
Opposing electrodes were connected to a single function generator using two resistance decade 
boxes to modulate applied voltage without altering phase. (f) Device schematic, with gold 
electrodes on glass substrate inverted over single cell array on PA gel. 
 
Operation of the inverted device was tested in preliminary studies by placing the 
electrodes over a single 10 μm polystyrene bead in suspension (Figure 2.3a).  When 10 
Vpp was applied to both electrodes, the bead was trapped in the device center where DEP 
force was zeo (Figure 2.3b).  When the resistance to the upper right electrode was 
increased (4, 40 or 400 kΩ), the voltage to that electrode was effectively decreased (4, 
1.4, and 1.2 Vpp, respectively).  Initially, the bead was pushed out of the device center by 
the directed DEP pushing force. The bead then became trapped in the zero DEP force 
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location (Figure 2.3c).  Brightfield image frames taken every 0.5 seconds were processed 
to measure bead movement following application of DEP force.  The bead moved faster 
and further with increasing electric field gradient strength (Figure 2.3d).   
 
Figure 2.3.  A polystyrene bead (10 μm in diameter) was manipulated using inverted electrodes.  
(a) Schematic illustrating the center of the electrodes as the device is lowered over a single 
polystyrene bead.  A single bead was first trapped (b) then pushed (c), scale bar is 25 μm.  Red 
arrows indicate the direction of the forces applied to the bead based on the voltages applied to the 
electrodes (either 1.2Vpp or 10 Vpp).  A video of bead manipulation was captured and 
deconstructed into individual frames.  (d) Analysis of bead movement between frames showed 
increasing velocity and distance with increasing electric field gradient. 
 
To prepare cell samples for testing with the inverted DEP device, single cells of 
defined spread area were created using micropatterned PA gels. An indirect 
micropatterning technique produced an array of 25 µm diameter fibronectin circles, with 
TMR-BSA added to the fibronectin to enable fluorescent imaging (Figure 2.4a).  The 
average spot diameter on a typical patterned PA gel was 24.9 ± 3.1 μm. Cells were 
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seeded on the micropatterned PA gels and incubated overnight, resulting in single cell 
arrays (Figure 2.4b). Cell adhesion quality was confirmed by labeling cells for vinculin 
and actin and imaging samples by confocal microscopy at the cell base. Punctate vinculin 
colocalized with peripheral actin fibers suggested that single cells on micropatterned PA 
gels formed focal adhesions by 16 hours (Figure 2.4c). 
 
 
Figure 2.4.  Porcine aortic endothelial cells were micropatterned onto 25 µm fibronectin circles to 
control spread area while allowing cell attachment. (a) Fibronectin (with TMR-BSA to enable 
fluorescent imaging) circles were patterned onto a PA gel by an indirect micropatterning 
technique.  (b) Cells adhered and spread on fibronectin circles following overnight incubation.  
Only circles with a single attached cell were used for analysis.  (c) A single cell attached to the 
micropatterned PA gel exhibited punctate focal adhesions (vinculin antibody, green) colocalized 
with peripheral actin fibers (rhodamine phalloidin, red). 
 
2.3.3. DEP device validation 
A single adhered porcine aortic endothelial cell was sequentially deformed using 
increasing DEP forces (increasing ΔV across opposing electrodes). The extent of cell 
centroid displacement was quantified by image analysis.  Figure 2.5a and 2.5b show 
representative pre-processed cell images before and during the pushing force, 
respectively.  The corresponding binarized images, which were used to find the cell 
centroid displacement at each time frame, are shown in Figure 2.5c and 2.5d.      
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When voltage to Electrode 2 was lowered, the cell centroid moved toward the low 
voltage electrode (in the predicted DEP force direction). When the same voltage was 
restored to both electrodes, the cell centroid recovered towards its original position. As 
the voltage was lowered further on Electrode 2, and therefore the applied DEP force 
increased, cell centroid movement also increased.  For 0.3 ΔV (predicted force 0.02 nN), 
the cell centroid moved 0.64 μm, whereas at 12.7 ΔV (predicted force 0.51 nN), the cell 
centroid moved 1.5 μm (Figure 2.5e). Cell centroid movement plateaued at 7.4 ΔV 
(predicted force 0.35 nN). From these data, 0.5, 1.2, and 7.4 ΔV (predicted forces 0.03, 
0.07, and 0.35 nN) were selected for future experiments since they were within the linear 
deformation range (Figure 2.5e). 
 
Figure 2.5.  Cell deformation increased with applied directed DEP pushing force, up to a 
maximum deformation level. Increasing directed DEP forces (different voltage on opposing 
electrodes) were applied to deform a single cell for 15 seconds each, with 15 seconds of restoring 
“centering force” (same voltage on opposing electrodes) applied between each deformation. 
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Brightfield images were taken every 0.5 seconds. Representative brightfield images are shown 
before (a) and during (b) the pushing force application. Images were converted to binary in 
Matlab (c and d).  The cell centroid was defined in each image, represented by a diamond in (c) 
and a circle in (d). Cell deformation was quantified as the change in distance between the cell 
centroid and a defined point outside the cell.  (e) Directed DEP pushing forces of increasing 
magnitude were sequentially applied to a single micropatterned porcine aortic endothelial cell.    
 
Porcine aortic endothelial cells were treated with cytochalasin D to determine if 
the DEP device could measure stiffness changes among cells. Cytochalasin D inhibits 
actin polymerization and is known to decrease cell stiffness [266].  Untreated endothelial 
cells showed average centroid displacements of 0.47, 0.62, and 0.88 µm with predicted 
DEP forces of 0.03, 0.07 and 0.35 nN (Figure 2.6b). Centroid movement increased 58 - 
64% in cytochalasin treated cells. Interestingly, cell centroid restoration to the center 
position was slower in cytochalasin treated cells (Figure 2.6a). This observation supports 
the role of the actin cytoskeleton in cell elasticity, while the cytosol exhibits viscous 
properties [283]. In fact, treatment of adherent endothelial cells with 0.1 μg/mL (~2 μM) 
cytochalasin D has been shown to decrease stiffness while having little effect on cell 
viscosity by magnetic twisting cytometry [284]. AFM confirmed that cytochalasin 
treatment decreased stiffness of micropatterned cells. The calculated cell elastic modulus 
in cytochalasin treated cells was 6-fold lower than untreated cells (0.3 vs. 1.8 kPa, Figure 
2.6c).   
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Figure 2.6.  When the actin cytoskeleton was disrupted with cytochalasin D, cell centroid 
displacement in response to applied DEP force increased as compared to untreated cells. (a) 
Porcine aortic endothelial cells were incubated on micropatterned PA gels overnight, and then 
treated with 200 nM cytochalasin D for 15 minutes at room temperature. Single untreated and 
treated cells were subjected to six sequential pushing forces (three DEP force magnitudes, two 
pushes per force magnitude) for 15 seconds each. Representative data for one untreated and one 
treated cell. (b) Cell centroid displacement was quantified at each predicted DEP force.  Data are 
mean ± standard deviation (n = 3 cells per condition, 2 deformations per cell at each force level).  
#p < 0.05, *p < 0.01, **p < 0.001 compared to untreated values at each force level, unless 
brackets indicate otherwise (Tukey’s test).  (c) Identically treated cells were indented by AFM 
using a silicon nitride cantilever with 1 µm spherical tip to measure cell elastic modulus. Cell 
modulus was estimated by fitting the first 200 nm of the indentation curve to the Hertz model 
(*p< 0.01, n = 6 cells per condition).    
 
Finally, the DEP device was used to measured changes in cell stiffness among 
normal (MCF10A) and cancerous (MCF10A-NeuT) breast epithelial cell phenotypes. 
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MCF10A-NeuT cell centroid displacement was 61-84% higher than MCF10A cells, with 
larger differences at higher applied DEP forces (Figure 2.7a, b). Similarly by AFM, the 
modulus of MCF10A cells was 56% higher than the modulus of MCF10A-NeuT cells 
(Figure 2.7c). These data confirm that the DEP device can detect cell stiffness differences 
among different cell types.   
 
 
 
Figure 2.7.  MCF10A-NeuT cells showed greater cell centroid displacement than MCF10A cells 
by DEP, as well as lower cell modulus by AFM. (a) Micropatterned MCF10A and MCF10A-
NeuT cells were incubated on micropatterned PA gels overnight. Single cells of each type were 
subjected to six sequential pushing forces (three DEP force magnitudes, two pushes per force 
magnitude) for 15 seconds each. Representative data for one MCF10A and MCF10A-NeuT cell. 
(b) Cell centroid displacement was quantified at each predicted DEP force.  Data are mean ± 
standard deviation (n = 3 cells per condition, 2 deformations per cell at each force level).  #p < 
0.05, *p < 0.01, comparing cell types at each force level, unless brackets indicate otherwise 
(Tukey’s test).  (c) A second set of cells were indented by AFM using a silicon nitride cantilever 
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with 1 µm spherical tip to measure cell elastic modulus. Cell modulus was estimated by fitting the 
first 200 nm of the indentation curve to the Hertz model (* p < 0.01, n = 7 cells per cell type).     
 
2.4. Discussion 
 
2.4.1. Advantages and applications 
 
These data demonstrate for the first time how an inverted DEP device can 
measure the stiffness of a material placed underneath the device, in our case a single 
attached cell. The inverted device configuration is an innovative feature that significantly 
increases device capabilities.  First, it enables analysis of attached cells while not 
necessitating that the cells be attached to the device surface.  Thus, within a single 
experiment the same DEP device can analyze multiple cells in series simply by changing 
the device position using the micromanipulator arm.  In addition, the DEP device can 
analyze cells attached to different substrates; the user can easily vary substrate 
parameters, such as stiffness or ECM coating, using PA gels. The DEP device could even 
be lowered over a cell attached to a tissue, for example an extravasating monocyte, to 
measure its stiffness. By inverting the DEP device, we can take advantage of the forces 
induced beneath inverted DEP electrodes and thus create even greater functionality and 
flexibility of lab-on-a-chip microdevices. 
      Beyond pushing single attached cells to analyze relative cell stiffness, an inverted 
quadrupole DEP device could be used to trap and pattern cells or other particles in 
suspension.  Recently dielectophoretic tweezers or single electrodes attached to 
micromanipulators have been used to capture and release cells in suspension [285, 286].  
This inverted DEP device could be used in a similar matter to trap, move, and release 
cells at desired locations through device movement using a micromanipulator. 
Furthermore, by varying the voltages applied to opposing electrodes, a suspended, 
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trapped cell could be shifted out of the device center (e.g., towards the lower voltage 
electrode) to increase device resolution.  As has been suggested for DEP tweezers, this 
inverted quadrupole DEP device could enhance the establishment of stably transfected 
cell lines through quickly and selectively isolating individual fluorescent protein 
expressing cells [287].  In addition, such cell manipulation capability could be useful in 
sorting cells into microwell arrays, ensuring single cell occupancy and enabling single 
cell assays [288]. 
 
2.4.2. Limitations and potential improvements 
      Despite the inverted device advantages, the current configuration has limited 
through-put. The inverted DEP device can only measure one cell at a time due to the 
limiting step of detecting and quantifying cell deformation by microscopy and image 
analysis, respectively. A non-optical detection system would enable a microarray of 
inverted quadrupole electrodes.  Recently, impedance sensors have been integrated into 
DEP cell trapping device to replace optical determination of trapping efficiency [289].  
Ideally, single attached cell centroid displacement could be quantified through a similar 
completely electrical detection system.  Thus an array of inverted DEP electrodes with a 
non-optical detection system has potential to increase the throughput of attached cell 
stiffness measurements.    
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3. Effect of substrate and arterial stiffness on endothelial adherens 
junctions in response to inflammatory permeability agonists 
 
3.1. Introduction 
 
A key function of the endothelium is the ability to act as an effective barrier 
between the blood and the blood vessel wall.  Loss of endothelial barrier function has 
been implicated in atherosclerosis, cancer metastasis, and pulmonary disease [290, 291].  
In atherosclerosis, endothelial permeability contributes to atherosclerotic plaque 
development by allowing lipoprotein diffusion and immune cell extravasation into the 
sub-endothelium, both of which contribute to plaque growth [24, 26, 292].  Thus better 
understanding of the mechanisms underlying endothelial barrier loss has potential to 
prevent the initiation and halt the progression of atherosclerosis. 
   The roles of both inflammation and arterial stiffening in atherosclerosis have 
been studied separately, but their compounded effects on endothelial barrier function 
have not been extensively investigated.  Atherosclerosis is well-accepted as an 
inflammatory disease [293].  Tumor necrosis factor alpha (TNF-α) is one of many 
inflammatory cytokines known to increase endothelial permeability in vitro and in vivo 
[185, 294].  In middle-aged men, TNF-α blood levels correlated with intima-media 
thickness (an indicator of atherosclerosis), and atherosclerosis was more prevalent in 
elderly individuals with elevated plasma TNF-α levels [295, 296].  In addition, 
individuals with rheumatoid arthritis exhibited decreased intima-media thickness 
following one year of anti-TNF-α therapy [297]. 
Arterial stiffening has long been viewed as a consequence of pathological 
vascular remodeling; however, recent studies revealed that early arterial stiffening is also 
a predictor of future hypertension and atherosclerosis [298, 299].  Based on data from the 
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Framingham Heart Study, a large ongoing longitudinal cardiovascular study that began in 
1948, increased pulse wave velocity (PWV, a non-invasive clinical measurement of 
arterial stiffness) was found to be an independent indicator of future cardiovascular 
events [7].  In another study on the general population, aortic PWV was found to be a 
significant predictor of cardiovascular mortality and development of coronary heart 
disease, which is characterized by atherosclerotic plaque development in the coronary 
artery [9, 300, 301].  These clinical results suggest arterial stiffening may contribute to 
endothelial barrier loss in atherosclerosis pathogenesis.   
Both TNF-α and sub-endothelial stiffening induce increased actinomyosin cell 
contractility in vitro, leading to increased monolayer permeability [134, 184].  TNF-α 
induces cell contractility via Rho/ROCK, which increases permeability in some 
endothelial cell sub-types [184, 188, 302-304].  Substrate stiffness induces cell 
contractility via Rho/ROCK, which increases untreated endothelial monolayer 
permeability [134, 146]. While both TNF-α and substrate stiffness increase permeability 
via Rho/ROCK, the combined effect is poorly understood. There have been published 
reports that thrombin-induced endothelial contractility signaling and cell-cell junction 
loss increases with substrate stiffness [146, 147].  Thus, thrombin was used as a positive 
control in this study.           
Based on published in vitro data suggesting that both substrate stiffness and 
inflammation increase cell contractility, we hypothesized that increased sub-
endothelial stiffness enhances TNF-α and thrombin-induced cell-cell junction 
tension and monolayer permeability.  This hypothesis was investigated using both in 
vitro and ex vivo systems.  In vitro we explored the effect of substrate stiffness on 
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intracellular tension induced by TNF-α and thrombin by examining endothelial 
monolayers on PA gel substrates (6-50 kPa) through immunofluorscent labeling, Western 
blot, and an in vitro monolayer permeability assay. Ex vivo, sub-endothelial stiffness of 
aortae from wild type and elastin haploinsufficient (ELN+/-) mice was measured by 
atomic force microscopy.  En face confocal microscopy was also used to characterize the 
vessel endothelium [178].   In this chapter we show that vinculin recruitment to cell-cell 
junctions in response to TNF-α and thrombin in vitro is greater on stiffer substrates, 
suggesting translation of tension from cell-matrix adhesions to cell-cell junctions.           
 
3.2. Methods 
 
3.2.1. Polyacrylamide (PA) gel sample preparation 
Polyacrylamide gels with elastic moduli of 6, 14, 29, or 50 kPa were prepared 
following well-established protocols [56].  Briefly, a bottom coverslip was made 
hydrophilic by consecutive incubations with 0.1 M NaOH, 3-
aminopropyltrimethoxysiliane, and 0.5% glutaraldehyde.  A top coverslip was made 
hydrophobic by applying Surfasil Siliconizing Fluid (1,7-dichloro-
octamethyltetrasiloxane).  A solution containing varying amounts of acrylamide and bis-
acrylamide was prepared based on the desired gel stiffness (Table 3.1).  Ammonium 
persulfate and tetramethylethylenediamine were added to the acrylamide/bis-acrylamide 
solution to achieve final concentrations of 0.1% w/v and 0.3% v/v, respectively, initiating 
gel polymerization.  A drop of polymerizing gel solution was added to the bottom 
coverslip, and the top coverslip was quickly inverted onto the polymerizing gel to create 
a flat surface.  After gel formation, the top coverslip was removed.  To make the surface 
adhesive to cells, the gel was UV-activated using sulfo-SANPAH in DMSO and 50 mM 
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HEPES buffer, then incubated with 100 μg/mL type I collagen at 37°C for at least 3 
hours at room temperature or at 4°C overnight.  The collagen-coated gel was rinsed well 
in sterile PBS and UV-sterilized prior to cell seeding. 
 
 
Table 3.1.  Composition of acrylamide and bis-acrylamide in polyacrylamide gel preparations 
 
PA gel elastic modulus % acrylamide % bisacrylamide 
6 kPa 7.5% 0.05% 
14 kPa 10% 0.1% 
29 kPa 10% 0.3% 
50 kPa 10% 0.6% 
 
The top and bottom coverslip size and the gel solution volume varied depending 
on the type of sample being prepared.  For immunofluorescent labeling, both the top and 
bottom coverslips were 12 mm diameter circular coverslips, and 50 μL gel solution was 
used.  For Western blot experiments, the top and bottom coverslips were 22x22 mm 
square coverslips, and 200 μL gel solution was used.  For the in vitro permeability assay, 
the bottom coverslip was a 22x22 mm square coverslip and the top coverslip was a 12 
mm diameter circular coverslip; 5 μL gel solution was used to produce a very thin gel.  In 
addition, 10 μM fluorescently labeled 40 kDa dextran (FITC-dextran) was added to the 
gel solution for the permeability assay samples to fluorescently detect the upper gel 
boundary.   
PAECs were seeded and allowed to attach and proliferate over two to three days 
to achieve a cell monolayer.  The cells were then incubated overnight in medium 
containing 1% FBS.  For Western blot, cells were seeded in 5% FBS DMEM without 
phenol red and serum-starved in 1% FBS DMEM without phenol red.  The following 
day, cells were left untreated or treated with 10 ng/mL TNF-α for varying durations.   
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3.2.2. Immunofluorescence 
Cell samples were rinsed once with ice-cold PBS and fixed using ice-cold 4% 
paraformaldehyde (Sigma Aldrich), permeabilized using 0.2% TritonX-100 (EMD 
Millipore) in PBS for 15 minutes at room temperature and rinsed once using PBS.  
Samples were blocked with 1% BSA, 0.3% TritonX-100 in PBS for 1 hour at room 
temperature and then rinsed twice with PBS.  Cells were labeled with the primary 
antibody (1:200 in 1% BSA) overnight at 4°C, then rinsed twice with PBS.  Actin and 
nuclei were labeled using rhodamine phalloidin (16.5 nM, Invitrogen) and bisbenzimide 
(0.2 μg/mL, Invitrogen), respectively.  Thrombin, which elicits increased cell contractility 
and drastic cell-cell junction loss, was used as a positive control in these studies (10 
U/mL, 30 minutes) [305, 306].  Figure 3.1 depicts the junction loss following thrombin 
treatment of cells on glass; β-catenin labeling shows wide junctions with honeycomb-like 
morphology in untreated cells (Figure 3.1a, selection magnified in Figure 3.1b).  This 
particular junction morphology indicates intact junctions and is referred to as “reticular 
junctions” [186].  Disrupted punctate junctions are observed in thrombin-treated cells, 
along with noticeable holes in the endothelial monolayer (Figure 3.1c, selection 
magnified in Figure 3.1d).   
For most figures, images were taken using an Olympus Fluoview 1000 confocal 
microscope.  Unless otherwise noted, images are compressed z-stack images with 0.25 
μm in between focal planes.  For Figure 3.1, figures were taken with an inverted 
epifluorescent microscope at 60X magnification (oil immersion).     
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Figure 3.1.  Thrombin disrupted reticular adherens junctions among adjacent endothelial cells.  
Cell monolayers on glass coverslips were untreated (a) or treated with 10 U/mL thrombin for 30 
minutes (c) prior to fixation and immunofluorescent labeling of β-catenin.  Selected cells from A 
and C are magnified in B and D, respectively, to emphasize the difference in morphology 
between “honeycomb-like” intact reticular junctions (b) and thrombin-disrupted junctions (d).   
 
 
3.2.3. Matlab image analysis 
Images were processed and analyzed using custom Matlab code to quantify levels 
of phosphorylated MLC.  Confocal z-stacks were compressed to produce a single image.  
Background intensity was determined by taking the average of a 50 by 50 pixel region; 
this intensity was multiplied by a user-determine modifier (0.6), which was held constant 
for all images within an experiment to decrease the background subtracted from the 
image.  These steps were repeated to complete the background subtraction process.  A 
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threshold for image binarization was calculated using Otsu’s method; the calculated 
threshold was multiplied by a modifier, which was held constant for all images (0.7).  To 
remove noise, any components smaller than 30 pixels were removed from the binarized 
image.  The amount of phosphorylated MLC was quantified by finding the sum of all 
remaining pixels in the image above the binarization threshold.     
 
3.2.4. In vitro permeability assay 
Tetramethylrhodamine-labeled fluorescent dextran (TMR-dextran) diffusion 
through a confluent endothelial monolayer into the gel substrate was used to quantify 
endothelial cell permeability.  Confluent endothelial monolayers were serum-starved in 
1% FBS DMEM overnight, then administered treatment—either 10 ng/mL TNF-α for 3 
hours or 10 U/mL thrombin for 30 minutes.  Following treatment, 10 μM 10 kDa TMR-
dextran in CO2-independent medium was added on top of the sample for 5 minutes to 
allow for dextran diffusion through the endothelial cell monolayer and into the gel 
substrate.  Approximately 60-80 z-stack images were acquired for each sample at 20X 
magnification using an Olympus Fluoview 1000 confocal microscope, with 1 μm steps 
between focal planes.     
Z-stack images were quantified in Image J.  Each z-stack was cropped to a size of 
199.96 x 199.96 square pixel area to minimize any gel surface unevenness.  Using the 
‘reslice’ function in Image J, the z-stacks were converted to produce an image of the z-
stack viewed from the side (converting from an xy view to an xz view).    
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3.2.5. Western blot 
PAEC were cultured on 22x22 mm square collagen-coated PA gels of varying 
stiffness for three days in 5% FBS phenol red free medium and serum-starved overnight 
in 1% FBS phenol red free medium.  Cells were rinsed once with ice-cold PBS.  Cells on 
PA gel samples were removed from PBS, and the side of the gel was gently dabbed on a 
Kimwipe to remove excess PBS.  Gels were inverted into a well of a clean 6-well plate 
containing 50 μL ice-cold lysis buffer (20 mM Tris, 150 mM NaCl, 1% Triton X-100, 
0.15 SDS, 2 mM EDTA, 2 mM NaVO4, 2 mM PMSF, 50 mM NaF, 10% glycerol, 
complete protease inhibitor, pH 7.4).  Samples were incubated for 10 minutes at 4°C to 
allow for cell lysis.  Gel samples were gently scraped to remove any remaining cell 
lysate, and lysates were collected into pre-chilled Eppendorf tubes.  The lysates from at 
least two 22x22 mm gels were pooled to collect enough protein content for each sample.  
Cell lysates were normalized for protein content using the bicinchoninic acid (BCA) 
assay and reduced at 70°C for 10 minutes prior to separation by SDS-PAGE on a 4-12% 
Bis-Tris gel and transfer to a nitrocellulose membrane.  For detection of vinculin, VE-
cadherin, or GAPDH, membranes were blocked for 1 hour at room temperature with 10% 
bovine serum albumin (BSA) in PBS-T (0.05% Tween 20 in PBS), and probed overnight 
at 4°C with the primary antibody (1:1000 in 5% BSA in PBS-T).  Following rinsing with 
PBS-T, membranes were probed with species-specific secondary horseradish peroxidase-
conjugated antibody (1:2000 dilution in 5% BSA) for 2 hours at room temperature and 
detected with an enhanced chemiluminescence kit.  Membranes were imaged with a 
Fluorochem digital imager.  AlphaEase FC software was used for quantification of band 
intensity.     
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3.2.6. En face imaging of mouse aorta 
The entire aorta was dissected and transferred to ice-cold HEPES buffer (140 mM 
NaCl, 5 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM Na2HPO4, 10 mM HEPES, 10 
mM sodium acetate, 5 mM glucose, pH 7.4).  Excess tissue was cleaned from the outside 
of the vessel, and the vessel was cut open longitudinally to expose the endothelium.  
Insect pins were used to pin the vessel flat onto a flat layer of cured polydimethylsiloxane 
(PDMS) in the bottom of a plastic dish.  While pinned open, the tissue was fixed with 
ice-cold 4% paraformaldehyde on ice for 30 minutes.  The vessel was then rinsed with 
PBS and simultaneously blocked and permeabilized with 1% BSA/0.3% Triton X-100 for 
60 minutes at room temperature.  The tissue was labeled with primary antibody in 1% 
BSA in PBS overnight at 4°C.  After several rinses with PBS, the vessel was incubated 
with secondary antibody, rhodamine phalloidin, and/or Hoechst for 1 hour at room 
temperature, protected from light.  The vessel was rinsed twice with PBS, mounted 
between two coverslips in 1:1 glycerol:PBS, and imaged using an Olympus Fluoview 
1000 confocal microscope at 60X magnification.  Images were taken every 0.5 μm, and 
z-stack images were compressed to visualize the endothelium. 
 
3.2.7. Atomic force microscopy  
Relative changes in cell stiffness were determined by atomic force microscopy 
(AFM, Veeco Bioscope).  PAEC were allowed to grow to confluence over three days in 
5% FBS DMEM, then serum-starved overnight in 1% FBS DMEM.  Cells were left 
untreated or treated with 10 ng/mL porcine TNF-α for increasing times between 3 and 24 
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hours, then immersed in CO2-independent medium.  Three AFM indentations were made 
per cell using a 0.06 N/m cantilever with a 1 μm spherical tip.  Force-indentation curves 
were fit using the Hertz model down to 200 nm indentation, and the stiffnesses measured 
at each of three locations were averaged to calculate cell stiffness.  Ten cells were 
analyzed per sample.  Fold change in cell stiffness was calculated as the average cell 
stiffness for TNF-α-treated samples divided by the average cell stiffness for untreated 
samples for each PA gel substrate stiffness.     
AFM was similarly used to quantify aortic stiffness in wild type and ELN+/- 
mouse aortae. The aorta was dissected, cleaned, and cut open longitudinally to expose the 
endothelium as described for en face imaging.  Each aorta was cut into four segments—
two thoracic segments and two abdominal segments—producing four samples per aorta.  
Samples were carefully mounted, endothelium facing up, on a coverslip using Loctite 401 
medical grade adhesive and submersed in PBS.  The endothelium was removed by gently 
scraping with a cotton-tip applicator, based on a published protocol [307].  Sub-
endothelial stiffness was determined by AFM using pre-calibrated cantilevers with spring 
constants between 0.10 and 0.17 N/m with 10 μm spherical tips.  Between three and nine 
indentations were made at different locations along each sample.  The force-indentation  
curve for each indentation was fit to the Hertz model down to 200 nm indentation using 
custom Matlab code to produce a stiffness value.  Sub-endothelial stiffness was 
calculated as the average of the individual stiffness values of each sample.   
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3.2.8. Statistical analysis 
All statistical analyses were conducted using Matlab’s statistical toolbox.  Graphs 
represent mean value ±standard deviation.  Multiple groups were compared using either 
two-way or n-way ANOVA, and two groups were compared by Student’s t-test.  For 
Western blot assessment of VE-cadherin and vinculin protein levels, conditions were 
tested in duplicate.  For other in vitro experiments, conditions were tested in triplicate.  
All experiments were run at least two times, excluding data supporting AFM method 
development (Figures 3.2 and 3.3). 
 
3.3. Results 
3.3.1. Ex vivo analysis of sub-endothelial stiffness in WT and ELN+/- mice 
Macroscale arterial stiffness, measured by pulse wave velocity, is increased in 
mice genetically engineered to produce less elastin (elastin haploinsufficient, ELN+/) 
[308].  However, the sub-endothelial stiffness has not been characterized in this mouse 
model.  We removed the endothelium from longitudinally dissected aortic sections 
(Figure 3.2) prior to measuring sub-endothelium stiffness by atomic force microscopy 
(AFM).  In the unscraped segment, nuclei aligned perpendicular to the blood flow 
direction (from smooth muscle cells) were observed wrapping around the vessel 
circumferentially, as well as nuclei aligned parallel to the blood flow direction (from the 
endothelium) (Figure 3.2a).  VE-cadherin labeling of the unscraped vessel reveals VE-
cadherin in the adherens junctions of the intact endothelium (Figure 3.2b).  In the scraped 
segment, the endothelial nuclei (parallel to the blood flow direction) were removed and 
the smooth muscle cell nuclei (perpendicular to the blood flow direction) remained 
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(Figure 3.2c).  VE-cadherin labeling of the scraped vessel showed some remaining debris 
but no endothelial adherens junction (Figure 3.2d).  These results indicated that the 
scraping method removed the endothelium from the aortic section and exposed the sub-
endothelium for AFM measurements.  
 
Figure 3.2.  Gentle scraping removed the mouse aortic endothelium while leaving the underlying 
smooth muscle cell layers intact (a) An unscraped vessel segment with Hoechst labeling of the 
nuclei in both the endothelium and the smooth muscle cell layer underneath (b) VE-cadherin 
labeling of endothelial adherens junctions in an unscraped vessel (c) Smooth muscle cell nuclei 
remained after endothelial scraping (d) VE-cadherin labeling of the scraped vessel segment.  
Scale bar is 25 μm. 
 
Aortic sections were then co-labeled for the adherens junction protein β-catenin, 
actin, nuclei, and the basement membrane protein collagen IV to confirm that the 
endothelial scraping method did not also remove the basement membrane (Figure 3.3).  
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In the unscraped aortic section (Figure 3.3a and b), all four components were visible, 
indicating an intact endothelium, basement membrane, and smooth muscle cell layer.  In 
the scraped aortic section (Figure 3.3c and d), endothelial β-catenin was almost entirely 
removed.  Some β-catenin debris was visible in the crevices between tissue folds (Figure 
3.3c), which would not have been accessible to the AFM cantilever tip during testing.  
Collagen IV in the scraped vessel was clearly seen as a distinct layer on top of the actin-
rich smooth muscle cell layer (in particular by viewing the confocal image z-stack from 
the side) and looked similar to collagen IV in the unscraped vessel.  These results 
indicated that the scraping method did not remove collagen IV, a major component of the 
sub-endothelial basement membrane, prior to AFM measurements.   
 
Figure 3.3.  Endothelial scraping maintained sub-endothelial basement membrane proteins.  For 
each condition the vessel segment is shown from the top and the side of a compressed confocal z-
stack (a) β-catenin (green), actin (red) and nuclei (blue) in an unscraped aortic segment. (b) 
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Collagen IV (white) in the sub-endothelial basement membrane in the unscraped aortic segment 
above actin (red) in the smooth muscle cell layer (c) β-catenin, actin and nuclei in a scraped aortic 
segment. (d) Collagen IV in the scraped aortic segment looked similar to the unscraped segment, 
suggesting an undisturbed basement membrane.  Scale bar is 50 μm.  
 
 
 
Next, aortic sub-endothelium samples were indented by AFM to detect any 
differences in sub-endothelial stiffness between the wild type and ELN+/- genotypes.  As 
shown in Figure 3.4a, each aorta was cut open longitudinally, mounted and scraped by 
the same method used to prepare the aortic segments in Figures 3.2 and 3.3.  The ELN+/- 
thoracic aortic sub-endothelium was 1.79-fold stiffer as compared to wild type (Figure 
3.4b). In addition, the abdominal aortic sub-endothelium from ELN+/- mice was 1.76-
fold stiffer as compared to wild type.     
 
 
Figure 3.4.  Sub-endothelial stiffness increased in the thoracic and abdominal aorta of ELN+/- 
mice.  Vessels were cut open longitudinally and pinned to a silicone-lined dish (A).  Each aorta 
was cut into four segments (upper and lower thoracic and abdominal aorta).  The renal arteries 
were not analyzed, but used as a reference to determine the relative location of the segments 
along the vessel (B) The endothelium of the vessel segments was removed by gentle scraping and 
sub-endothelial stiffness was determined by AFM indentation using a 10 μm spherical tip on a 
pre-calibrated cantilever.  The aortae from five mice per genotype were analyzed and compared 
by Student’s t-test (*p<0.05, *p<0.01).  Data are shown as average stiffness ± standard deviation.   
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3.3.2. Immunofluorescent characterization of wild type and ELN+/- aortic 
endothelium 
To determine if decreased elastin content in ELN+/- mice affected endothelial 
cell-cell junction composition, wild type and ELN+/- aortic sections were fixed, labeled 
and imaged en face by confocal microscopy (Figure 3.5).  Immunofluorescent labeling 
for VE-cadherin and vinculin showed vinculin co-localization with VE-cadherin at 
adherens junctions in the thoracic aortic section of both wild type and ELN+/- mice 
(Figure 3.5a). Vinculin localization differences between the two genotypes were observed 
in the abdominal aorta.  In the ELN+/- mice, vinculin also co-localized with VE-cadherin 
at adherens junction in the abdominal aortic section.  In contrast, in the abdominal aorta 
of WT mice (the section with the softest sub-endothelium by AFM) vinculin localized 
mainly to punctate structures at the endothelial basal surface thought to be focal 
adhesions.  Following image quantification (Figure 3.5b), VE-cadherin localized with 
vinculin in thoracic aortic sections did not change between WT and ELN+/- mice; 
however, percent co-localization was nearly 20% lower in abdominal aortic sections from 
WT mice compared to ELN+/- mice (38% vs. 46% co-localization, respectively).   
As shown in Figure 3.5c, aortic segments were also labeled for focal adhesion 
kinase (FAK), a signaling molecule known to associate with both focal adhesions and 
adherens junctions. In WT thoracic and abdominal sections, pFAK was not detected at 
the cell periphery; however, in ELN+/- thoracic and abdominal sections, pFAK was 
localized near adherens junctions.  Image quantification (Figure 3.5d) showed a 
significant two-fold increase in vinculin co-localized with pFAK in the combined ELN+/- 
thoracic and abdominal aortic sections compared to WT aortic sections. In summary, both 
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vinculin and pFAK labeling revealed differences in endothelial cell-cell junction 
composition between WT and ELN+/- aortic sections.  Since vinculin localization to cell-
cell junctions is dependent on increased tension on the junction protein α-catenin, we 
hypothesized that endothelial cells in areas of increased sub-endothelial stiffness 
experienced higher tension at their cell-cell junctions.   
 
 
Figure 3.5.  Vinculin and pFAK showed more co-localization with cell-cell junctions in the aortic 
endothelium of ELN+/- mice.  (a) Immunofluorescent labeling of VE-cadherin (red), vinculin 
(green), and nuclei (blue) in thoracic and abdominal sections of mouse aortae imaged en face by 
confocal microscopy.  Z-stacks of confocal images were compressed to show labeling through the 
entire endothelium.  (b) Images were processed and quantified using custom Matlab code to 
determine the percent VE-cadherin co-localized with vinculin.  (c) Immunofluorescent labeling of 
pFAK (yellow), vinculin (green), and nuclei (blue).  (d) Image quantification of percent vinculin 
co-localized with pFAK.  Scale bar is 25 μm.  Data are shown as average ± standard deviation.     
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3.3.3. Substrate-dependent changes in adherens junction composition, actin 
cytoskeleton, cell contractility, and focal adhesion activation in response to 
TNF-α and thrombin in vitro 
In vitro experiments were conducted to further investigate the role of sub-
endothelial stiffness on cell contractility and cell-cell junction structure.  Porcine aortic 
endothelial cells were seeded on collagen-coated PA gels with elastic moduli between 6 
and 50 kPa (to simulate increasing vessel stiffness) and treated with TNF-α or thrombin 
to induce cell contractility.  Immunofluorescent labeling of endothelial monolayers 
attached to PA gels was used to observe cell-cell junction morphological changes in 
response to stiffness, TNF-α, and thrombin.   
Figure 3.6 shows co-labeling of VE-cadherin and vinculin in the apical plane of 
representative cells within untreated, TNF-α -treated, or thrombin-treated confluent 
endothelial monolayers.  In untreated cells, vinculin was minimally detected at adherens 
junctions in cells on the 29 kPa gel and distinctly absent from cell-cell junctions on the 6 
kPa gel.  With TNF-α treatment, no changes in junction morphology or vinculin 
localization were observed in cells on the 6 and 14 kPa gels.  On the 29 kPa gels, apical 
adherens junctions were linear with small disruptions; in addition, vinculin co-localized 
with VE-cadherin.  In thrombin-treated cells, both VE-cadherin labeled junction 
linearization and vinculin with VE-cadherin co-localization increased with substrate 
stiffness.  Since vinculin localization to cell-cell junctions occurs following tension-
dependent conformational changes of α-catenin, these results suggest that tension at cell-
cell junctions following exposure to TNF-α or thrombin is higher on stiffer substrates.  
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Figure 3.6.  Stiff substrates enhanced vinculin co-localization with VE-cadherin at apical 
adherens junctions in response to TNF-α and thrombin.  Cell monolayers on 6, 14, and 29 kPa 
substrates were treated with 10 ng/mL TNF-α for 3 hours or 10 U/mL thrombin for 30 minutes, 
fixed, and labeled for VE-cadherin (red), vinculin (green), and nuclei (blue).  Confocal z-stacks 
were acquired at 60X magnification, and the uppermost plane was selected as the apical cell 
surface.  Representative cells from within confluent monolayers are shown to highlight 
differences in vinculin localization.  Scale bar is 10 μm.       
 
Total vinculin content was examined by Western blot to determine if the changes 
cell-cell junction vinculin in cells on stiff substrates was due to increased translocation or 
vinculin protein production (Figure 3.7a).  Total vinculin levels, normalized to GAPDH, 
were not significantly different among all conditions tested, suggesting vinculin 
translocation to junctions instead of increased vinculin production (Figure 3.7b).  
Interestingly, total VE-cadherin decreased with increased substrate stiffness (Figure 
3.7c).  There was no significant effect of TNF-α or thrombin treatment on total VE-
cadherin levels.     
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Figure 3.7.  Total vinculin did not change with substrate stiffness, TNF-α, or thrombin treatment; 
total VE-cadherin decreased with substrate stiffness, but not TNF-α or thrombin treatment.  (a) 
Total vinculin, VE-cadherin, and GAPDH protein levels in cells that were untreated, TNF-α –
treated (10 ng/mL, 3 hours), or thrombin-treated (10 U/mL, 30 minutes) on 6, 14, and 29 kPa 
substrates or tissue culture plastic were analyzed by Western blot.  Vinculin and VE-cadherin 
levels were normalized to GAPDH and analyzed by n-way ANOVA.  There was no significant 
effect of stiffness or treatment in total normalized vinculin.  For total normalized VE-cadherin, 
the effect of stiffness was significant (p<0.001) while the effect of treatment was insignificant.  
Data are shown as average ± standard deviation.   
 
Next we examined cell-cell junction structure in endothelial monolayers on 
substrates of different stiffness following TNF-α or thrombin treatment, to determine if 
increased tension at the junctions corresponded with morphological changes. Confocal 
images of the junction protein β-catenin in cells on 6, 14, and 29 kPa substrates are 
shown in Figure 3.8.   Untreated, TNF-α-treated and thrombin-treated confluent 
monolayers imaged at 60X magnification are shown in Figure 3.8a, with representative 
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individual junctions magnified in Figure 3.8b.  In untreated cells, junction size 
qualitatively diminished with increasing substrate stiffness.  Thick junctions with 
“honeycomb-like” structure, as seen between untreated cells on 6 kPa gels, represent 
areas where adjacent cells overlap, called “reticular adherens junctions”. With TNF-α 
treatment, cell-cell junction thinning was minimal on 6 kPa gels and increased with 
substrate stiffness.  Junction thinning corresponded with the loss of the “honeycomb” 
morphology.  With thrombin treatment, cell-cell junctions thinned to a greater extent 
when compared to TNF-α treatment.  Junctions between cells on 6 kPa gels exposed to 
thrombin still maintained some junction thickness.  On 29 kPa thrombin-treated samples, 
junctions lost the “reticular” morphology and more closely resemble focal adherens 
junctions, with diminished, punctate contact between adjacent cells [309].  The transition 
from thick “reticular adherens junctions” to punctate “focal adherens junctions” occurs as 
cells separate from each other; thus, these results indicate that endothelial cell-cell 
junction loss following exposure to TNF-α or thrombin is enhanced by stiff substrates. 
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Figure 3.8.  Substrate stiffening exacerbated reticular adherens junction thinning in response to 
TNF-α and thrombin.  Cells on 6, 14, and 29 kPa polyacrylamide gels were untreated, treated 
with 10 ng/mL TNF-α for 3 hours, or treated with 10 U/mL thrombin for 30 minutes prior to 
fixation.  (a) Images show β-catenin labeling in confluent monolayers.  Areas highlighted by 
rectangular regions are magnified in (b) to highlight differences in junction morphology.  Scale 
bar is 25 μm.      
 
 
Next, we hypothesized that increased junction tension and cell-cell junction loss 
on stiff substrates depended on increased actinomyosin contractility.  To see if substrate 
stiffness increased actin fiber formation in confluent endothelial monolayers in response 
to TNF-α or thrombin, endothelial cells on 6, 14, and 29 kPa PA gels were labeled for 
actin.  Figure 3.9 shows compressed confocal z-stacks, which captured actin cytoskeletal 
morphology throughout the cell layer.  In untreated cells, peripheral actin bundles were 
present in cells on all substrates but were particularly distinct in cells on 6 kPa gels.  
Following 3 hours of 10 ng/mL TNF-α treatment, peripheral actin was maintained in cells 
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on 6 kPa gels but diminished in cells on 14 and 29 kPa gels.   Following 30 minutes of 10 
U/mL thrombin treatment, peripheral actin was diminished in cells on all substrates and 
actin stress fibers were increased in cells on 29 kPa gels.  These results indicate that actin 
fiber stress formation was enhanced on stiff substrates. 
 
 
Figure 3.9.  Actin stress fiber formation in response to TNF-α and thrombin was greater on stiff 
substrates as compared to soft substrates.  Cells on 6, 14, and 29 kPa collagen-coated PA gels 
were untreated (left), treated with 10 ng/mL TNF-α for 3 hours (middle) or treated with 10 U/mL 
thrombin for 30 minutes (right) prior to fixation and labeling with rhodamine phalloidin (red, 
actin) and Hoechst (blue, nuclei).  Images are compressed confocal z-stacks at 60X 
magnification.  Scale bar is 25 μm.       
 
To assess if increased actin stress fiber formation corresponded with increased 
endothelial monolayer contractility on stiff substrates, immunofluorescent labeling of 
phosphorylated myosin light chain (pMLC) was conducted following TNF-α or thrombin 
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treatment (Figure 3.10a).  pMLC localized to punctate peripheral structures at cell-cell 
junctions in untreated cells.  Punctate pMLC labeling was lost with TNF-α and thrombin 
treatment; instead pMLC co-localized with actin fibers, and this effect increased with 
substrate stiffness.  In Figure 3.10b, pMLC image quantification revealed an increase in 
total pMLC with both TNF-α and thrombin treatment (p<0.0001 by two-way ANOVA 
for both cases).  Substrate stiffness showed significant interaction with both TNF-α 
(p<0.05) and thrombin (p<0.01).  These results indicate that increasing substrate stiffness 
enhanced the increase in TNF-α and thrombin-induced total pMLC.  Interestingly, 
differences in pMLC localization between TNF-α and thrombin were observed.  In TNF-
α -treated cells, pMLC mostly localized to stress fibers in the cell periphery on all 
substrates.  In contrast, some pMLC localized to peripheral actin in thrombin-treated cells 
on the 6 kPa gels but was distinctly present along longitudinal stress fibers in cells on the 
29 kPa gels. 
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Figure 3.10.  Total pMLC was greater on stiff substrates in response to TNF-α and thrombin.  
pMLC localized to peripheral actin with TNF-α treatment and longitudinal actin with thrombin 
treatment on the stiffer substrates.  (a) Cells on gels of varying stiffness were treated with 10 
ng/mL TNF- α for 3 hours or 10 U/mL thrombin for 30 minutes, fixed, and labeled for pMLC 
(green).  Linear pMLC represents myosin localization along actin fibers.  (b) Images were 
processed and quantified to assess total pMLC.  By two-way ANOVA, TNF-α and thrombin 
significantly increased pMLC labeling (p<0.01).  The interactions between substrate 
stiffness/TNF and substrate stiffness/thrombin were significant (p<0.05 and p <0.01, 
respectively).  *p<0.01, **p<0.001 (Tukey-Kramer post-hoc test).  Data are shown as average ± 
standard deviation.   
 
Next, we investigated changes in activated focal adhesions, the structures 
responsible for substrate stiffness sensing, following substrate-dependent cell 
contractility due to TNF-α and thrombin exposure.  Immunofluorescent pFAK labeling 
was used to visualize focal adhesion activation in cells on substrates of increasing 
stiffness (Figure 3.11).  In untreated cells on all substrate stiffnesses, punctate pFAK 
labeling revealed generally small, evenly distributed focal adhesions.  With TNF-α 
treatment (middle column), pFAK labeling did not change in cells on 6 and 14 kPa 
substrates.  On 29 kPa substrates, some larger focal adhesions were observed around the 
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cell peripheries.  With thrombin treatment, pFAK labeling did not change in cells on the 
6 kPa substrate.  To a lesser extent on 14 kPa substrates and a greater extent on 29 kPa 
substrates, larger pFAK-containing focal adhesions were observed at cell peripheries.  
pFAK was mainly co-localized with vinculin in focal adhesions at the basal membrane; 
little pFAK was observed at cell-cell junctions under the conditions tested.  These results 
implicate focal adhesions in substrate-dependent responses to TNF-α and thrombin.  
  
 
Figure 3.11.  Larger, activated focal adhesions formed at the cell periphery in response to TNF-α 
and thrombin on stiffer substrates.  Cells were treated with 10 ng/mL TNF-α for 3 hours or 10 
U/mL thrombin for 30 minutes, fixed, and labeled for pFAK (yellow), vinculin (green) and nuclei 
(blue).  Confocal z-stacks were acquired at 60X magnification with optical zoom of 2 and 
compressed. Scale bar is 25 μm.   
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3.3.4. Role of ROCK signaling in actin reorganization, vinculin translocation, and 
adherens junction morphology on substrates of difference stiffness in 
response to TNF-α and thrombin 
The ROCK inhibitor Y-27632 was used to investigate the role of cell contractility 
in substrate-dependent vinculin recruitment to adherens junctions following TNF-α and 
thrombin treatment (Figure 3.12).  While punctate pMLC was still present at the cell 
periphery after ROCK inhibition, pMLC localization to actin fibers after TNF-α and 
thrombin treatment was abolished by Y-27632.  Actin fibers appeared disorganized with 
Y-27632 treatment alone; however, peripheral actin bands still formed in cells on 6 and 
14 kPa with Y-27632 and TNF-α treatment.  This observation suggests that peripheral 
actin fiber formation is controlled by a ROCK-independent pathway or upstream of 
ROCK signaling.  Some actin stress fibers were still observed in the center of cells on 29 
kPa gels following Y-27632 and thrombin treatment.   
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Figure 3.12.  ROCK inhibition with Y-27632 abolished pMLC localization to actin fibers with 
TNF-α and thrombin treatment on all substrate stiffnesses.  Cell monolayers on 6, 14, and 29 kPa 
substrates were pre-treated with 5 μM Y-27632 for 30 minutes prior to the addition of 10 ng/mL 
TNF (3 hours) or 10 U/mL thrombin (30 minutes).  Samples were fixed and labeled for pMLC 
(green), actin (red), and nuclei (blue).  Confocal z-stacks were acquired at 60X and compressed.  
Scale bar is 25 μm.     
 
As shown in Figure 3.13, Y-27632 also abolished vinculin recruitment to 
adherens junctions in cells on 29 kPa gels following TNF-α and thrombin treatment.  This 
result confirms the hypothesis that vinculin localization at cell-cell junctions was 
dependent on cell contractility. However, Y-27632 also adversely affected adherens 
junction morphology alone or concurrent with TNF-α or thrombin (Figure 3.14).  Cell-
cell junctions in all Y-27632-treated cells appeared invaginated, although no holes 
between cells were observed.  This observation suggests that a basal level of cell 
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contractility is necessary for normal junction structure.  Taken together, these findings 
indicate that substrate-dependent cell contractility was responsible for vinculin 
localization to junctions in response to TNF-α and thrombin, but is also necessary for 
maintenance of normal reticular adherens junction morphology. 
 
Figure 3.13.  ROCK inhibition prevented vinculin localization to apical adherens junctions 
following TNF-α or thrombin treatment on all substrate stiffnesses.  Cell monolayers on 6, 14, 
and 29 kPa substrates were pre-treated with 5 μM Y-27632 for 30 minutes prior to the addition of 
10 ng/mL TNF (3 hours) or 10 U/mL thrombin (30 minutes).  Samples were fixed and labeled for 
VE-cadherin (red), vinculin (green) and nuclei (blue).  Images are the apical plane of 
representative cells from confluent monolayers.  Scale bar is 10 μm.     
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Figure 3.14.  ROCK inhibition induced an invaginated cell-cell junction morphology that was 
unchanged by TNF or thrombin treatment.  Cells were pre-treated with 5 μM Y-27632 for 30 
minutes prior to the addition of 10 ng/mL TNF (3 hours) or 10 U/mL thrombin (30 minutes).  
Samples were fixed and labeled for β-catenin (green) and nuclei (blue).  Confocal z-stacks were 
acquired at 60X magnification and compressed.  Images show representative cells within 
confluent monolayers.  Scale bar is 10 μm.   
 
3.3.5. Functional ramifications of substrate stiffening:  monolayer permeability and 
cell stiffness 
We used an in vitro dextran diffusion permeability assay to see if morphological 
differences in adherens junctions with substrate stiffness and TNF-α and thrombin 
treatment corresponded to functional endothelial barrier disruption.  Representative side-
views of analyzed samples are shown in Figure 3.15a. The bright band at the top 
represents the fluorescent-dextran above the endothelial cell monolayer; the endothelial 
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monolayer is approximately between the two dashed lines; and the area beneath the 
dashed lines represents the gel.  To verify assay functionality, monolayers were treated 
with barrier enhancing BW245C or barrier degrading thrombin as negative and positive 
controls, respectively [134].  On 6 kPa gels, endothelial monolayer permeability 
increased by 28% with thrombin treatment and decreased by 16% with BW245C 
treatment (Figure 3.15b).   
This assay was then used to determine endothelial monolayer permeability on 6, 
14, 29, and 50 kPa gels under three treatment conditions:  untreated, TNF-α-treated (10 
ng/mL, 3 hours), or thrombin-treated (10 U/mL, 30 minutes) (Figure 3.15c).  Monolayer 
permeability increased with substrate stiffness by n-way ANOVA (p<0.001).  There was 
no significant interaction between substrate stiffness and TNF-α treatment.  However, the 
interaction between substrate stiffness and thrombin treatment was significant (p<0.05).  
The fold increase in permeability between untreated and TNF-α or thrombin treated 
samples ranged between 1.23 and 1.75.  These results indicate that substrate stiffness did 
not enhance TNF-α-induced endothelial monolayer permeability at the time point tested 
in this study on 6-50 kPa gel substrates.  Substrate stiffness did enhance thrombin-
induced monolayer permeability. 
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Figure 3.15.  In vitro endothelial monolayer permeability increased with substrate stiffness and 
TNF-α and thrombin treatment. (a) Representative xz-images images of in vitro permeability 
samples with and without thrombin treatment.  Dotted lines indicate the approximate location of 
the cell monolayer; the gel substrate is beneath the dotted lines.  Monolayer permeability was 
quantified by measuring fluorescence intensity in the gel.  Fluorescence values for each cell 
sample were normalized to the fluorescence in gels without cell monolayers; this output is 
referred to as normalized intensity, which increases with monolayer permeability (b) Normalized 
fluorescent intensity for cells treated with 10 U/mL thrombin or 1 μM BW245C for 30 minutes as 
positive and negative controls, respectively, for assay validation. (c) Monolayer permeability was 
measured in samples that were untreated, treated with 10 ng/mL TNF-α for 3 hours or treated 
with 10 U/mL thrombin for 30 minutes. The effect of stiffness (p<0.001) and treatment (p<0.01) 
were by significant by n-way ANOVA with a Tukey-Kramer post-hoc test (**p<0.001).  The 
interaction between stiffness and thrombin was significant (p<0.05); however, there was no 
significant interaction between stiffness and either TNF-α. 
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In addition to endothelial barrier function, the ability of the endothelium to 
produce the vasodilator nitric oxide is key to healthy vascular function.  Since nitric 
oxide production decreases with increasing endothelial cell stiffness, we studied changes 
in cell stiffness in response to TNF-α on substrates of different stiffness.  The effect of 
substrate stiffness on changes in individual endothelial cell stiffness within a confluent 
monolayer in response to TNF-α was evaluated by AFM.  The results are shown in 
Figure 3.16 as fold change in cell stiffness compared to untreated cells on the same 
stiffness substrate; fold change in stiffness >1 indicates cell stiffening while fold change 
<1 indicates cell softening.  Cells on stiff 50 kPa PA gels were 1.37-fold stiffer than 
untreated cells after three hours of TNF-α treatment.  Cell stiffness then decreased over 
24 hours of TNF-α treatment.  Cells on PA gel substrates of medium 14 kPa stiffness 
originally softened by 3 hours of TNF-α treatment and remained softer than untreated 
cells up through 24 hours of treatment.  TNF-α -treated cells on soft 6 kPa gels also 
softened, reaching the greatest level of softening following 6 hours of treatment (0.65-
fold) and remained soft.  Interestingly, sub-confluent endothelial cells attached to glass 
initially stiffen and then soften over 24 hours of exposure to TNF-α [220]. These results 
demonstrate that substrate-dependent response to TNF-α extends beyond endothelial 
barrier loss to other key endothelial functions, possibly affecting nitric oxide production 
through changes in cell stiffness.    
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Figure 3.16.  TNF-α treatment caused cells on stiff substrates to stiffen and then soften, while 
cells on soft substrates softened and remained soft. Cells were seeded on 6, 14, or 55 kPa PA gels 
and grown to confluency.  Cells were treated with or without 10 ng/mL TNF-α, and cell stiffness 
was measured by AFM over 24 hours.  Fold change in average cell stiffness was calculated 
relative to untreated cells on PA gel of the b same stiffness (# p < 0.05, * p < 0.01, n = 10 cells 
per sample).  Data are shown as average ± standard deviation.       
 
3.4. Discussion 
 
 While arterial stiffness is a major risk factor for cardiovascular disease and 
systemic inflammation is key to cardiovascular pathogenesis, it is not understood how 
these stimuli interact to induce endothelial barrier loss that is critical to atherosclerotic 
plaque development.  In this study, we determined that sub-endothelial stiffness increased 
in elastin haploinsufficient (ELN+/-) mice.  Vinculin recruitment to endothelial adherens 
junctions in the abdominal aorta, which requires cell-cell junction tension, was increased 
in ELN+/- mice in situ.  In vitro experiments using PA gels of varying stiffness were 
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conducted to further investigate the link between sub-endothelial stiffness, induced cell 
contractility, and cell-cell junction loss.  We demonstrated for the first time that substrate 
stiffness enhanced vinculin recruitment to adherens junctions in vitro and increased cell-
cell junction loss induced by TNF-α and thrombin.  Substrate stiffness also enhanced 
ROCK-dependent cell contractility, and ROCK inhibition eliminated vinculin recruitment 
to junctions following exposure to TNF-α and thrombin.  In an in vitro functional 
permeability assay, substrate stiffness exacerbated thrombin-induced, but not TNF-α-
induced, barrier loss.  In addition, cells on stiff substrates stiffened and cells on soft 
substrates softened in response to TNF-α; this result is significant because nitric oxide 
production inversely correlates with cell stiffness. Collectively, these studies support the 
hypothesis that increased substrate stiffness enhances ROCK-dependent cell-cell junction 
tension in response to inflammatory stimuli, translating to increased monolayer 
permeability in response to thrombin. 
 
3.4.1. The protective role of vinculin against junction opening and therapeutic 
considerations    
The recognized importance of vinculin, which is highly conserved among species, 
in the regulation of cardiovascular homeostasis is growing [310].  Vinculin localizes to 
endothelial adherens junctions under tension caused by treatment with VEGF, thrombin, 
or TNF-α.  Vinculin at adherens junctions prevents force-induced junction loss in 
endothelial monolayers [178].  Observations supporting the idea that vinculin bolsters 
cell-cell junctions have also been made in epithelial cells; the expression of an α-catenin 
mutant incapable of binding vinculin decreased cell-cell attachment strength measured by 
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a dual pipette assay [311].  Interestingly, the vinculin localization we see at adherens 
junctions in cells on stiff substrates indicates increased ROCK-dependent junctional 
tension, but also suggests a mechanism to compensate for increased tension and prevent 
junction loss on stiff substrates.  Our results suggest that the vinculin/α-catenin complex 
plays a crucial role in endothelial barrier maintenance in response to cell contractility.  In 
fact, it has been suggested that therapies to enhance the interaction between α-catenin and 
vinculin could combat endothelial barrier dysfunction [312].   
More broadly, vinculin’s beneficial role was recently demonstrated in cardiac 
muscle. Total cardiac output was increased in aged (24 months) compared to young (6 
months) rats while cardiac output normalized to body weight was unchanged with age, 
suggesting a mechanism for age-related cardiac protective remodeling.  Cardiac vinculin 
expression increased with age between 6 and 24 months, which coincided with increased 
vinculin localization at intercalated disks.  In the same study, overexpression of cardiac 
vinculin enhanced the contractility of drosophila hearts and significantly increased fruit 
fly life span [313].  Taken together, these data support the notion that vinculin 
localization to cell-cell junctions is crucial to protective cardiovascular force-adaptation.          
Endothelial cell contractility, specifically through the Rho/ROCK pathway, is also 
being considered as a possible therapeutic target for the treatment of pathological 
endothelial barrier loss.  In vitro ROCK knockdown lessened the increase in endothelial 
permeability due to increasing substrate stiffness; in vivo treatment with the ROCK 
inhibitor Y-27632 improved endothelial barrier function in aged (20-25 months) mice to 
a level comparable to that of young (10-11 weeks) mice.  The authors of this study 
suggested that the Rho/ROCK pathway may be a viable therapeutic target for the 
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prevention of atherosclerotic plaques, citing both the ROCK inhibitor Fasudil and statins 
[134].  Fasudil has also been shown to prevent plaque formation and progression in a 
mouse model of atherosclerosis (ApoE knock-out), in addition to several other beneficial 
effects demonstrated in other animal studies [314, 315].  Recently, Rho/ROCK pathway 
inhibition has been suggested as a possible therapeutic strategy to curtail inflammation-
induced vascular leakage in response to the Ebola virus [316].  In fact, the promise of 
Rho/ROCK as a therapeutic target for cardiovascular diseases is evident in a number of 
human studies; as of 2013, at least thirteen human studies involving Fasudil had been 
completed or were on-going [315].  While the results reported in this chapter support the 
therapeutic value of decreasing endothelial cell contractility, it is important to consider 
that some basal contractility level may be needed to maintain normal endothelium barrier 
function.    
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3.4.2. Proposed mechanism 
We now present a potential mechanism for the substrate-dependent responses to 
TNF-α and thrombin.  Endothelial monolayer focal adhesion activation is low on soft 
substrates (Figure 3.17a, b) and increased on stiff substrates (Figure 3.17c, d, e).  Focal 
adhesions maintains a basal level of Rho/ROCK activation through focal adhesion kinase 
phosphorylation (pFAK).  On soft substrates, TNF-α or thrombin-induced activation of 
the Rho/ROCK pathway is maintained at a low level due to low integrin activation 
(Figure 3.17b).  On stiff substrates, the combination of substrate stiffness and either TNF-
α or thrombin treatment increases Rho/ROCK signaling and cell contractility through 
phosphorylation of MLC.  In the case of TNF-α (Figure 3.17d), cell contractility is 
sufficient to induce tension-dependent recruitment of vinculin to adherens junctions, 
which plays a protective role against junction opening.  Despite increased contractility in 
response to TNF-α on stiff substrates, vinculin reinforcement prevents the exacerbation 
of junction loss by increased substrate stiffness.  On stiff substrates, Rho/ROCK signaling 
is higher in response to thrombin (Figure 3.17e) than TNF-α, which translated to 
substrate-enhanced monolayer permeability.   
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Figure 3.17.  Proposed mechanism for substrate-dependent endothelial adherens junction loss in 
response to TNF-α and thrombin.  (a) On soft substrates in untreated samples, TNF-α and 
thrombin receptor are present but not activated.  (b) Both TNF-α and thrombin elicit low levels of 
Rho/ROCK signaling on soft substrates.  (c) On stiff substrates there is a low level of basal 
Rho/ROCK activity. (d) TNF-α treatment on stiff substrates induces Rho/ROCK contractility and 
recruits vinculin to junctions, which provides a protective effect against junction opening. (e) 
Thrombin treatment induces a large increase in Rho/ROCK contractility that also recruits vinculin 
to junctions, but overwhelms to protective effect of vinculin. 
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3.4.3. Alternative signaling pathways   
While these data support the role of cell contractility endothelial adherens 
junction integrity, loss of junction integrity is not purely mechanical.  In fact several 
biochemical signaling pathways are involved in junction loss, including cell-cell junction 
protein phosphorylation [317, 318].  For example, in human lung microvascular and 
pulmonary artery endothelial cells in vitro, TNF-α induced VE-cadherin, β-catenin, γ-
catenin, and p120 catenin phosphorylation.  Increased monolayer permeability following 
TNF-α treatment was completely eliminated by pre-treatment with the protein tyrosine 
kinase inhibitors genistein, herbimycin A, and geldanamycin [319].  In addition, TNF-α 
induces reactive oxygen species (ROS) production in the endothelium, which can 
contribute to adherens junction loss [184].  This alternative pathway is further 
investigated in the next chapter.  Successful therapies to treat or prevent endothelial 
permeability may need to address both contractility-dependent and contractility-
independent barrier loss.   
3.4.4. Similarities and differences between the endothelium in vivo and cultured 
endothelial cells in vitro  
This study highlights important differences between endothelial cells in vivo and 
in vitro.  One clear difference is in adherens junction morphology.  While PAECs 
displayed large adherens junctions in vitro, endothelial cells in the mouse aorta displayed 
small, less pronounced junctions between adjacent cells that appear similar to the 
“reticular” junctions.  However, the study of reticular adherens junction in cultured 
endothelial cells is still informative to the behavior of the endothelium in vivo, as 
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reticular junctions in intact vessels contain the same junction proteins as reticular 
junctions in vitro [186].   This difference in adherens junction morphology may be due to 
the fact that the cells in culture are not exposed to shear strain or cyclic stretch; the static 
culture environment may enable more stable junction formation.  In a published study, 
HUVECs exposed to physiological shear stress for 48 hours exhibited small reticular 
junctions similar to those seen in vivo [320].  
There were also striking differences in focal adhesion size between endothelial 
cells in vitro and in vivo.  Cultured cells (particularly on stiff substrates, as shown in 
Figure 3.11) form large focal adhesions containing both vinculin and the signaling 
molecule pFAK, even in the absence of biochemical stimuli.  Strikingly, focal adhesions 
are considerably smaller in the intact mouse endothelium and generally do not contain 
pFAK under resting conditions.  pFAK was observed at focal adhesions in areas where 
the endothelium had been damaged prior to fixation of the vessel (data not shown).  This 
difference in focal adhesion size between in vitro and in vivo endothelial cells may 
explain the differences observed in actin cytoskeletal structure, as basal actin fibers 
originate from focal adhesions.  In vivo, where focal adhesions are generally small, few 
basal actin fibers are observed; conversely, endothelial cells in vitro have both large focal 
adhesions and significant amounts of basal stress fibers.  These observations have 
implications for the transition between in vitro and in vivo testing; treatments that 
normally elicit major actin-dependent morphological changes in vitro may produce less 
dramatic effects in vivo.     
In addition, under the conditions that we tested, there was very little to no pFAK 
at cell-cell junctions in PAECs on the PA gel substrates used in this study.  pFAK was 
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observed at cell-cell junctions in the ELN+/- aortic endothelium (Figure 3.5C).  The 
function of pFAK at endothelial cell-cell junctions is still under investigation.  In cultured 
human pulmonary artery endothelial cells (HPAECs), treatment with sphingosine 1-
phosphate, which promotes barrier integrity, induced pFAK translocation to cell-cell 
junctions [321].  Conversely, in response to VEGF, FAK co-localized with VE-cadherin 
in vitro and in vivo and played a role in increasing vascular permeability [322].  FAK 
activity at cell-cell junctions may also play a key role in the control of the endothelial 
barrier in the context of cancer; VEGF-dependent tumor metastasis into the lungs was 
decreased through FAK knock-down in mice [323].  In this work, increased pFAK 
labeling at ELN+/- aortic endothelial cell-cell junctions suggests decreased endothelial 
barrier function or increased junction turnover.              
In both in vitro and ex vivo immunofluorescent labeling, pFAK was detected in 
the endothelial nuclei.  While the role of pFAK in the nucleus is not completely clear, 
some studies have suggested that FAK may modulate gene expression through interacting 
with transcription factors [324, 325].  In neonatal rat ventricular myocytes, FAK 
localized to the nucleus following the application of 10% static strain for 30 minutes, 
suggesting FAK translocation to the nucleus is mechanosensitive [326].  Recent 
published studies have suggested that pharmacological FAK inhibition may prevent TNF-
α-induced inflammatory vascular cell adhesion molecule-1 (VCAM-1) expression 
through FAK’s role as a nuclear scaffold protein [327]. As nuclear localization of pFAK 
was observed in both cultured endothelial cells and the intact mouse aortic endothelium, 
this represents an area of possible further investigation.  Since early results indicate that 
FAK translocation to the nucleus is mechanosensitive and occurs in response to 
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inflammation, FAK’s ability to act as a nuclear scaffold protein may represent another 
mechanism for biomechanical and biochemical cross-talk in the endothelium.     
 
3.5. Study limitations 
While our research demonstrates important interactions between substrate stiffnes 
and inflammation, it is not without limitations. First, the in vitro model chosen to study 
the effects of vessel stiffness, polyacrylamide gels, does not accurately replicate vessel 
mechanical properties.  While this in vitro system has been widely used to investigate the 
effects of substrate stiffness on cultured cells, the mechanical properties of PA gels differ 
from those of tissues.  Namely, PA gels are linearly elastic while most tissues are 
viscoelastic [56, 328].  A recently published study demonstrated that degree of 
viscoelasticity affected cell spread area, proliferation, and nuclear translocation of the 
transcriptional co-activator Yes-associated protein (YAP).  In particular, fibroblasts were 
unable to spread on elastic substrates with initial modulus of 1.4 kPa; yet cells spread, 
formed actin stress fibers and large focal adhesions on stress-relaxing substrates with the 
same initial modulus [329].  Whether or not stress-relaxing materials will reveal 
additional substrate-dependent effects on contractility-dependent barrier loss of 
endothelial monolayers has yet to be investigated. 
Our in vitro model is also limited by the lack of shear stress, which in constantly 
present in blood vessels in vivo.  Systems capable of applying shear stress to endothelial 
cells on substrates of varying stiffness have been published within the last year [330, 
331].  Following 5 hours of flow adaptation, cells on 30 kPa substrates were more 
sensitive to TNF-α than cells on 3 kPa substrates, as determined by translocation of the 
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transcription factor NF-κB to the nucleus; however, TNF-α sensitivity was normalized 
between cells on 3 and 30 kPa substrates following 24 hours of flow adaptation [331].  In 
another system, shear stress-induced RhoA activation was lower in cells on 2.5 kPa 
substrates compared to cells on 10 kPa substrates and glass.  Cell-cell junction width was 
higher in cells on 10 kPa substrates compared to cells on 2.5 kPa substrates in both static 
and shear stress samples.  Shear stress decreased cell-cell junction width in cells on 2.5 
and 10 kPa substrates [330].  These published studies demonstrate that shear stress can 
modulate cell response to substrate stiffness in vitro; thus, the addition of shear stress to 
our model would more closely simulate conditions in vivo and improve our understanding 
of how vessel stiffness affects endothelial cell response to inflammatory conditions.                 
The results presented in this chapter demonstrated that ROCK-dependent cell 
contractility was necessary for vinculin translocation to cell-cell junctions in response to 
TNF-α and thrombin on stiff substrates.  ROCK increases the availability of activated 
myosin  by direct phosphorylation of myosin light chain (MLC) and preventing de-
phosphorylation of MLC through inhibiting myosin phosphatase [126].  However, the 
contractility pathway is composed of multiple signaling molecules, beyond those 
illustrated in Figure 3.17.  The enzyme myosin light-chain kinase (MLCK) also 
phosphorylates myosin light chain, yet the role of MLCK in substrate-dependent 
contractility was not specifically presented in this chapter [144].  In our preliminary 
studies on MLCK inhibition, treatment with the MLCK inhibitor ML-7 resulted in 
diminished peripheral actin and loss of junctions between cells on glass (data not shown).  
This observation might be explained by published reports on the differential roles of 
MLCK and ROCK in cell contractility.  In single fibroblasts, ML-7 treatment eliminated 
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peripheral actin fibers, while ROCK inhibition by Y-27632 eliminated longitudinal actin 
fibers but maintained peripheral actin fibers [139].  The fact that ML-7 treatment resulted 
in cell-cell junction loss suggests that basal peripheral actinomyosin contractility is 
necessary for junction maintenance in our cells.  In addition, ROCK has been implicated 
in increased permeability of untreated endothelial cell monolayers with substrate 
stiffening.  Thus, while Y-27632 only inhibits part of the contractility pathway, ROCK 
was the most relevant component based on our own observations and those in published 
literature.            
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4. Effect of substrate stiffness on ROS production and non-contractile 
endothelial adherens junction loss 
 
4.1. Introduction 
Endothelial adherens junction loss can occur due to increased actinomyosin cell 
contractility, as discussed in the previous chapter, or through alternative mechanisms.  
Specifically, TNF-α activates the Rho GTPase Rac, which is involved in the production 
of reactive oxygen species (ROS) through NADPH oxidase and src-dependent 
phosphorylation and internalization of adherens junction proteins [184].  ROS are a 
family of highly reactive oxygen-containing molecules, as detailed in Chapter 1, which 
plays an important role in a variety of signaling pathways, such as cell proliferation and 
survival, metabolism, and iron homeostasis [332].  This chapter focuses on the role of 
ROS in substrate stiffness-dependent endothelial adherens junction loss. 
While physiological ROS production is important to healthy cellular function, 
ROS over-production is pathological and referred to as “oxidative stress”.  Oxidative 
stress has been implicated in the pathogenesis of both hypertension and atherosclerosis; 
yet it is still unclear whether ROS production is an early causative factor or a 
consequence of these cardiovascular diseases [333].  In an ApoE-/- mouse model of 
atherosclerosis, increased NADPH oxidase (NOX2) expression in the endothelium 
preceded plaque development, and NOX knock-down decreased lesion size, which 
suggests a causative role [334].  In humans, women with hereditary NOX2 deficiency 
exhibited lower intima-media thickness, an indicator of atherosclerotic burden, compared 
to age-matched controls [335].  While superoxide is likely produced in many stages of 
atherosclerosis, these findings suggest superoxide may play an early role in endothelial 
barrier dysfunction prior to atherosclerotic plaque initiation. 
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Since a variety of pathways are activated in endothelial cells following TNF-α 
exposure, it is difficult to isolate the effect of any one pathway (in this case, the ROS 
pathway).  Therefore, to isolate the effect of substrate stiffness on endothelial cell ROS 
production, we chose an activator of protein kinase C (PKC) widely used as a positive 
control for ROS production—phorbol 12-myristate 13-acetate (PMA).  In published 
studies, PMA treatment increased endothelial monolayer permeability but did not 
increase markers of actinomyosin contractility, such as silicon substrate wrinkling, 
myosin light chain (MLC) phosphorylation or myosin light chain kinase (MLCK) 
activation [144, 207].  Other studies have suggested that phorbol esters may induce 
barrier loss through intermediate filament reorganization (vimentin or caldesmon effects) 
or actin cytoskeleton reorganization [209, 211, 336].  Thus, PMA represents a 
permeability-inducing stimulus dependent on ROS production instead of actinomyosin 
contractility.         
The role of vessel or substrate stiffness in modulating ROS production in 
endothelial cells has been largely unstudied, although endothelial superoxide production 
is mechanosensitive, specifically in response to shear stress [337].  Cultured bovine aortic 
endothelial cells produced three times more superoxide under oscillatory shear stress 
compared to laminar flow [338].  Shear stress activates Rac, which is downstream of 
integrin activation and contributes to ROS production [339, 340].  In endothelial cells, the 
effect of substrate stiffness-dependent integrin activation has not been reported.  In 
epithelial cells, MMP-3-stimulated ROS production was approximately 3.5-fold higher 
on 4.02 kPa substrates compared to 0.13 kPa substrates; β1 integrin sub-unit knock-down 
eliminated ROS production in response to MMP-3 [215].  These findings support earlier 
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studies in fibroblasts showing that integrin activation regulates Rac1 localization [217].  
Thus, we hypothesized that substrate stiffening increases endothelial ROS 
production, resulting in increased non-contractile actin fiber formation and cell-cell 
junction loss.      
This chapter presents both in vitro and ex vivo data on the effect of substrate and 
vessel stiffness, respectively.  Using the polyacrylamide gel substrate system introduced 
in Chapter 3, we studied PMA-induced junction loss and actin fiber reorganization 
through immunofluorescent labeling.  A live cell ROS assay was used to assess ROS 
production on substrates of varying stiffness.  Abdominal aortae were dissected from 
wild type and elastin haploinsufficient mice (shown to have varying sub-endothelial 
stiffness in Chapter 3) and treated with PMA ex vivo prior to actin cytoskeleton 
visualization by en face confocal imaging.  In this chapter we present data showing, for 
the first time, that substrate stiffness enhances ROS production in endothelial monolayers 
in vitro.    
 
4.2. Methods 
4.2.1. Cell culture and polyacrylamide (PA) gel sample preparation  
 Porcine aortic endothelial cells (PAEC) were cultured as described previously and 
used up to Passage 9.  When used in the ROS and PKC kinase activity assays, cells were 
seeded on PA gel substrates in phenol-red free DMEM containing 5% FBS, 1% PSG and 
serum-starved overnight in phenol-red free DMEM containing 1% FBS, 1% PBS. PA gel 
substrates were prepared as described previously; the size and volume of gel solution 
used to prepare samples for each type of assay are provided below. 
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4.2.2. Immunofluorescence (in vitro and ex vivo samples) 
In vitro samples on glass coverslips and PA gel substrates were fixed, 
permeabilized, and labeled for immunofluorescence as described previously.  For cell 
imaging on gels, 12 mm circular PA gel substrates were prepared using 50 μL gel 
solution.  Cells on 12 mm circular glass coverslips were mounted using 1:1 glycerol:PBS 
solution prior to imaging.  Mouse aortae were fixed with ice-cold 4% paraformaldehyde 
solution, blocked and permeabilized simultaneously in PBS containing 1% BSA and 
0.3% TritonX-100.  Actin and nuclei were labeled using 16.5 nM rhodamine phalloidin 
and 0.2 μg/mL bisbenzimide, respectively, prior to mounting in 1:1 glycerol:PBS.  
Confocal image z-stacks were acquired for all samples with either a 0.25 or 0.5 μm step 
size (for in vitro and ex vivo samples, respectively) using an Olympus Fluoview 1000 
confocal microscope.    
 
4.2.3. Matlab image analysis 
Custom Matlab code was created to extract quantifiable data from confocal 
images of cells on polyacrylamide gel substrates.  For all experiments in this chapter, 
confocal z-stacks were acquired to capture immunofluorescence through the entire 
endothelial layer, then images in the z-stack were compressed to produce to one image 
per z-stack.  For samples labeled for phosphorylated myosin light chain (pMLC), 
background was subtracted using a 50x50 pixel area.  Images were then binarized.  The 
threshold for binarization was determined using Otsu’s method, which calculates a 
threshold for each image based on the distribution of pixel intensities within that image 
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[277].  Noise was removed from binarized images by excluding any objects (also referred 
to as “connected components”) smaller than 30 pixels.  The number of remaining pixels 
with intensities above the threshold (pMLC “positive” pixels) was counted for each 
image.  Three images per sample were quantified using this method and averaged to 
calculate the MLC activation in each sample.   
  For the ROS assay, image processing and quantification were conducted using a 
similar process.  Background was subtracted using a 50x50 pixel region, images were 
binarized by Otsu’s method, and connected components smaller than 9 pixels were 
discarded to remove noise.  Remaining “positive” pixels were counted.   The mean pixel 
counts for three images were calculated to produce the final quantification of ROS 
production per sample.   
 
4.2.4. PKC kinase activity assay 
PAECs were seeded in 6-well dishes or on 22x22 mm PA gels in 6-well dishes 
and allowed to reach confluence over three days.  Cells were serum-starved in 1% FBS-
containing medium overnight prior to use in the assay.  Cells were treated with 1 μM 
PMA for the times indicated in individual figures, then rinsed quickly with ice-cold PBS.  
For cells on tissue culture plastic, 50 μL of lysis buffer (20 mM MOPS, 50 mM β-
glycerolphosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM EGTA, 
2 mM EDTA, 1% NP40, 1 mM dithiothreitol, 1 mM benzamidine, 1 mM 
phenylmethanesulphonylfluoride, 10 μg/mL leupeptin, 10 μg/mL aprotinin) was added to 
each well.  For cells on gel substrates, gels were removed from the 6-well plate in which 
they were seeded and excess liquid was removed by gently dabbing the side of each gel 
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on a Kimwipe.  Gels were then inverted into a new 6-well plate containing 50 μL lysis 
buffer, and cells were lysed for 10 minutes at 4°C.  Lysed cells were scraped from the 
plastic or gel substrates, and lysate was collected into pre-chilled Eppendorf tubes.  For 
gel samples, the lysates from at least two samples were combined to obtain enough lysate 
material.  Lysates were centrifuged at 4°C for 15 minutes at 13,000 rpm, and supernatants 
were transferred to new pre-chilled tubes.  Protein concentration was determined by BCA 
assay.  For each sample, 30 μL clarified lysate was used in the ELISA-based PKC kinase 
assay (Enzo) following manufacturer’s instructions.  Briefly, control or sample lysates 
were incubated with ATP for 90 minutes at 30°C in a 96-well microtiter plate pre-coated 
with a PKC substrate, which is phosphorylated by active PKC.  The 96-well plate was 
manually shaken every 20 minutes.  The reaction was stopped by removing the contents 
of the plate.  A phosphospecific substrate antibody was added to each well and incubated 
for 60 minutes at room temperature with gentle manual shaking every 20 minutes.  The 
plate was washed and then incubated with anti-rabbit IgG:HRP conjugate for 30 minutes 
at room temperature with gentle manual shaking every 10 minutes.  The plate was 
washed and then incubated with the tetramethylbenzidine substrate for 30 minutes, during 
which time color developed in the plate proportional to PKC phosphotransferase activity.  
Plate development was stopped by adding acid stop solution, and absorbance at 450 nm 
was measured on a microplate reader (Thermo Labsystems, Multiskan Spectrum).  
Relative kinase activity was calculated using the equation: 
ܴ݈݁ܽݐ݅ݒ݁	݇݅݊ܽݏ݁	ܽܿݐ݅ݒ݅ݐݕ ൌ ሺܣݒ݁ݎܽ݃݁	ܾܽݏ݋ݎܾܽ݊ܿ݁௦௔௠௣௟௘ െ ܣݒ݁ݎܽ݃݁	ܾܽݏ݋ݎܾܽ݊ܿ݁௕௟௔௡௞ሻܳݑܽ݊ݐ݅ݐݕ	݋݂	ܿݎݑ݀݁	݌ݎ݋ݐ݁݅݊	ݑݏ݁݀	݌݁ݎ	ܽݏݏܽݕ 	 
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4.2.5. ROS assay 
Thin circular PA gels were prepared using 5 μL PA gel solution between a 22x22 
mm square hydrophilic bottom coverslip and 12 mm diameter circular hydrophobic top 
coverslip.  Gels were coated with collagen as described previously. Gels or collagen-
coated 35 mm glass-bottom dishes were seeded with cells in phenol red-free DMEM 
containing 5% FBS, 1% PSG as previously described and allowed to reach confluence.  
Cells were serum-starved in phenol red-free DMEM containing 1% FBS, 1% PSG 
overnight prior to the assay.  Samples were treated with 1 μM PMA for the durations 
specified in each figure.  For a positive control, cells in glass-bottom dishes were treated 
with 100 μM tert-butyl hydroperoxide (tBHP) for 60 minutes.  The general oxidative 
stress dye 5-(and 6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA) was reconstituted in dimethyl sulfoxide (DMSO) and then diluted into 
warmed phenol red-free medium at a final concentration of 25 μM.  The treatment (either 
PMA or tBHP) was removed from the cells, followed by one rinse with warmed HBSS 
buffer (0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 5.6 mM glucose,0.44 mM 
KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3).  CM-H2DCFDA was 
added to each sample (400 μL), and incubated for 25 minutes in a 37°C incubator, 
protected from light.  To label nuclei, bisbenzimide was added to each sample for a final 
concentration of 0.2 μg/mL.  The samples were returned to the dark incubator for an 
additional 5 minutes, then rinse twice with warmed HBSS buffer.  Samples were 
immersed in warmed phenol red-free media and transferred to the Olympus Fluoview 
1000 microscope.  Samples were imaged by acquiring z-stack images with a 1 μm step 
size.     
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4.2.6. Ex vivo vessel treatment 
The abdominal aorta was dissected from wild type (WT, C57BL/6) or elastin 
haploinsufficient (ELN+/-) mice and immersed in cold HEPES buffer (140 mM NaCl, 5 
mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM Na2HPO4, 10 mM HEPES, 10 mM 
sodium acetate, 5 mM glucose, pH 7.4) while excess adipose tissue was removed from 
the outside of the vessel.  Untreated segments were fixed immediately following 
dissection.  Treated aortic segments were cannulated (Figure 4.1), submerged in a bath of 
HEPES buffer maintained at 37°C, pressurized to 80 mmHg, and allowed to equilibrate 
for 30 minutes.  DMEM containing 5 μM PMA was administered intraluminally through 
the cannulation set-up, and the vessel was re-pressurized to 80 mmHg for the duration of 
the 30-minute treatment time.  Ice-cold 4% paraformaldehyde was then simultaneously 
administered intraluminally and added to the bath.  The vessel was fixed for 30 minutes, 
then cut open longitudinally and pinned flat with insect pins for the immunofluorescent 
labeling process (described above). 
 
4.2.7. Statistical analysis 
All statistical analyses were conducted using Matlab’s statistical toolbox.  Graphs 
represent mean ± standard deviation.  Multiple groups were compared using either two-
way or n-way ANOVA with post-hoc Tukey-Kramer test, and two groups were compared 
by Student’s t-test.  Within each PKC assay, conditions were tested in duplicate.  For 
measurement of ROS production, conditions were tested in triplicate.  All experiments 
were run at least two times, excluding ex vivo immunofluorescent labeling. 
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Figure 4.1. Vessel pipette cannulation set-up.  (a) Cannulation apparatus (white) was placed on a 
microscope stage.  Treatments were administered to the vessel intraluminally through tubing 
connecting to glass pipettes.  A temperature-controlled bath held the cannulated vessel, as viewed 
through the microscope in (b).  Aortic segments were affixed to glass pipettes using black string.   
 
4.3. Results 
4.3.1. Timing and magnitude of ROS production in cultured endothelial cells on 
substrates of different stiffness 
  To assess the timing of when PMA induced endothelial cell ROS production, 
ROS levels were measured in PAEC on glass following PMA treatment for 5 to 30 
minutes (Figure 4.2).  Nuclear labeling (left, Hoechst) confirmed the presence of cells in 
the field of view. ROS production (right, CM-H2DCFDA) was not detected in the 
untreated sample, but was elevated in the positive control (tBHP). ROS production 
peaked with 10 minutes (2.5-fold) of PMA treatment and diminished nearly to control 
levels with 30 minutes of PMA treatment.  Based on this time course, cells on 6, 14, and 
29 kPa gels were treated with PMA for 10 minutes.   
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Figure 4.2.  ROS production peaked with 10 minutes of PMA treatment for endothelial cells on 
glass.  (a) PAEC monolayers were treated with 1 μM PMA for 0, 5, 10, 15, or 30 minutes to 
determine ROS production timing.  Cell nuclei were labeled with Hoechst (left), and ROS was 
fluorescently detected using CM-H2DCFDA (right).  Samples were imaged by confocal 
microscopy at 20X magnification and confocal z-stacks were compressed.  Scale bar is 25 μm. 
(b) ROS production was quantified using custom Matlab code.  PMA-treated samples were 
normalized to the positive control (100 µM tBHP, 60 minutes).   #p<0.05 compared to untreated 
samples by Student’s t-test. 
  
To test the hypothesis that ROS production increases with substrate stiffness, cells 
on 6, 14, and 29 kPa gels were treated with 1 μM PMA for 10 minutes prior to ROS 
detection by CM-H2DCFDA.  ROS in untreated samples was minimal on all substrate 
stiffnesses (Figure 4.3).  On 6 kPa substrates, there was no significant difference in 
detected ROS between untreated and PMA-treated cells; on 29 kPa substrates, the 
increase in detected ROS following PMA exposure was approximately 1.5 fold over 
untreated cells.  By one-way ANOVA, fold change in ROS increased with substrate 
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stiffness (p<0.01).   These results demonstrate that substrate stiffening increases ROS in 
response to PMA in cultured aortic endothelial cells. 
 
Figure 4.3.  ROS increased with substrate stiffness following PMA treatment.  (a) PAEC 
monolayers on 6, 14, and 29 kPa gels were treated with 1 μM PMA for 10 minutes.  Cell nuclei 
were labeled with Hoechst (left), and ROS was fluorescently detected using CM-H2DCFDA 
(right).  Samples were imaged by confocal microscopy at 20X magnification and confocal z-
stacks were compressed.  Scale bar is 25 μm. (b) ROS production was quantified using custom 
Matlab code.  PMA-treated samples were normalized to untreated samples on the same substrate 
stiffness.  The effect of substrate stiffness was significant by one-way ANOVA (p<0.01).  
#p<0.05, *p<0.01 by post-hoc Tukey-Kramer test.     
 
4.3.2. Role of PKC activation, actin reorganization, and actinomyosin contractility 
in endothelial cell response to PMA on substrates of different stiffness 
Since PMA is known to induce ROS production through PKC signaling, a PKC 
kinase activity assay was used to determine if PKC activation increased on stiffer 
substrates.  To determine the duration of PMA stimulation needed to elicit PKC 
activation, PAECs on tissue culture plastic were treated with PMA for 5 or 10 minutes.  
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PKC activity in cells on tissue culture plastic increased 3.7-fold following 5 minutes of 1 
μM PMA treatment, and this activation level was sustained following 10 minutes of 
treatment (Figure 4.4a).  Based on this time course, cells on 6, 14, or 29 kPa gel 
substrates were exposed to PMA for 5 minutes prior to measuring PKC kinase activity.  
PMA increased PKC activity 2.6=2.9 fold for cells on substrates of varying stiffness 
(Figure 4.4b). By two-way ANOVA, the PMA effect was significant (p<0.001), while the 
stiffness effect was not significant.  Therefore, substrate-dependent differences in PKC 
activation did not account for increased ROS production on stiffer substrates in response 
to PMA. 
114 
 
 
 
Figure 4.4.  PKC kinase activity increased by 5 minutes following PMA exposure in endothelial 
cells on PA gels independent of substrate stiffness.  (a) PKC kinase activity was measured 
following 1 μM PMA treatment in cells on tissue culture polystyrene.  Purified active PKC was 
the positive control.  *p<0.01 compared to untreated by Student’s t-test (b) Endothelial cell 
monolayers on 6, 14, and 29 kPa substrates were treated with 1 μM PMA for 5 minutes.  PMA 
treatment effect was significant by two-way ANOVA (p<0.001), but substrate stiffness effect was 
not significant.  #p<0.05 by post-hoc Tukey-Kramer test compared to untreated.     
 
ROS production is known to induce actin fiber formation in endothelial cells 
[199].  To see if substrate-dependent ROS production increased actin fiber formation, 
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PMA-stimulated cells on substrates of increasing stiffness were labeled for actin.  In 
untreated samples, peripheral actin fibers were observed in cells on all substrates, but 
were particularly pronounced in cells on the softest 6 kPa gels (Figure 4.5).  Following 15 
minutes of PMA treatment, no noticeable changes in actin structure were observed.  
Following 30 minutes of PMA treatment, peripheral actin was still observed with some 
longitudinal stress fiber formation.  On 14 kPa gels, stress fiber formation was more 
prominent, and on 29 kPa the cells displayed pronounced stress fibers with minimal 
peripheral actin.  In summary, PMA induced greater longitudinal actin fiber formation 
and peripheral actin loss in cells on stiff substrates. 
  
Figure 4.5.  Actin stress fiber formation was greater on 29 kPa substrates following PMA 
treatment.  (a) PAEC monolayers on 6, 14, or 29 kPa gels were untreated or treated with 1 μM 
PMA for 15 or 30 minutes prior to fixation and immunofluorescent labeling of actin using 
rhodamine phalloidin.  Areas highlighted by rectangular regions are magnified in (b) to highlight 
differences in morphology.  Images are compressed confocal z-stacks of endothelial monolayers 
imaged at 60X.  Scale bar is 25 μm. 
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To determine whether ROS-induced actin stress fiber formation was associated 
with increased actinomyosin contraction in our cells, PAECs were labeled for 
phosphorylated myosin light chain (pMLC), followed by image quantification.  For the 
positive control (10 U/mL thrombin for 30 minutes), cells on 29 kPa substrates localized 
pMLC along actin fibers (Figure 4.6a) and increased overall pMLC approximately 14-
fold (Figure 4.6b).  1 μM PMA treatment for 15 or 30 minutes did not induce pMLC 
translocation to actin fibers or increase overall pMLC labeling.  These results indicated 
that the changes in actin fiber organization did not coincide with increased substrate-
dependent actinomyosin contractility at the time points tested. Therefore, any cell-cell 
junction loss observed was related to ROS-induced signaling. 
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Figure 4.6.  PMA treatment did not increase pMLC in endothelial monolayers on substrates of 
varying stiffness.  (a) PAEC monolayers on 6, 14, or 29 kPa gels were untreated or treated with 1 
μM PMA for 15 or 30 minutes, prior to fixation and immunofluorescent labeling of 
phosphorylated myosin light chain (pMLC).  For the positive control, cells on a 29 kPa gel were 
treated with 10 U/mL thrombin for 30 minutes.  Images are compressed confocal z-stacks of 
endothelial monolayers imaged at 60X.  Scale bar is 25 μm. (b)  Number of pixels positive for 
pMLC was quantified using custom Matlab image processing code.  The effects of stiffness and 
PMA treatment were not significant when assessed by n-way ANOVA. 
 
 
4.3.3. ROS-mediated substrate-dependent changes in adherens junction 
morphology in response to PMA 
 Increased ROS induces cell-cell junction loss, which has been attributed in part to 
cell-cell junction protein phosphorylation and internalization [206, 341, 342].  We next 
tested the hypothesis that substrate stiffening worsens ROS-mediated adherens junction 
loss in response to PMA.  In untreated cells on all substrates, areas of wide reticular 
adherens junctions were visible between adjacent cells (Figure 4.7).  After 15 minutes of 
PMA treatment, reticular junctions were mostly maintained in cells on the 6 kPa substrate 
whereas some reticular junction structure loss was observed in cells on the 29 kPa 
substrate.  Following PMA exposure for 30 minutes, wide reticular junctions were 
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maintained in cells on the 6 kPa substrate (indicating little junction loss) and to a lesser 
extent in cells on the 14 kPa substrate.  On the stiffest 29 kPa substrate, nearly all 
junctions lost their reticular structures with some junctions appearing wavy or disrupted.  
These results demonstrate that endothelial reticular junction structure loss is exacerbated 
by stiffer substrates in response to the ROS stimulant PMA.     
 
Figure 4.7.  Reticular adherens junction loss was greater in endothelial cell monolayers on stiffer 
substrates following PMA treatment.  PAEC monolayers on 6, 14, or 29 kPa gels were untreated 
or treated with 1 μM PMA for 15 or 30 minutes, prior to fixation and immunofluorescent labeling 
of the cell-cell junction protein β-catenin.  Areas highlighted by rectangular regions are magnified 
in (b) to highlight differences in morphology.  Images are magnified subsets of compressed 
confocal z-stacks of endothelial monolayers imaged at 60X.  Scale bar is 25 μm. 
 
 
To confirm that ROS led to PMA-induced junction loss, ROS scavengers were 
administered prior to PMA treatment.   ROS scavengers were applied to cells on glass 
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coverslips, instead of gel substrates, because junction loss following PMA exposure was 
most extreme in cells on glass; thus, the effect of scavenger pre-treatment on PMA-
induced morphological changes was most evident in cells on coverslips.   ROS 
scavengers themselves did not affect cell-cell junction structure, since samples treated 
with ROS scavengers alone still exhibited reticular junctions.  Cells treated with PMA 
along showed wavy and invaginated junctions (indicating junction loss); this PMA-
induced change in junction morphology was prevented by ROS scavengers (Figure 4.8a, 
b).  More strikingly, ROS scavengers prevented PMA-induced actin reorganization 
(Figure 4.8c).  In untreated cells and cells treated with the ROS scavengers, peripheral 
actin bands were observed.  In PMA-treated cells, peripheral actin was lost and actin 
stress fibers were prominent.  In PMA-treated cells with ROS scavengers, peripheral 
actin fibers were maintained.  Thus ROS production appeared to be responsible for PMA-
induced reticular junction loss and actin fiber formation. 
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Figure 4.8.  ROS scavengers prevented PMA-induced adherens junction loss and actin fiber 
redistribution in endothelial cells on collagen-coated glass coverslips.  Endothelial cell 
monolayers were pre-treated with or without ROS scavengers (4 mM N-acetyl cysteine, 50 mM 
sodium pyruvate) for 1 hour, prior treatment with or without 1 μM PMA for 30 minutes.  (a) 
Samples were fixed and immunofluorescently labeled for β-catenin, with individual 
representative cells magnified in (b); immunofluorescently labeled for actin (rhodamine 
phalloidin, c).  Areas highlighted by rectangular regions are magnified in (d) to highlight 
differences in morphology.  Images are compressed confocal z-stacks of endothelial monolayers 
imaged at 60X.  Scale bar is 25 μm. 
 
4.3.4. PMA-induced actin reorganization in the abdominal aortic endothelium of 
wild type and elastin haploinsufficient mice 
 To investigate the relevance of our in vitro observations to endothelial response in 
vivo, aortic segments from wild type (WT) and elastin haploinsufficient (ELN+/-) mice 
were exposed to PMA in an ex vivo cannulated system.  The endothelium from the WT 
mouse exhibited few actin fibers (Figure 4.9).  Peripheral actin fibers were slightly more 
prominent in the untreated ELN+/- aortic endothelium.  With PMA treatment (5 μM, 30 
minutes), peripheral actin was observed in the WT aortic endothelium and to a much 
greater extent in the ELN+/- aortic endothelium.   
When VE-cadherin (green) and actin (red) images were merged (Figure 4.9), in 
the WT mouse aorta most peripheral actin was co-localized with VE-cadherin (indicated 
by yellow) following ex vivo PMA treatment.  In the PMA-treated aortic segment from 
the ELN+/- mouse, more peripheral actin but less VE-cadherin labeling was observed 
(indicated by less yellow and more red).  These merged images highlight the PMA-
induced actin fiber formation differences between the two genotypes.  Interestingly, little 
to no longitudinal actin stress fibers were observed, as are frequently observed in vitro.       
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Figure 4.9.  Peripheral actin fiber formation was greater in stiffer (ELN+/-) vessels in response to 
PMA. Abdominal aorta from WT or ELN+/- mice were either fixed without treatment (left) or 
treated with 5 μM PMA for 30 minutes and fixed (middle), prior to labeling actin (rhodamine 
phalloidin).  Images on the right show both actin (red) and VE-cadherin (green), with areas of 
colocalization (yellow).  The endothelium of intact aortae were imaged en face by confocal 
microscopy with 0.5 μM step size.  Confocal z-stacks were compressed.  Scale bar is 25 μm.        
 
4.4. Discussion 
 In this chapter we demonstrated that substrate stiffening exacerbated ROS 
production in cultured endothelial cells in response to PMA.  PMA-induced stress fiber 
formation was greater on stiff substrates, but stress fiber formation was not associated 
with increased myosin phosphorylation, suggesting that PMA did not elicit cell 
contractility.  PKC activation was consistent among substrates, which indicated that 
substrate-dependent responses to PMA were not PKC dependent.  Cells on stiffer 
substrates exhibited increased cell-cell junction loss in response to PMA, which was 
prevented through pre-treatment with ROS scavengers.  Lastly, stiffer aortas from 
ELN+/- mice showed increased peripheral actin fiber formation in response to PMA.     
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4.4.1. Proposed mechanism 
 Figure 4.10 presents a potential mechanism for how PMA stimulates more ROS 
production in endothelial cells on stiff substrates.  Since integrin activation is low on 
softer substrates (Figure 4.10a), Rac1 activity is maintained at a low level. Since Rac1 is 
essential to NADPH oxidase assembly at the cell membrane, basal NADPH oxidase 
activity is low on soft substrates.  On stiffer substrates, integrin activation is increased, 
enabling greater Rac1 activation and increased NADPH oxidase complex formation 
(Figure 4.10b).  When PMA binds and activates PKC, which initiates NADPH oxidase 
assembly through the phosphorylation of NADPH oxidase sub-units, the low Rac1 
activity in cells on soft substrates results in minimal ROS production (Figure 4.10c).  
PMA stimulation of cells on stiff substrates (Figure 4.10d) results in increased ROS 
production through increased integrin-dependent Rac1 activation.  Elevated ROS 
production on stiff substrates results in actin stress fiber formation and adherens junction 
proteins phosphorylation, which results in cell-cell junction loss [205].   
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Figure 4.10.  Proposed mechanism for substrate-dependent ROS-mediated cell-cell 
junction loss. (a) On soft substrates in untreated samples, integrin-dependent Rac1 activity and 
NADPH oxidase (NOX) localization to the membrane are low.  (b) On stiff substrates in 
untreated samples, integrin-dependent Rac1 activity and NOX localization to the membrane are 
increased.  (c)  In PMA-treated cells on soft substrates, superoxide production is minimal due to 
low levels of NOX assembled at the cell membrane. (d) In PMA-treated cells on stiff substrates, 
superoxide production is elevated due to increased integrin-dependent NOX at the membrane.  
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4.4.2. Broader cardiovascular implications:  alternative effects of endothelial 
superoxide and superoxide production by non-endothelial cell types  
 The goal of this work was to study substrate-dependent ROS-mediated endothelial 
cell-cell junction loss.  However, ROS also leads to other adverse effects on the 
endothelium.  Specifically, superoxide interacts with nitric oxide (NO) to form 
peroxynitrite (ONOO-).  This interaction effectively decreases the availability of NO, 
which is needed for vasodilation [46, 343].  Secondly, superoxide can decrease NO 
production through eNOS uncoupling.  Under normal conditions, eNOS converts L-
arginine and molecular oxygen to NO and citrulline [344].  This reaction requires several 
co-factors, including tetrahydrobiopterin (BH4).  eNOS uncoupling can occur when BH4 
is oxidized by superoxide and therefore is not available [345, 346]. Uncoupled eNOS 
produces superoxide (O2-) instead of NO [347].  eNOS uncoupling represents just one 
example of how ONOO- causes cardiovascular damage; in fact, protein nitration by 
ONOO- has been widely observed in a variety of cardiovascular diseases [348].  Thus, if 
vessel stiffness exacerbates endothelial ROS production as this work proposes, the 
damaging effects would go beyond endothelial barrier function. 
While this study focused on endothelial-derived ROS, superoxide is also 
produced in other cardiovascular cell types [194].  For example, cardiomyocytes produce 
superoxide via NADPH oxidase.  Increased superoxide was associated with heart failure; 
interestingly, while cardiomyocytes in non-failing and end-stage failing hearts expressed 
comparable NADPH oxidase sub-unit levels, p47phox membrane localization increased 
in failing hearts [349].  Vascular smooth muscle cells also produce ROS.  In a mouse 
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model of atherosclerosis (ApoE-/-), NADPH oxidase sub-unit p47phox knockdown 
resulted in decreased smooth muscle cell superoxide production and decreased total 
lesion area [350].  Based on superoxide and oxidized low density lipoprotein (ox-LDL) 
co-localization in human atherectomy samples (excised atherosclerotic plaques), ROS 
produced by smooth muscle cells and fibroblasts may further oxidate ox-LDL, a 
component of atherosclerotic lesions [351, 352].  If the effect of increased vessel stiffness 
on ROS production extends to vascular smooth muscle cells and cardiomyocytes, the 
harmful effects of oxidative stress could be amplified.  
              
4.4.3. ROS as a therapeutic target 
Oxidative stress, created through a combination of ROS overproduction and 
inadequate ROS inactivation, has been implicated in a variety of cardiovascular diseases; 
specifically, the enzyme responsible for superoxide production (NADPH oxidase) has 
been identified as a therapeutic target for atherosclerosis [352, 353].  However 
antioxidants, such as vitamin E, have shown inconsistent success in preventing 
cardiovascular events or improving cardiovascular function in human clinical studies.  A 
variety of reasons behind the lackluster clinical trial results have been provided.  For one, 
relatively low ROS levels are necessary for normal cellular functions; thus, treatments 
resulting in severe reduction of ROS below normal levels could be harmful.  Screening of 
study participants for oxidative stress biomarkers has been suggested as a way of 
improving study results [354].   
If follow-up studies confirm that increased arterial stiffness exacerbates ROS 
production in vivo, non-invasive patient screening for arterial stiffness by pulse wave 
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velocity (PWV) could be used in conjunction with oxidative stress biomarker screening 
to determine the best treatment option.  In elderly patients, increased arterial stiffness was 
strongly correlated with multiple indicators of atherosclerosis (carotid intima-media 
thickness, and severity of carotid and aortic plaques) [355].  In patients undergoing 
coronary angiography, increased superoxide production by activated neutrophils 
positively correlated with measurements of arterial stiffening (augmentation index and 
pulse pressure amplification [356].  However, to our knowledge, there has been limited 
investigation of the correlation between arterial stiffening and endothelial superoxide 
production in humans.             
 
4.4.4. Limitations 
 While our work shows that PMA-induced ROS production increases with 
substrate stiffness, our research is not without limitations. Phorbol esters, including PMA, 
are found in certain plants and can cause toxicity in animals when consumed [357].  Yet 
the physiological relevance of endothelial response to PMA is questionable; it is not 
involved in the pathogenesis of any cardiovascular diseases.  We chose to use PMA 
because it useful in isolating the effect of ROS production, as it elicits ROS-mediated 
cell-cell junction loss without inducing cell contractility [144, 207].  
Most data presented in this chapter were from in vitro studies of endothelial cells 
on polyacrylamide gel substrates.  In this in vitro system, cells were not exposed to shear 
stress or strain as they would normally experience in vivo.  En face images of actin in 
mouse aortic endothelium were presented; however, superoxide was not detected in intact 
vessels under physiological conditions.  Superoxide detection in vessels could better 
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directly demonstrate increased ROS production in stiffened vessels and its effect on the 
observed actin reorganization.   
 Next, there were some limitations in the methods presented in this chapter.  The 
dye used for ROS detection (CM-H2DCFDA) is transformed to its fluorescent form by a 
variety of different ROS, and as such is a general oxidative stress indicator—not specific 
to superoxide [358].  Since substrates stiffness-dependent ROS production has not been 
previously demonstrated, a general ROS dye was chosen to increase the chance of 
observing an effect.  In future studies, an indicator specific to superoxide such as 
dihydroethidium, could be used to support the hypothesis that integrin activation 
enhances superoxide production by NADPH oxidase [359].  Lastly, immunofluorescent 
labeling of pMLC was used as an indirect measure of contractility.  Other direct 
measures, such as traction force microscopy, could be used to assess cell contractility.  
However, pMLC labeling is specific for actinomyosin contraction and is widely accepted 
in the literature as an indicator of contractility. 
 Despite these limitations, this work illustrates a novel potential mechanism for 
substrate-enhanced ROS production in the endothelium; further study of the interaction 
between arterial stiffness and ROS holds the potential for improving therapies to prevent 
or ameliorate endothelial barrier dysfunction.                
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5. Conclusions and future work 
 
5.1. Thesis summary 
 Cardiovascular diseases represent a major risk to global health, contributing to 
approximately one-third of all deaths worldwide [360].  Although cardiovascular diseases 
are diverse and develop in response to many different factors, arterial stiffening is 
becoming more widely recognized as a major risk factor.  Increased arterial stiffness is 
correlated with cardiovascular mortality, coronary heart disease, and stroke [9].  
Inflammation plays a role in many cardiovascular diseases, including atherosclerosis and 
hypertension [27, 361]; however, little is known about the combined impact of arterial 
stiffening and inflammation on endothelial dysfunction—specifically endothelial cell 
stiffening and endothelial barrier loss.     
 I demonstrated that dielectrophoresis can be used to detect changes in single 
attached endothelial cell deformability using a novel inverted quadrupole device.  I 
further showed that vinculin localization to cell-cell junctions increased in the stiffened 
abdominal aorta of ELN+/- mice.  I demonstrated that vinculin also localized to cell-cell 
junctions in vitro when intracellular tension was increased following exposure to 
inflammatory cytokines TNF-α and thrombin. This effect was enhanced on stiff 
substrates and was prevented through blocking the cell contractility pathway.  In addition, 
I found that substrate stiffness modulated cell stiffening in response to TNF-α, which 
could impact nitric oxide production.  Lastly, I investigated how substrate stiffness 
modulates endothelial reactive oxygen species (ROS) production.  ROS-mediated cell-
cell junction loss was increased on stiff substrates concomitant with actin fiber formation, 
but was independent of cell contractility.  
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 Taken collectively, these data contribute to our understanding of how arterial 
stiffening exacerbates endothelial response to inflammation (through increased 
contractility and ROS production).  This study also supports recent reports that vinculin 
localization to junctions is protective against cell-cell junction opening, a mechanism 
which could be potentially utilized for therapeutic interventions again endothelial barrier 
loss [178].  
 
5.2. Specific discoveries 
The over-arching objective of this work was to investigate how arterial stiffening 
influenced endothelial cell stiffening (which affects nitric oxide production) and 
endothelial barrier function in response to systemic inflammation.  This goal was 
achieved through a combination of in vitro single cell and monolayer studies and ex vivo 
mouse aorta studies.   
In Chapter 2, I presented the simulation, microfabrication, and validation of an 
inverted quadrupole dielectrophoretic (DEP) device for measuring single attached cell 
deformability, which reflects cell stiffness.  I demonstrated that cell deformability in the 
DEP device corresponded to atomic force microscopy measurements, the gold standard 
for assessing cell stiffness.  Differences in cell deformability were demonstrated between 
endothelial cells with or without cytoskeletal disruption by cytochalasin D and between 
transformed and untransformed mammary epithelial cells.   
In Chapter 3, I demonstrated that aortic sub-endothelial stiffness was increased in 
genetically modified elastin haploinsufficient (ELN+/-) mice.  Vinculin co-localization 
with VE-cadherin at endothelial cell-cell junctions in intact aortic sections correlated with 
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sub-endothelial stiffness; vinculin was observed at cell-cell junctions in all segments, but 
was decreased in the softest segment (abdominal aorta of wild type mice).  In vitro, 
substrate stiffening enhanced ROCK-dependent myosin phosphorylation, actin fiber 
formation, and vinculin co-localization with VE-cadherin following exposure of 
endothelial cell monolayers to TNF-α and thrombin.  Substrate stiffness exacerbated 
thrombin-induced, but not TNF-α-induced, monolayer permeability in vitro.  Cells on 
stiff 50 kPa substrates initially stiffened and then softened following TNF-α exposure, 
while cells on soft 6 kPa substrates softened and remained soft. 
In Chapter 4, I demonstrated that substrate stiffening enhanced ROS production in 
endothelial monolayers in response to the PKC activator phorbol 12-myristate 13-acetate 
(PMA).  PMA did not promote increased myosin phosphorylation at the times tested, but 
did induce enhanced reticular adherens junction loss and actin stress fiber formation on 
stiff substrates.  PMA-induced junction loss and stress fiber formation were prevented by 
pre-treatment with ROS scavengers.     
 
5.3. Contributions to the field 
 This thesis contributes to a wide variety of disciplines within the field of cell 
mechanobiology.  The areas of contribution range from cell mechanics device 
development to comparisons of endothelial function in vivo and ex vivo to mechanisms 
underlying substrate-dependent cell-cell junction loss.  The ways in which this thesis 
relates to the broader field of cell mechanobiology are detailed below. 
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5.3.1. Dielectrophoretic device    
First, the dielectrophoretic (DEP) device presented in Chapter 2 represents a novel 
method for applying forces to attached single cells in order to access global 
deformability.  Currently no other non-contact device is capable of deforming attached 
single cells.  Optical stretchers are effective at deforming cells in suspension [279]; yet 
nearly all cell types are adhered within a tissue in vivo, and substrate attachment modifies 
cell stiffness.  Specifically, integrin activation modulates both RhoA and Rac activity, 
which regulate actin polymerization [362].  As fibroblasts in suspension attached to 
fibronectin-coated surfaces, Rho activity decreased within the first 30 minutes, then 
increased [363].  Recently published results suggest that integrin engagement influences 
cell stiffness in cells that are attached but not yet spread; passivation of the attachment 
surface with bovine serum albumin decreased epithelial cell stiffness compared to cells 
attached to a non-passivated surface for 10 minutes [364].  Considering the importance of 
integrin activation in cell stiffness, the ability of our device to measure attached cell 
deformability represents a significant contribution to the field of cell mechanobiology.        
In addition, this device could be transformed into a high-throughput screening 
device through multiplexed electrodes.  An electrode array would enable multiple 
simultaneous measurements, which would improve the capabilities of this device as a 
drug-screening instrument.  Various stimuli, including biochemical (e.g. drug candidates) 
and biomechanical (e.g. shear stress), could be applied to arrays of single cells to 
determine their effect on cell deformability.  Simultaneous use of fluorescent dyes (such 
as DAF-FM diacetate for nitric oxide or dihydroethidium for superoxide) with our device 
would provide data linking the stimuli of interest, cell deformability, and cell function.  
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Thus, the adaption of the DEP device to a multiplexed format would increase the number 
of measurements and the use of live-cell dyes would connect cell stiffness with cell 
function in a high-throughput device.     
Moreover, the DEP device is moveable through the use of a micromanipulator 
and could therefore be adapted to serve even broader purposes, such as the accurate 
positioning or isolation of cells in suspension.  Isolating specific single cells in 
suspension could improve the establishment of stably transfected cell lines; transfected 
cells expressing fluorescent markers could be identified by fluorescence microscopy and 
selected using this DEP device [365].  DEP tweezers have been recently used to isolate 
fluorescent cells [287].  However, fabrication of the tweezers is more complicated than 
fabrication of our device, which is based on photolithography, a technique now widely 
implemented in academic laboratories. 
 
5.3.2. Sub-endothelial stiffness in contractility-dependent endothelial monolayer 
barrier function and cell stiffness 
Our data also show that elastin haploinsufficient (ELN+/-) animals can be used to 
measure the effects of arterial stiffening.  Recent clinical data supporting arterial 
stiffening as a cardiovascular risk factor has promoted interest in animal models to study 
the repercussions of increased vessel stiffness [366].  Since arterial stiffness increases 
with age due to elastin degradation, aged animals have been used to study how the loss of 
vessel elasticity affects endothelial barrier function [134, 367].  However, using aged 
animals is problematic since long lead times are necessary to allow for the aging process 
to occur.  Elastin haploinsufficient (ELN+/-) animals represent a more time-efficient 
134 
 
 
model of arterial stiffening.  This work reports, for the first time, that aortic sub-
endothelial stiffness is increased in ELN+/- mice.  This characterization is an important 
contribution to the field because it establishes this animal model as a viable alternative to 
using aged animals.   
This work contributes to vascular biology through highlighting differences 
between cultured primary endothelial cells in vitro and endothelial cells within an intact 
aorta ex vivo.  Few published studies compare and contrast immunofluorescent labeling 
of intact endothelium and cultured endothelial cells [145, 368-370].  While imaging of 
cultured primary endothelial cells provides a convenient way of observing changes in cell 
morphology in response to particular stimuli, the morphological changes of the 
endothelium in vivo or ex vivo may differ in key aspects.  As one example, the actin 
cytoskeleton is considerably more pronounced in cultured endothelial cells compared to 
intact endothelium. Thus this study supports the need for ex vivo imaging of vessels 
through highlighting these differences. 
 Another important contribution of this work is in improving our understanding of 
vinculin’s role in bolstering cell-cell junctions under tension.  The fact that tension-
dependent unraveling of α-catenin enables binding of vinculin to cell-cell adhesions is 
well established [175].  Relatively recent work demonstrated that vinculin localization to 
endothelial adherens junctions provided reinforcement against junction opening, and 
similar work in epithelial cells supports this conclusion [178, 311].  This thesis reports, 
for the first time, that vinculin recruitment to junctions is enhanced on stiff substrates 
following exposure to contractility-inducing agents (TNF-α, thrombin).  Therapeutic 
interventions that enhance vinculin’s ability to support cell-cell junctions could take 
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advantage of this naturally occurring protective system; such therapies could prevent or 
decrease endothelial barrier loss in response to systemic inflammation, which plays a role 
in a variety of diseases including atherosclerosis, hypertension, rheutamoid arthritis, and 
sepsis.  
This work enhances the understanding of the effects of substrate stiffness on 
endothelial monolayers.  Initial work into substrate-dependent endothelial responses 
focused on single cells, which spread to a greater extent on stiff substrates compared to 
soft substrates.  A study by Yeung et al from 2005 demonstrated that the circumference 
of single bovine aortic endothelial cells increased on PA gel substrates of increasing 
stiffness between 0.2 and 10 kPa; this study also showed by phase contrast microscopy 
that substrate stiffness did not appear to influence cell shape or size of endothelial cells 
within a confluent monolayer [74].  More recent studies have investigated the role of 
substrate in endothelial monolayers.  For example, in vitro neutrophil transmigration 
through HUVEC monolayers was enhanced with substrate stiffening (0.42 to 280 kPa) 
through an MLCK-dependent mechanism [80].  Another study demonstrated that ROCK-
mediated endothelial permeability and leukocyte transmigration through BAEC 
monolayers was higher on stiffer substrates [134].  However, these previous reports did 
not detail the effects of substrate stiffness on inflammation-induced cell-cell junction 
tension, as was included in our study.  Thus, in addition to contributing evidence that 
substrate stiffness affects endothelial monolayers, this work deepens our understanding of 
substrate-dependent changes in junction composition.   
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5.3.3. Sub-endothelial stiffness in endothelial production of ROS 
  The role of substrate stiffness in ROS production has been demonstrated in 
epithelial cells, but not endothelial cells [215].  This work reports for the first time that 
endothelial cell monolayers on stiff substrates produce more reactive oxygen species in 
response to the PKC-activator PMA.  While PMA is not produced in the human body, 
PKC activation is implicated in a variety of conditions, including endothelial barrier loss 
and hyperglycemia [371, 372].  If the proposed model for enhanced ROS production 
through increased integrin activation is confirmed in vivo, the implications would be 
wide-ranging.  Tissue stiffening could potentially exacerbate the effects of any stimulus 
that elicits NOX-dependent superoxide production.    
Improved understanding of the mechanisms underlying ROS production could 
impact the understanding of other diseases beyond atherosclerosis.  Decreased NO-
mediated vasodilation in a diabetic mouse model was attributed to increased endothelial 
superoxide production [373].  In addition, ROS are known to play a role in sepsis, 
although the vascular tissue that most contributes to septic ROS production is less clear 
(i.e. endothelium, smooth muscle cells, immune cells, etc.) [189, 374].  If environmental 
stiffness enhances ROS production in tumors, our results could have implications beyond 
vascular diseases.  Heightened ROS has been observed in tumors, which are often stiffer 
than surrounding tissue [61, 375].  In fact, extracellular matrix cross-linking has been 
suggested to increase integrin signaling in breast cancer [60].  Since oxidative stress has 
been implicated in several diseases, this research on the crosstalk between tissue stiffness 
and ROS production could contribute to the discovery of novel therapeutic targets.   
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5.3.4. Clinical implications 
More broadly speaking, this work supports the importance of clinical arterial 
stiffness screening combined with screening for system inflammation.  Pulse wave 
velocity enables simple, non-invasive measurement of arterial stiffness.  Such screening 
could be useful in patients at increased risk of cardiovascular disease, such as those with 
a family history or those being treated for a disease known to cause vascular 
complications, such as diabetes or rheumatoid arthritis.  Since studies show that arterial 
stiffening precedes the development of hypertension, a major risk factor for 
atherosclerosis, early PWV screening of patients at risk for cardiovascular diseases could 
alert patients of the need to adjust diet and exercise choices.  In addition, use of PWV 
screening in conjunction with screening for inflammation (by measuring blood levels of 
inflammatory markers such as TNF-α, C-reactive protein, and IL-6) could inform doctors 
on the best course of treatment.  For example, individuals showing evidence of arterial 
stiffening could be good candidates for anti-TNF-α therapies, such as etanercept [376].  
This work also provides evidence for a connection between arterial stiffness and 
ROS production and suggests a need to better understand the clinical impact of arterial 
stiffening on oxidative stress.  Animal studies suggest cross-talk between arterial 
stiffening and ROS; in ELN+/- mice, both knockdown of the NADPH oxidase sub-unit 
p47phox and pharmacological treatment with the NADPH oxidase inhibitor apocynin 
were successful in reducing mean arterial pressure at 16 weeks of age [377].  In humans 
with elastin insufficiency (Williams-Beuren syndrome), a deletion in the gene that 
encodes p47phox (NCF1) correlated with a decreased occurrence of hypertension [378].  
While anti-oxidant therapies have had inconsistent success at improving cardiovascular 
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function in the clinic, such therapies may be more effective in individuals with increased 
arterial stiffness.  It is possible to assess markers of superoxide production in the blood 
[356]; concurrent PWV and oxidative stress screening may provide improved diagnosis 
and treatment decisions to prevent endothelial dysfunction.  
 
5.4. Future studies 
5.4.1. Protective function of vinculin in the endothelium 
 Further investigation is necessary to better understand the protective role of 
vinculin against substrate-dependent contractility-induced cell-cell junction opening.  Our 
studies showed that cell contractility increased with increasing substrate stiffness; 
however, the increase in functional endothelial permeability with increasing substrate 
stiffness was subtle.  One possible reason for this disconnect between induced cell 
contractility and permeability could be that vinculin recruitment following increased 
intracellular tension protected against cell-cell junction opening.  In fact, other recently 
published results support the protective properties of vinculin in age-related 
cardiomyocyte remodeling [313].   
Future work would focus on better understanding the point at which this 
protective function is overwhelmed by intracellular forces.  Recently published in vitro 
studies which applied increasing force to purified proteins using magnetic tweezers 
reported that vinculin dissociated from α-catenin at forces > 30 pN [174].  Future 
experiments using cultured endothelial monolayers on PA gel substrates could investigate 
the forces needed to break the vinculin-α-catenin association within cells.  Traction force 
microscopy used in conjunction with cells expressing fluorescently tagged vinculin could 
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connect the magnitude of cell-generated forces and the localization of vinculin to cell-cell 
junctions.  Fluorescence microscopy images taken at increasing intervals following the 
application of a contractility stimulus could determine traction forces and cell-cell 
junction morphology at each time. 
The elastin haploinsufficient mouse model could be used in future studies to 
better understand the role of vinculin in endothelial cell-cell junction maintenance in 
vivo.  Specifically, vinculin could be over-expressed in ELN+/- mice to test the protective 
capacity of vinculin.  Vessel permeability studies could be used to assess the effect of 
increased vinculin on basal vessel permeability and permeability following the 
stimulation of systemic inflammation.  In addition to measuring functional endothelial 
barrier function, en face imaging of the endothelium would be required to determine if 
vinculin was associating with focal adhesions, cell-cell junctions, or both.        
In long-term future studies, strategies to enhance the interaction between vinculin 
and α-catenin with the goal of eventually pharmacologically improving endothelial 
barrier function in vivo would be of key interest.  Better understanding this interaction 
could provide new therapeutic strategies for strengthening endothelial barrier function, 
which would contribute to the treatment of both atherosclerosis and potentially the 
prevention of cancer metastasis, as breaching the endothelial barrier is one key step in the 
spread of circulating tumor cells.    
 
5.4.2. Role of substrate stiffness in VE-cadherin glycosylation 
VE-cadherin, the endothelial-specific adherens junction protein, is key to cell-cell 
junction maintenance in vitro and in vivo.  Interestingly, in whole cell lysate samples 
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separated by SDS-PAGE and probed for VE-cadherin, we observed differences in the 
number of bands by Western blot depending on the cell substrate. When PAEC adhered 
to tissue culture polystyrene (plastic), one main band was observed around 105 kDa 
(Figure 5.1a, lane 4).  However, two bands were observed in samples from PAEC on 6, 
14, and 29 kPa PA gel substrates (Figure 5.1a, lanes 1-3).  In the literature, Western blots 
of human, mouse, bovine and porcine endothelial cells show a single VE-cadherin band.  
When reported, the molecular weight of the single band was between 100 and 140 kDa   
[379-382].  However, the predicted molecular weight of VE-cadherin is ~90 kDa, based 
on its amino acid sequence [383].  The observation that the ratio between the top and 
bottom bands was substrate-dependent, as shown in Figure 5.1b, led to further 
investigation for possible causes and function implications.   
Protein degradation is one possible cause for the appearance of multiple bands.  
Multiple bands have been reported when examining VE-cadherin in HUVEC lysates 
(~100 and 120 kDa); in this paper the authors referred to the 100 kDa band as a 
degradation product without further substantiation [203].  In a later paper from the same 
research group, double VE-cadherin bands were observed only in the TritonX-100-
soluble fraction (protein not associated with the cytoskeleton); the lower molecular 
weight band (~100 kDa) was absent from the TritonX-100-insoluble fraction (protein 
associated with the cytoskeleton).  In this paper, the lower molecular weight band was 
again referred to as a degradation product [384]. 
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Figure 5.1.  VE-cadherin molecular weight varied with substrate stiffness (a) Total VE-cadherin 
in confluent PAECs on 6, 14, or 29 kPa collagen-coated polyacrylamide gels or tissue culture 
polystyrene (plastic) was determined by Western blot (b) Higher and lower molecular weight 
bands in (a) were quantified.  Effect of substrate stiffness on the ratio of the top and bottom bands 
was significant by one-way ANOVA (p<0.01). **p<0.001 by post-hoc Tukey-Kramer test. 
 
 
Another possible cause of multiple bands is varying degrees of VE-cadherin 
glycosylation.  VE-cadherin has seven extracellular glycosylation sites, and protein 
glycosylation can increase protein molecular weight [385].  Treating HUVECs with the 
enzyme peptide-N4-(N-acetyl-β-glucosaminyl)asparagine amidase F (PNGase F) to 
remove extracellular glycans reduced the apparent molecular weight of VE-cadherin from 
135 kDa to 90 kDa [383].  While it has been suggested that cell-cell junction protein 
glycosylation may modulate cell-cell interactions, few studies have directly investigated 
the functional implication on endothelial barrier function [386].  In HUVECs, removal of 
extracellular glycoproteins (specifically sialic acid) reduced homophilic interactions 
between the cell-cell junction protein platelet endothelial cell adhesion molecule 
(PECAM-1) [387].  Conversely, studies in epithelial cells have demonstrated that E-
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cadherin glycation resulted in unstable adherens junctions [388].  These reports suggest 
that VE-cadherin glycosylation may modulate endothelial barrier function, but more 
investigation is necessary to better understand the underlying mechanisms.   
The preliminary data in Figure 5.1 point to a possible effect of substrate stiffness 
on VE-cadherin; future studies would first determine whether or not the differences in 
molecular weight are due to glycosylation through PNGase F treatment of PAECs on 
substrates of different stiffness.  If the increased molecular weight of VE-cadherin in cells 
on stiff substrates is due to glycosylation and VE-cadherin glycosylation leads to unstable 
cell-cell junctions, these results suggest an alternative pathway contributing to increased 
endothelial monolayer permeability with substrate stiffening.   
 
5.4.3. Further characterization of differences between the endothelia of wild type 
and elastin haploinsufficient mice 
This thesis presents evidence that genetically modified elastin haploinsufficient 
(ELN+/-) mice have increased sub-endothelial stiffness.  Thus, ELN+/- mice represent an 
interesting model in which to study the effects of increasing vessel stiffness on the 
endothelium.  The main focus of our ex vivo studies was to characterize the effect of 
increased sub-endothelial stiffness on endothelial adherens junctions; however, some 
differences in basement membrane structure were observed between wild type and 
ELN+/- mice.  Specifically, collagen IV in the basement membrane of the WT mouse 
thoracic aorta was homogenous at all locations. However, collagen IV was aggregated in 
basement membrane in the upper thoracic aorta from an ELN+/- mouse (Figure 5.2a).  In 
the same ELN+/- vessel, aggregated collagen IV was not observed in the lower thoracic 
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aorta (Figure 5.2b).  β-catenin labeling of endothelial cell junctions shows the shorter, 
less elongated cells characteristic of the upper thoracic aorta (Figure 5.2c) and the more 
elongated endothelial cells of the lower thoracic aorta (Figure 5.2d); these differences in 
cell morphology confirm that Figure 5.2a depicts the thoracic aortic basement membrane 
while Figure 5.2b depicts the abdominal aortic basement membrane. 
 
 
Figure 5.2.  Collagen IV aggregation was observed in the basement membrane of the upper 
thoracic aorta but not the lower thoracic aorta in an ELN+/- mouse.  An intact ELN+/- mouse 
aorta was labeled for collagen IV (a and b) and β-catenin (c and d).  Confocal microscopy images 
were taken of the upper thoracic aorta (a and c) and the lower thoracic aorta (b and d).  Scale bar 
is 25 μm.   
 
144 
 
 
These results warrant future investigation.  The fact that elastin haploinsufficient 
mice exhibit accumulated, aggregated aortic sub-endothelial basement membrane has 
been reported in the literature.  In this published study, it was noted that the accumulated 
basement membrane further separated the endothelium from the diminished internal 
elastic lamina in ELN+/- mice [44].  However, this study did not report any differences in 
the basement membrane structure between the thoracic and abdominal aorta, as is shown 
in Figure 5.2.  The fact that collagen IV accumulation was not observed in the abdominal 
ELN+/- aorta suggests that the effect is not solely due to decreased elastin content, but 
stimulated by some difference between the thoracic and abdominal aortic sections—
possibly intraluminal pressure or vessel extensibility.   
Collagen IV aggregation has been observed in the thickened intima of human 
atherosclerotic plaques [389].  Yet, the effect of aggregated collagen IV on endothelial 
function is still under investigation [390].  Thus, better understanding of basement 
membrane deposition or reorganization by the endothelium in the ELN+/- mouse could 
potentially contribute to our understanding of atherosclerotic plaque development.                
 
5.4.4. Inflammation-induced aortic permeability in wild type and elastin 
haploinsufficient mice 
 Characterization of aortic sub-endothelial stiffness in wild type and ELN+/- mice 
by atomic force microscopy presented in this thesis demonstrate that elastin 
haploinsufficiency is an appropriate animal model for studying the effect of vessel 
stiffness on endothelial function.  While this work focused on structural changes to actin 
and cell-cell junctions in intact aortic sections from these mice, studies on vessel 
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permeability in response to systemic inflammation in ELN+/- would also clarify the 
effect of decreased aortic elasticity on functional barrier loss.  Vessel permeability could 
be determined through intraluminal injection of Evan’s blue dye or fluorescently labeled 
dextran, followed by imaging of the intact vessel or vessel homogenization [134, 391, 
392].  
The fact that ELN+/- mice develop high blood pressure contributes a confounding 
factor; in other words; are the effects observed due to arterial stiffness or adaptation to 
increased blood pressure?  Future studies with this mouse model that utilize concurrent 
treatment to lower blood pressure would help clarify the contribution of arterial stiffening 
to endothelial dysfunction.  In addition, the contribution of vessel stiffening to integrin-
dependent cell-cell junction loss would be of particular interest, since sensing of sub-
endothelial stiffness occurs at focal adhesions.  The role of increased integrin activation 
on stiff vessels could be investigated in the ELN+/- mouse model using pharmacological 
inhibition of the integrin-associated signaling molecule focal adhesion kinase (FAK).  
This approach would be complicated by the fact that FAK is active at both focal 
adhesions and cell-cell junctions; however, FAK inhibition has been successful in 
enhancing endothelial barrier function and preventing tumor cells extravasation in mice 
[323, 393].  FAK inhibition prior to the stimulation of endothelial cell-cell junction loss 
would further elucidate the role of sub-endothelial stiffening and increased integrin 
activation in endothelial permeability.     
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